

Index

- A**
- A antigen, 164–167, 165f–166f
2-AB (2-aminobenzamide), 640, 648
Abbreviations, for monosaccharides, 21
ABC (ATP-binding cassette) transporters, 270, 275–276
A/B glycosyltransferase, 164
ABO blood group, 130
 altered expression in cancer, 603
 antigens, 164–167, 165f–166f
 blood typing, 167
 Bombay phenotype, 167
 evolution and, 167
 expression of antigens, 165–166
 galectin binding, 472, 475
 Helicobacter pylori pathogenesis and, 167
 incompatibility, 739
 isoagglutinin response, 166–167
 malaria and, 167
 para-Bombay phenotype, 167
 polymorphism, 166, 261–262
 transfusion reaction, 167, 587
Abrin, 401, 405
Abrus precatorius, 401, 404f
Acanthamoeba
 A. keratitis, 550
 A. polyphaga, mimivirus of, 93
 lysosomal enzymes, 431
Acarbose, 730f, 733t
ACE (affinity coelectrophoresis), 384
Acetal, hemiacetal conversion into, 27, 27f
Acetylation
 donors for glycan modification, 61, 62t
 O-acetylation, 74, 113
Acetyl CoA:α-glucosaminide
 acetyltransferase deficiency, 557t
Acetyl-CoA N-acetyltransferase, in heparan sulfate degradation, 560f
Acetyltransferase
 acetyl CoA:α-glucosaminide
 acetyltransferase deficiency, 557t
 acetyl-CoA N-acetyltransferase, in heparan sulfate degradation, 560f
 N-acetyltransferase, in heparan sulfate degradation, 560
Achondrogenesis type IB (ACG-IB), 580
Acid glucosylceramidase, 692, 692f
Acid hydrolases, 423. *See also* Lysosomal enzymes
Acid phosphatase, 425, 432
Acinetaminic acid, 180f, 181
- Acquired human diseases, 583–594
 cardiovascular, 584
 atherosclerosis, 584
 reperfusion, 584
 dental, 584–585
 dermatology, 585
 endocrinology and metabolism, 585–586
 gastroenterology, 586
 infections, 586
 protein-losing enteropathy, 586
 ulcerative colitis, 586
 hematology, 587–589
 anticoagulants, 587
 cold agglutinin disease, 589
 paroxysmal cold hemoglobinuria, 169, 588
 paroxysmal nocturnal hemoglobinuria, 149, 588, 604
 plasma fibrinogen, abnormal glycosylation, 588
 Tn polyagglutinin syndrome, 589
 transfusion reactions, 587
 immunology and rheumatology, 589–590
 rheumatoid arthritis, 589–590
 infectious disease, 527–537, 590
 nephrology, 591
 IgA nephropathy, 591
 nephrotic syndrome, 591
 systemic lupus erythematosus (SLE), 591
 neurology and psychiatry, 592–593
 Alzheimer's disease, 592–593
 autoimmune neural damage, 592
 oncology, 593
 pulmonary, 593–594
 acute respiratory distress syndrome, 593–594
 bronchial asthma, 593
 cystic fibrosis, 594
 vascular disease, 594
Acquired immunodeficiency syndrome (AIDS), 536
Acrosome reaction
 sea urchins, 352
 SPAM1 secretion, 203
Ac5SGlcNAc, 706, 706f
Actin-binding protein, 237
Actinohivin, 411
Activator proteins, 562, 563–564
Acute respiratory distress syndrome, 593–594
Acyclic monosaccharides, 21, 22f, 25
- Acylation, donors for glycan modification, 61, 62t
Adams–Oliver syndrome type 4, 156
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), 157
ADCC (antibody-dependent cellular cytotoxicity), 659
Adenia digitata, 405
Adhesins, 99, 363–365, 368
 fimbriae and pili, 485–486, 485f–486f, 590
 glycosphingolipids and, 135
 mechanisms of colonization and invasion, 531–532, 532f
 pathogenesis, role in, 590
 receptors, 531–532, 532f
 table of examples, 487t
Adipogenesis, role of galectins in, 478
ADPKD (autosomal-dominant polycystic kidney disease), 450
Advanced glycation end (AGE) products, 585
Aerolysin, 150
Aeromonas hydrophilia, 150
Affinity chromatography
 glycan–protein interaction analysis, 377–378, 378f
 serial lectin, 619, 620f
Affinity coelectrophoresis (ACE), 384
African clawed frog, 353–355, 354f
Agarose (agar), 316
AGE (advanced glycation end) products, 585
Agglutination
 glycan–protein interaction analysis, 383
 lectin for, 621–622
Agglutinins. *See* Lectin(s)
Aggrecan, 209–210, 209f, 211t, 214, 450
 family of proteoglycans, 210, 211t, 220
 modular organization, 201, 201f, 202f
Aggregatibacter actinomycetemcomitans, 533
Aggrus, 443
Aglycone, 5–6, 8
Agrin, 211t, 213
Agrobacterium tumefaciens, 277
AIDS, 536
Airway physiology, glycans in, 523
Alboaggregin A, 450
Alcaligenes, 37f
Alcohol oxidase (AOX), 300
Alcohols, 757
Aldehyde group, 3, 5

- Alditols, 26, 26f
Aldohexose, 20–21
Aldose, 3, 20, 20f
Aleuria aurantia lectin (AAL), 614f, 619
Alg5, 337
Algae, 305–306, 316, 734
ALG gene (altered in glycosylation), 102, 571t
Alginic acid, 316
Alglucosidase alfa, 733t
Alkylacylglycerol, 126f
Alkylation of glycans, 74
Allosamidin, 733t
Allose, structure of, 22f
Alloxan, 706
 α anomer, 25
 α -crystallin, O-GlcNAc on, 245
 α -dystroglycan, 157–158, 178, 368, 524, 576
mutants, 628, 629f, 630
 α -fucosidase
defect in, 556t
FUCA2, 537
N-glycan degradation, 555f
specificity and uses, 642t
 α -fucosyltransferase
 α 1-3/ α 1-4FucT, 167–168, 168f
 α 1-2 fucosyltransferase (α 1-2FucT), 164–168, 537
 α 1-3 fucosyltransferase (α 1-3FucT), 722
 α 1-6 fucosyltransferase, arthropod, 336
Caenorhabditis elegans, 323, 324f, 328
 α -galactosidase
deficiency, 557t
glycolipid degradation, 563, 563f
N-glycan degradation, 558
recombinant, 567
saposins and, 563
 α 1-4 galactosyltransferase (α 1-4GalT), 169
 α 1-3 galactosyltransferase (α 1-3GalT), 170–171, 170f
 α 1-3GalNAcT, 164
 α -glucosidase
 α -glucosidase I, 295, 504, 504f, 506f, 704, 705t
 α -glucosidase II, 295, 323, 324f, 504–505, 504f, 506f, 507, 704, 705t
Caenorhabditis elegans, 323, 324f
inhibitors, 704, 705t, 709
recombinant, 567
 α -iduronidase
deficiency, 557t
degradation of dermatan sulfate and chondroitin sulfate, 561, 561f
heparan sulfate degradation, 560, 560f
recombinant, 567
 α -linkages, 5, 7
 α (1-4)-linked galacturonic acid (GalA), 33–34
 α -mannosidase
 α -1-2 mannosidase, arthropod, 336
 α -1-6 mannosidase, arthropod, 337
 α -mannosidase I
Caenorhabditis elegans, 323, 324f
ER, 507–508
inhibitors, 704, 705t
in N-glycan synthesis, 104, 106
 α -mannosidase II
arthropod, 337, 337f
Caenorhabditis elegans, 323, 324f
defect, 631
inhibitors, 565, 704, 705t
knockout in mice, 358–359
in N-glycan synthesis, 106, 107f, 314
plant, 314
Caenorhabditis elegans, 323, 324f, 330
defect in, 556t
inhibition of, 565–566, 704, 705t
N-glycan degradation, 555f, 558
specificity and uses, 642t
 α -mannosidosis, 556t
 α 1-6-mannosyltransferase, yeast, 721
 α 2-mannosyltransferase, 710
 α -methylmannoside, 438f
 α -N-acetylgalactosaminidase
defect in, 556t, 559
O-glycan degradation, 559
 α -N-acetylglucosaminidase
deficiency, 557t
heparan sulfate degradation, 560f
 α -2-3 sialyltransferases, 174, 174f
 α -2-6 sialyltransferases, 174–175, 175f, 724
 α -2-8 sialyltransferases, 175–177, 176f
 α -tubulin, 246
ALS (amyotrophic lateral sclerosis), 248
Altrose, structure of, 22f
Alzheimer's disease, 463
O-GlcNAc and, 248
paired helical filamentous (PHF)-tau, 248
role of glycans in the histopathology of, 592–593
Amber, 395, 397
Ambystoma mexicanum, galectins, 472
Amine, 26, 27f
2-aminobenzamide (2-AB), 640, 648
Amino groups, in monosaccharides, 28
2-aminopyridine (2-AP), 648
Amish infantile epilepsy, 581
Ammonium sulfate, precipitation by, 384
Amphotycin, 704
Amyloid precursor protein (APP), 248
Amyotrophic lateral sclerosis (ALS), 248
Analytical methods, technological advances in, 763–764
Anaplasma phagocytophilum, 447
Angiogenesis
galectin-1 role in, 476
glycosaminoglycans and, 522
Animal development. *See* Development
Animal lectins, 362–363, 365, 367f
R-type lectins, 407–411
Animals, cell-surface polysaccharides of, 34–36
Anion transport protein, 165
Annexin V, 369
Anomeric carbon
determination of configuration at, 25, 25f
glycosidic linkages, 27, 28–29
glycosyltransferases and, 70
monosaccharide chemistry at anomeric center, 25–27
mutarotation, 25
stereochemistry at, 32, 33
Anomeric center, 5, 25–27. *See also* Anomeric carbon
Anomers, 2
Anopheles mosquito, 541, 542f
Anthrax, 529
Antibiotics, peptidoglycan as target of, 270
Antibody. *See also* Monoclonal antibody
antiglycan, 739–740
cold-dependent agglutinating antibody (cold agglutinin), 163
single-chain variable fragments (scFvs) of antibodies, 614
use in
animal cell glycosylation mutant generation, 622
cell-surface glycoconjugate characterization, 621–622
cloning glycosyltransferase genes by expression, 622–623
glycan purification, 619–621
glycan recognition, 616–619
interference studies of glycans, 85f
Antibody-dependent cellular cytotoxicity (ADCC), 659
Anticoagulation
acquired due to circulating heparan sulfate, 587
heparin, 34, 207, 220, 587
Antigenic variation, 543
Antigen-presenting cells, 444, 522
Antiglycan antibodies, 739–740
Antiporters, 59
Antithrombin, 36, 217f, 219–220, 736
deficiency, 499
heparin binding to, 363, 498–499, 498f
structure, 498f, 499
Antithrombin III, 522
AOII (atelosteogenesis type II), 580
AOX (alcohol oxidase), 300
2-AP (2-aminopyridine), 648
Apiogalacturonans, 311
Apiose, 58
Apoptosis
O-GlcNAcase and, 244
roles of galectins in, 477
suppression in cancer, 601
Arabidopsis thaliana
galectins, 471
gibberellic acid signaling, 245
glycan-associated genes, 307t
glycoside hydrolases, 94
glycosylation engineering, 722
glycosyltransferases of, 94
GPI biosynthesis, 149
as model organism, 317–318
mur mutants, 318
UDP-Gal transporter, 317–318, 623

- Arabinofuranosylation, 686, 688f
Arabinogalactan, 266, 271f, 272, 314, 686, 688f, 722
Arabinoglucuronoxylans, 313
Arabinomannan, 278
Arabinose, structure of, 22f
Arabinoxylan, 306f, 310
 synthesis of library, 686, 687f
Arabinoxylan pectin arabinogalactan protein 1 (APAP1), 309f, 314
Archaea, 283–292
 background, 283–284
 cell wall, 283, 284–287, 285f
 diversity of glycosylation in, 260
 genomics of glycosylation, 91f, 95
 glycosylation pathways in, 44, 287, 289
 N-glycosylation, 287–291, 289f
 halophiles, 289–290
 methanogens, 290–291
 N-glycan diversity, 287, 288f
 pathways, 287, 289
 physiological roles of, 291–292
 thermophiles, 291
 S-layer, 284, 287, 289–291
Archaellins, 287, 289–291
Arenaviruses, 157–158
Arixtra, 736
Arrays, glycan, 92, 382, 383f, 618–619, 618f
Arthrobacter ureafaciens, 189
Arthropoda, 335–349
 chitin, 346
 glycoproteins, 336–343
 mutations affecting glycans, 337, 338t–339t, 339, 340f
 N-linked glycans, 336–337, 336–340, 337f, 340f
 O-linked glycans, 340–343, 341f
 glycosaminoglycans (GAGs), 343–344, 345f
 glycosphingolipids, 346–347, 347f
 historical perspective, 335–336
 lectins, 347–348
 morphogen signaling and organ size control, 344
 nucleotide sugar transporters, 348
 proteoglycans and glycosaminoglycans, 343–346
Arthroseries glycans, 346–347, 347f
Arylsulfatase A (cerebrosidase sulfatase) deficiency, 557t, 563
 glycolipid degradation, 563, 563f
 saposins and, 563
Ascaris lumbricoides, 539
Ascaris suum, 332
Ashwell, Gilbert, 362
Ashwell–Morell receptor, 435, 438–440, 440f, 469, 590, 725
Asialoglycoprotein receptor (ASGPR), 174–175, 362–364, 435, 437f, 725.
 See also Ashwell–Morell receptor
Asparagine-linked oligosaccharide. See N-glycan(s)
Aspartylglucosaminidase, defect in, 556t
Aspartylglucosaminuria, 556t
Aspartyl-N-acetylglucosaminidase, N-glycan degradation and, 555f
Aspergillus, 303
 A. fumigatus, 298, 300
 A. niger, 298
 GPI-anchors, 299f
 O-glycans, 297f
Asthma, 593
Atelosteogenesis type II (AOII), 580
Atherosclerosis, 584
Atomic force microscopy, for study of
 glycan–protein interactions, 381
Atopic dermatitis, 585
ATP-binding cassette (ABC) transporters, 270, 275–276
AuNPs (gold nanoparticles), 744–746
Australine, 704, 705t
AutoDock programs, 396, 397
Autoglycosylation, 224
Autoimmune disease
 antiglycosphingolipid antibodies, 134
 cold agglutinin disease, 589
 neural damage, 592
 systemic lupus erythematosus, 591
Autosomal-dominant polycystic kidney disease (ADPKD), 450
Avery, Oswald, 529
Avidity, 374
- B**
BabA, 537
Bacillus
 B. anthracis, 529
 B. sphaericus, 407
 B. thuringiensis, 328, 488t, 489
Bacillus thuringiensis (Bt) toxins, 330–331
Bacteria, 265–281. See also specific species
 adhesins, 485–486, 485f–486f, 487t, 590
 antibacterials targeting peptidoglycan assembly, 270
 capsular polysaccharide, 266, 278, 279f, 280
 cell envelope architectures, 265–266, 267f
 commensals, 536–537
 diverse sugars in, 58
 diversity of glycosylation in, 260
 exopolysaccharide, 266, 278, 279f, 280
 genomics of glycosylation, 93
 glycan-based interactions between host and gut microbiota, 531–533
 glycan-binding proteins (GBPs), 363–365, 367f
 glycan turnover in, 48
 glycosylation engineering, 717t, 719–720
 glycosylation pathways in, 44
 glycosyltransferase toxins, 228–228
 Gram-negative, 266, 267f, 269, 272–276, 273f, 275f, 279f, 280
 Gram-positive, 266, 267f, 268–270, 271f, 280
 hyaluronan capsules in, 205, 205f
 intracellular glycans and glycosylated molecules, 281
 lectins, 363–365, 367f
 lipopolysaccharide (LPS), 266, 272–276
 assembly and export, 274–276, 275f
 structure and function, 273–274, 273f
 mechanisms of colonization and invasion, 531–533
 adhesins and receptors, 531–532, 532f
 biofilms, 532–533, 533f
 invasion factors, 532
 mycobacteria, 267f, 272
 Nod factors, 515–516, 516f
 osmoregulated periplasmic glucans, 277–278
 peptidoglycan, 266–270
 assembly, 269–270
 structure, arrangement and function, 268–269, 268f
 polysaccharides, 36–39, 37f, 643
 polysialic acids, 185
 probiotic, 280
 protein glycosylation, 276–277
 sialic acids, 185
 sialyltransferase, 185
 S-layer biosynthesis, 44
 surface glycans as virulence factors, 528–531
 lipopolysaccharide (LPS), 529–531, 530f
 polysaccharide capsules, 528–529, 529f
 toxins, 436, 482, 487–489, 488f, 488t, 719
 trans-sialidases, 188
 vaccines, 738
Bacterial autotransporter heptosyltransferase (BAHT), 532
Bacteriophage-encoded glycosyltransferase, 229
Bacteroides fragilis, 278
Bacteroides thetaiotaomicron, 537
Bactoprenol phosphate, 269
Baculovirus, glycosyltransferase of, 93, 260
BAHT (bacterial autotransporter heptosyltransferase), 532
B antigen, 164–167, 165f–166f
Base J, 229
Basement membrane proteoglycans, 213, 220
Basidiomycetes, 301
Basigin, 454
B blood group α -1-3 galactosyltransferase (B transferase), 66, 66f
B-cell receptor (BCR)
 α 2-6 sialic acid and, 175
 CD22 and, 458–459, 460f
 β 1-2 acetylglucosaminyltransferase, *Caenorhabditis elegans*, 325
 β -agalsidase, 733t
 β -amyloid precursor protein (APP), 248
 β anomer, 25
 β -cyclodextrin, 751
 β -cyclodextrin-quantum dots, 747
 β -elimination, 116, 644, 659
 β 1-4 galactosyltransferase
 catalytic mechanism of, 67, 71, 72f
 loss of activity, 574

- β -galactosylceramidase
 - deficiency, 557t
 - glycolipid degradation, 563, 563f
 - β -galactosidase
 - deficiency, 556t, 557t, 558
 - degradation of keratan sulfate, 560, 561f
 - glycan detection, 643
 - glycolipid degradation, 563, 563f
 - Kluyveromyces lactis*, 300
 - N-glycan degradation, 555f, 558
 - saposins and, 563
 - specificity and uses, 642t
 - β -galactosylceramidase, saposins and, 563
 - β 1-3 galactosyltransferase (β 1-3GalT), 162f, 166f, 323, 326, 600, 600f
 - β 1-4 galactosyltransferase (β 1-4GalT), 162f, 169f, 172–173, 172f, 175f
 - β 4 galactosyltransferase (β 4GalT), 153, 153f
 - β -galactosides, 708
 - β 1-3GalNAcT, 169, 169f
 - β 1-4GalNAcT, 171–173, 172f, 173f
 - β -glucoceramidase
 - deficiency, 557t
 - glycolipid degradation, 562, 563f
 - β -glucocerebrosidase, 132, 134, 432
 - β -glucosidases, plant, 310
 - β -glucosides, 708
 - β -glucuronidase
 - deficiency, 557t
 - degradation of dermatan sulfate and chondroitin sulfate, 561–562, 561f
 - heparan sulfate degradation, 560, 560f
 - hyaluronan degradation, 559, 559f, 560f
 - N-glycan degradation, 558
 - Betaglycan, 212t
 - β -hexosaminidase, 134
 - Caenorhabditis elegans*, 323, 324f, 326
 - defect in, 556t, 557t
 - inhibitors of, 706, 706f
 - insects, 723
 - plants, 722
 - β -lactamase, 270
 - β -lactams, 270
 - β -linkages, 5, 7
 - β -linked O-glucose, 152t, 155–156
 - β -mannosidase
 - defect in, 556t
 - N-glycan degradation, 555f, 558
 - β -mannosidosis, 556t
 - β -N-acetylgalactosaminides, 708
 - β -N-acetylglucosaminidase (O-GlcNAcase). *See* O-GlcNAcase
 - β -N-acetylglucosaminides, 708
 - β 1-3 N-acetylglucosaminyltransferase (β 3GnT), 153
 - β 1-6 N-acetylglucosaminyltransferase V (Mgat5), 477
 - β -N-acetylhexosaminidase
 - dermatan sulfate and chondroitin sulfate degradation, 561–562, 561f
 - glycolipid degradation, 563f
 - GM2 activator protein and, 564
 - hyaluronan degradation, 559, 560f
 - keratan sulfate degradation, 561f, 562
 - N-glycan degradation, 555f, 556, 558
 - β -propeller fold, 390–391, 391f
 - β -sandwich fold, 390, 453
 - β -trefoil lectin, 390
 - β -trefoil structure, 310f, 403, 405f, 411
 - β 1-2 -xylotransferase, 722
 - B3GALNT2, 158
 - B4GAT1, 158
 - B3GLCT* gene, 157
 - Bi Bi sequential kinetic mechanism, 73
 - Bifidobacteria*, 280
 - Biglycan, 209f, 211t
 - Bikunin, 202
 - Bindin, 352
 - Binding enthalpy, of glycan–protein interactions, 378
 - Bioenergy, glycans in, 17, 756–757
 - Bioethanol, 756
 - Biofilms, 280, 532–533, 533f
 - Biohydrocarbons, 757
 - Bioinformatics, 768. *See also* Informatics
 - Biological functions, of glycans, 77–88
 - approaches to elucidating, 84–88
 - competition by glycan or mimic, 85f, 86–87
 - finding glycan ligands, 85f, 86
 - finding receptors for glycans, 85f, 86
 - glycosidase experiments, 85f, 87
 - lectin or antibody interference, 85f
 - metabolic inhibition or alteration, 85–86, 85f
 - mutants, study of, 85f, 87–88
 - diversity of, 82–83
 - “junk” glycans, 84
 - as ligands for cell–cell interactions, 81
 - as ligands for cell–microbe interactions, 81–82
 - overview, 77–79, 78f
 - structural and modulatory, 79–81
 - Biological information, flow of, 2
 - Biomass, 756–757
 - BioPortal, 677
 - Biosimilars, 732
 - Biotechnology, glycans in, 17, 729–740
 - Biotin hydrazide/streptavidin-alkaline phosphatase, 640
 - Bis(monoacylglycero)phosphate (BMP), 564
 - Bisubstrates, 707
 - Blix, Gunnar, 180
 - Blood groups
 - A, B, and H antigens, 164–167, 165f–166f
 - ABO, 130, 164–167, 261–262
 - altered expression in cancer, 603
 - I and i, 164f
 - Lewis, 167–169, 168f
 - P, 169–170, 169f
 - Sd^a, 173–174, 173f
 - transfusion reaction, 167, 168, 169, 587
 - Blood typing, 167
 - BMP (bis(monoacylglycero)phosphate), 564
 - Boat conformation, 35
 - Bombay phenotype, 167
 - Bone morphogenetic protein (BMP), 344
 - Bordetella pertussis* filamentous hemagglutinin (FHA), 531
 - Botulinum toxin, 134, 191
 - Bradyrhizobium*, 277
 - Bradyrhizobium japonicum*, glycan synthase of, 96f
 - Brainiac (brn)* gene, 346
 - Branching, oligosaccharide, 31–33, 32f
 - Breast cancer, 739
 - Bre* genes, *Caenorhabditis elegans*, 331
 - Brenner, Sydney, 360
 - Brevican, 202, 210, 211t, 450
 - Bronchial asthma, 593
 - Brucella*, 167
 - Bt toxins, 488t, 489
 - B-type lectins, 368
 - Buckminsterfullerene, 748
 - Bufo arenarum* galectins, 472
 - Burkitt’s lymphoma, 603
- ## C
- Cadherins, 576–577
 - Caenorhabditis elegans*, 321–332
 - C-type lectins, 437
 - developmental biology, 321–322, 322f
 - functional analysis of glycoconjugates, 326–331
 - galectins, 471, 472
 - glycan-binding proteins, 331–332
 - glycans, 323–324, 324f, 325f
 - N-glycans, 323, 324f
 - O-glycans, 323–324, 325f
 - glycolipids, 330–331, 331f
 - glycosaminoglycans, 329–330, 330f
 - glycosyltransferase genes, 325–326
 - glycosyltransferases of, 95
 - life cycle, 322f
 - OGT* gene, 243, 246, 247
 - proteoglycans, 210, 213, 215, 329–330, 330f
 - structure, 322f
 - Calloselasma rhodostoma*, 443
 - Calmegin, 510
 - Calnexin, 105f, 296, 364, 368, 418–419, 419f, 504–505, 506f, 510
 - Calorimetry, isothermal titration, 378, 379f
 - Calreticulin, 105f, 364, 368, 418–419, 419f, 504–505, 506f, 510
 - Cambridge Structural Database, 651
 - Campylobacter*
 - C. jejuni*
 - autoimmune reaction and, 592
 - glycoengineering in, 719–720
 - glycosylation, 276, 277
 - Guillain–Barré syndrome, 134
 - lipooligosaccharide (LOS), 531
 - PglB, 720
 - sialoadhesin, 458
 - lipooligosaccharide (LOS), 274, 531
 - N-glycosylation, 93

- Canavalia ensiformis*, 414, 612f
- Cancer
- detection using glyconanomaterials, 751
 - galectins, roles of, 477
 - glycosylation changes in, 593, 597–608
 - altered branching and fucosylation of N-glycans, 598, 599f
 - blood groups, altered expression of, 603
 - in cancer stem cells, 607
 - clinical significance, 607–608
 - during EMT, 607
 - glycosphingolipids, altered expression of, 603
 - GPI-anchor expression, loss of, 603–604
 - historical background, 597–598
 - hyaluronan, changes in, 604, 605f
 - increased mucins and truncated O-glycans, 599–600, 601f
 - mechanisms of altered glycan expression, 607
 - nonrandom nature of changes, 598
 - O-GlcNAc, changes in, 606–607
 - selectin ligand expression, increase in, 602–603, 602f
 - sialic acid expression, 601–602, 601f
 - sulfated glycosaminoglycans, changes in, 606
 - hyaluronan oligosaccharides and, 206
 - loss of O-mannose glycans, 157
 - Notch signaling dysregulation, 154
 - O-GlcNAc and, 249
 - O-glycans and, 120–122
 - sialic acids in, 194
 - sialyl Lewis epitopes/structures, 122
 - vaccine, 738–739
- Cancer Genome Atlas, 607
- Candida albicans*, 301–302
- galectin binding, 476
 - host interactions, 302
 - mannans of, 298
 - mannose receptor binding, 408
- Capillary electrophoresis, 659–660
- Capping reactions, in N-glycan synthesis, 106, 108
- Capsular polysaccharide, 266, 278, 279f, 280
- Capsule, 36, 38, 528–529
- assembly and export, 280
 - Cryptococcus neoformans*, 302–303, 303f
 - Escherichia coli* K1, 93
 - Haemophilus influenzae*, 39, 528–529
 - hyaluronan in, 12, 93, 205, 205f, 528
 - Neisseria meningitidis*, 38, 93, 528
 - Pasteurella multocida*, 93
 - polysialic acids, 185
 - sialic acid, 93
 - Streptococcus pneumoniae*, 278, 528, 529f
 - structure and function of, 278, 279f, 280
- Carbohydrate-active enzymes (CAZy)
- database, 69, 73, 90–91, 307, 307t, 389, 672, 715
- Carbohydrate-binding module (CBM), 611
- cell-surface glycoconjugate characterization, 621–622
 - glycan recognition, 616–619
 - R-lectin, 403
- Carbohydrate-recognition domain (CRD)
- bacterial adhesins, 482
 - C-type lectins, 435–436, 437f, 444, 446
 - galectins, 469, 473f, 474, 478
 - in glycan-binding proteins, 92
 - lectins, 365–366, 366f, 368–371, 370f
 - R-type domain, 403, 404f
- Carbohydrates
- biological roles of, 2
 - defined, 3
 - simple and complex, 20
- Carbohydrate Structure Database (CSDB), 672
- Carbonic anhydrase II, 232, 235
- Carbon nanotubes, 745f, 748–750, 749f
- Carbon sequestration, 763
- Carbonyl group, 3
- Carboxymethyl cellulose, 757
- Cardin, Alan, 497
- Cardiovascular system
- acquired diseases, 584
 - atherosclerosis, 584
 - reperfusion, 584
 - physiology, glycans in, 522–523
- Carrageenan, 316
- CASD1, 188
- Casein kinase II, O-GlcNAc on, 247
- Caspase-3, 244
- CASPER program, 675
- Castanospermine, 104, 109, 704, 705t
- Castanosperum australe*, 704
- Catch bonds, 449
- Cathepsin A, 556t, 558
- Cathepsin D, 427
- Cation-dependent M6P receptor (CD-MPR), 427–429, 428f, 431
- Cation-independent M6P receptor (CI-MPR), 427–432
- CAZy database. *See* Carbohydrate-active enzymes (CAZy) database
- CBM (carbohydrate-binding module), R-lectin, 403
- CBP35, 470
- CBP70 proteins, 235, 236
- CCR5, 536
- CD2, 455
- CD4, 511, 536
- CD22 (Siglec-2), 365
- α-2-6 sialic acid and, 175
 - discovery, 454
 - domain structure, 455f
 - expression patterns and functions, 457–459, 460f
- CD33 (Siglec-3), 462–463
- CD44, 204, 212t, 213, 371, 518, 518f, 532, 604, 605f, 607–608
- CD59, 588
- CD83, 455
- CD147, 454
- CD162. *See* PSGL-1 (P-selectin glycoprotein ligand-1)
- CD169. *See* Sialoadhesin
- CD170, 463
- CD206, 407
- CD280, 409
- CD209a, 442
- CD62E. *See* E-selectin
- CD62L. *See* L-selectin
- CD-MPR (cation-dependent M6P receptor), 427–429, 428f, 431
- cDNA expression, for study of glycan–protein interactions, 384
- CD62P. *See* P-selectin
- CD33-related Siglecs (CD33rSiglecs)
- CD33 (Siglec-3), 462–463
 - discovery, 454
 - domain structure, 455f
 - evolution, 454, 461, 462f
 - genomic organization, expression patterns, and functions, 461–465, 462f
 - Siglec-5 (CD170), 455f, 463, 466
 - Siglec-6, 455f, 463–464, 467
 - Siglec-7, 455f, 456, 456f, 457, 464
 - Siglec-8, 455f, 456, 457, 464
 - Siglec-9, 455f, 457, 464
 - Siglec-10, 455f, 465
 - Siglec-11, 455f, 457, 465, 466
 - Siglec-12, 466
 - Siglec-13, 466
 - Siglec-14, 455f, 457, 463, 466
 - Siglec-15, 455f, 457, 461
 - Siglec-16, 455f, 457, 465
 - Siglec-17, 466
- CEBiP (chitin oligosaccharide elicitor binding protein), 515
- Cell biology of glycosylation, 13
- Cell–cell interactions, glycans as ligands for, 81
- Cell–cell recognition, role of glycosphingolipids, 132
- Cell envelope architectures, 265–266, 267f
- Cellobiohydrolases, 310
- Cellobiose, structure of, 33, 33f
- Cell signaling. *See* Signaling
- Cell sorting, 621
- Cell-surface phosphatidylserine, induction of exposure, 477
- Cellulase, 310, 364
- Cellulose, 5, 33, 305, 306, 306f, 309–310, 312, 755
- abundance in nature, 254
 - bioenergy and, 756
 - degradation, 281
 - nanomaterials, 758–759, 758f, 759f
 - polymers, 757
- Cellulose acetate, 757
- Cellulose acetate butyrates, 757
- Cellulose acetate propionate, 757
- Cellulose butyrate succinate, 757
- Cellulose synthase, 310, 313
- Cellulosome, 96, 310

- Cell wall
algae, 316
archaea, 283, 284–287, 285f
fungal, 294–295, 295f
Mycobacterium tuberculosis, 365
plant, 305, 307–313, 755–756
- Cell wall, bacteria
cell envelope architectures, 265–266, 267f
lipopolysaccharide (LPS), 266, 272–276
assembly and export, 274–276, 275f
structure and function, 273–274, 273f
mycobacteria, 267f, 272
peptidoglycan, 266–270
assembly, 269–270
structure, arrangement and function, 268–269, 268f
- Central nervous system
chondroitin sulfate proteoglycans and, 500
role of glycans in, 525
- Ceramide, 125–127, 128f
role in epidermal permeability barrier, 132
structure, 126f
synthesis, 129–130
- Ceramide glycanases, 129
- Cerebroside sulfatase. *See* Arylsulfatase A CERK1, 515
- Ceruloplasmin, 362, 438
- CFG (Consortium for Functional Glycomics), 670
- CFTR- Δ F508, 510
- C1GALT1 (core-1 galactosyltransferase), 357, 600, 600f
- Cgl* gene, 318
- Chagas' disease, 544
- Chair conformation, 21, 21f, 24, 24f, 35
- Chaperone
Cosmc, 117, 120
N-glycan synthesis and, 104
role in protein folding, 503–504
- Chaperone therapy, 735–736
- Charcot–Leyden crystal protein, 471
- CHARMM, 395
- Chemical-shift mapping of protein-binding sites for glycans, 392–393, 393f
- Chemical synthesis of glycans and glycoconjugates, 681–689
automated, 684, 686, 687f
computational chemistry-assisted glycan assembly, 686, 688, 688f
one-pot assembly, 686, 688, 689f
perspectives on, 688–689
protective group manipulation, 683–684, 683f
regiochemistry, controlling, 681–682
solid-phase, 684, 686, 687f
solution phase, 684, 685f
stereochemistry, controlling, 682–683, 682f
technological advances in, 764
- Chemical tools for inhibiting glycosylation, 701–712
- Chemoenzymatic synthesis of glycans and glycoconjugates, 691–698
glycosyltransferase-mediated, 692–694, 693f–695f
glycosynthases, 695–698, 696f–697f
outlook for, 698
transglycosylation, 695–698
- Chewing gum, 737
- Chinese hamster ovary cells (CHO cells), 627–628, 629f, 632f, 632t–634t, 634–636
glycosylation engineering, 715, 716t, 724–726
glycosylation mutant generation, 622
- Chiral anomeric center, 5
- Chiral carbon, 20
- Chitin, 34, 294–295, 302
abundance in nature, 254
arthropod, 346
assembly at plasma membrane, 44
Entamoeba cyst wall, 547
oligosaccharides
plant defense response, 515
role in animal embryogenesis, 517
- Chitinase, 517
- Chitinase, human acidic, 95–96
- Chitin synthases, 294
- Chitobiose, 233, 508
- Chitosan, 294
- Chitosan-based nanoparticles, 750
- Chlamydomonas reinhardtii*, 316
- Chlorate, sulfation blocked by, 702
- Chlorella, 205, 233, 260
- Chloroplasts, 235–236, 305, 316
- CHO cells. *See* Chinese hamster ovary cells
- Cholera toxin, 134, 511, 745
binding, 487
ganglioside GM1 as toxin receptor, 174
structure, 488f
- Cholesterol, in membrane lipid rafts, 131
- Chondroitin
biosynthesis, 36
structure, 11
- Chondroitinases, 218, 525, 642t
- Chondroitin proteoglycans (CPGs), of *Caenorhabditis elegans*, 329, 330f
- Chondroitin sulfate, 202, 202f
Caenorhabditis elegans, 323, 326, 327f, 329
cell signaling and, 518
changes in cancer, 606
degradation, 561, 561f
evolutionary diversity, 259
insect, 343
mutants in biosynthesis, 634, 634t
for osteoarthritis, 737
Plasmodium adherence to, 542
proteoglycans, 207, 209–210, 209f, 213
biosynthesis, 215f, 216, 217f, 218–219
degradation, 218, 220
galactose sulfation, 215
linkages, 214
structure, 210f, 209
types, 218t
small leucine-rich proteoglycans (SLRPs), 210
structure, 34, 35f
- Chondroitin synthases, 95, 96f, 216
- Chondromucoid, 207
- Chromatography, affinity, 377–378, 378f
- Chronic obstructive pulmonary disease (COPD), 463
- CID (collision-induced dissociation), 661, 662f, 664–665, 664f
- CI-MPR (cation-independent M6P receptor), 427–432
- Circle of life, 255f
- CLECs, 442–443
- Cloning glycosyltransferase genes by expression, 622–623
- Clostridium*
C. difficile, 229
C. novyi, 229
C. perfringens, 590
C. sordellii, 229
C. thermocellum, cellulosome of, 96
cellulose degradation, 281
toxins, 228–229, 421
- CLR (C-type lectin receptor), 444
- CMAH gene, 185–186, 195, 258
- C-mannosylation, 159, 159f, 543
- C-mannosyltransferase, *Caenorhabditis elegans*, 324
- CMP-Neu5Ac hydroxylase, 258
- CMP-sialic acid, 693
- c-Myc, O-GlcNAc and, 247
- COG (conserved oligomeric Golgi) complex, 47, 575
- COG7 gene, 571t, 575
- Cold agglutinin disease, 589
- Cold-dependent agglutinating antibody (cold agglutinin), 163
- Collagen
O-linked glycans, 159
type XVIII, 211t, 213
- Collectins, 441
- Collision-induced dissociation (CID), 648, 661, 662f, 664–665, 664f
- Colomonic acid, 185
- Comitin, 237
- Commensals, 536–537
- Complement, 365
C-mannosylation of proteins, 159
complement control protein (CCP) modules, 444
triggering by IgM isoagglutinins, 167
- Complex carbohydrate, 20
- Complex Carbohydrate Structure Database (CCSD), 670
- Computational chemistry-assisted glycan assembly, 686, 688, 688f
- Computational modeling
glycan recognition, 394–399
methods, 395–396
molecular docking, 396–399

- Concanavalin A (ConA), 362, 747, 751
glycan purification, 619, 620f
initial isolation, 413
N-glycan recognition by, 612, 612f, 617
proteolytic modification, 418
structure, 414, 414f, 416
- Congenital disorders of glycosylation, 110
future impact of study on, 762
overview, 569–570, 570f
table of defects, 571t
type I, 572, 574
type Ib, 586, 734
type II, 47, 574–575
- Congenital muscular dystrophies, 157, 576–578
- Conglutinin, 441
- Conserved oligomeric Golgi (COG)
complex proteins, 47, 575
- Consortium for Functional Glycomics (CFG), 670
- Contact dermatitis, 585
- Coprinopsis cinerea*, 301
- Coprinus cinereus*, 471
- Correlation spectroscopy (COSY), 649–650
- COS cell line, 622–623
- Cosmc, 117, 120
- COSMC gene, 579, 589, 591, 600
- COSY (correlation spectroscopy), 649–650
cow gene, 343
- CPGs (chondroitin proteoglycans), of
Caenorhabditis elegans, 329, 330f
- Crasostrea virginica*, 478–479
- CRD. *See* Carbohydrate-recognition domain
- C-reactive protein, 420
- CREB (cyclic-AMP-responsive element-binding protein),
O-GlcNAcylation of, 247
- CREG (cellular repressor of E1A-stimulated genes), 432
- Cre-loxP targeting for making conditional knockouts, 358, 358f
- CRISPR/Cas9, 718, 727
- Crohn's disease, 441, 734
- Cross-linking, in bacterial polysaccharides, 39
- Cross-matching blood, 167
- Crotalus atrox*, 450
- Cryo-electron microscopy (cryo-EM), 388, 399, 763
- Cryptococcus*
C. laurentii, 301
C. neoformans, 302–303, 303f
O-glycans, 297f
- Cryptosporidium parvum*, 550
- Crystallography
databases of crystal structure, 389
folding and oligomerization facilitate binding to cell surfaces, 390–391, 391f
glycan recognition, 388–391
interactions in carbohydrate-binding sites, 389–390, 390f
limitations, 389
- CSDB (Carbohydrate Structure Database), 672
- CSPG4, 212t, 213
- CT antigen, 173, 173f
- CTLD. *See* C-type lectin domain
- C-type lectin domain (CTLD)
in *Caenorhabditis elegans*, 331–332
C-type lectins, 435–437, 441–443, 449–450
in mannose receptor family, 407–409
- C-type lectin receptor (CLR), 444
- C-type lectins, 365, 368, 370, 389, 435–450, 522
definition, 435
dendritic cells (DCs) and, 442–444, 536
discovery, 435–436
groups, 436–437, 439f
collectins, 441
endocytic receptors, 440–441, 440f
myeloid lectins, 442–444
proteoglycans, 449–450
selectins, 444–449, 445f
insect, 348
schistosome glycan recognition, 550
structural motifs, 435–436
- Cucumaria echinata*, 407
- Cultured cells, glycosylation mutants of, 15, 627–636
cell lines, 631
dominant mutations, 633, 633t
glycolipid defects, 634–635
in GPI-anchor biosynthesis, 633
history, 627–628
isolation of mutants, 630
O-glycan defects, 634–635
in proteoglycan assembly, 634, 634t
recessive mutations, 631, 632f, 632t
resistance to plant lectins, 630, 631
screening by replica plating, 629f, 630
uses of mutants, 635–636
- Cumulus oophorus expansion, 202
- CXCL12 α , 397–398, 397f
- CXCR4, 536
- Cyclic form of monosaccharides, 21, 23–25, 23f–24f
- Cystic fibrosis, 510, 594
- Cystic fibrosis transmembrane conductance regulatory (CFTR), 594
- Cytokeratins, O-GlcNAc on, 245–247
- Cytomegalovirus, 511
- Cytoplasm
glycoproteins, 229–233
glycosylation in, 43, 223–237
bacterial glycosyltransferase toxins, 228–229
evolutionary variations in glycans, 259–260
examples, 225t
glycogenin, 224
hydroxyproline-linked Skp1 glycans, 224, 226, 227f, 228
mitochondria and chloroplasts, 235–236
prokaryotic monoglycosylation, 228
widespread nature of, 229–235
- D**
- Dally, 343, 344, 345, 345f
- Damage-associated molecular patterns (DAMPs), 83, 441, 465, 519
- Danio rerio*. *See* Zebrafish (*Danio rerio*)
- DAP-12 (DNAX activation protein-12), 457, 463
- Databases, 669–672, 671t
accumulation versus curation, 670, 672
carbohydrate-active enzymes (CAZy)
database, 69, 73, 90–91, 307, 307t, 389, 672, 715
Complex Carbohydrate Structure Database (CCSD), 670
of crystal structure, 389
of glycan and glycoconjugate structures, 669–672, 671t
lectins, 672
standardization and ontologies, 672–673
- Data interpretation, software tools for, 673–676
- Datura stramonium* agglutinin (DSA), 613f
- DCAL-1 (dendritic-cell-associated lectin-1), 442
- D configuration, 21
- DCs. *See* Dendritic cells
- DC-SIGN, 272, 389, 438, 440f, 442, 536, 550
- Deacetylation of glycans, 74
- DEC-205, 409, 442
- Decapentaplegic (Dpp), 344, 345, 345f, 346
- Decay-accelerating factor, 588
- Decorin, 209f, 211t
- Dectin-1, 436, 440, 442
- Dectin-2, 442
- Delta, 152, 154, 155f, 342
- Dendritic-cell-associated lectin-1 (DCAL-1), 442
- Dendritic cells (DCs)
as antigen-presenting cells, 444
C-type lectins on, 442–444, 536
human immunodeficiency virus (HIV) and, 536
schistosome glycan recognition, 550
Siglecs and, 457–458, 461, 464–465
- Dengue virus
binding to heparan sulfate, 484, 485f
galectins and, 478
- Density functional theory (DFT), 686
- Dental diseases, 584–585
- Deoxygenation
of glycans, 74
of hydroxyl groups, 28
- 2-deoxyglucose, glycosylation inhibited by, 702–703
- Deoxyhexoses, 8, 58
- Deoxymannojirimycin, 106, 704, 705t
- Deoxynojirimycin, 104, 109, 704, 705t
- Deoxynonosonic acid, 181
- Deoxynorleucine (DON), 249
- Depots (sinks), glycans as, 80
- Dermatan sulfate, 207, 209–210, 209f, 219
biosynthesis, 36, 217f, 218
cell signaling and, 518
changes in cancer, 606

- Dermatan sulfate (*Continued*)
degradation, 561–562, 561f
processing and turnover, 22–23, 220
role in skin, 524
small leucine-rich proteoglycans (SLRPs), 210
structure, 11, 35f, 210f, 214, 217f
- Dermatology, 585
- Detection of glycans, 640–643
glycolipids, 641
glycoproteins, 641–643
GPI-anchors, 643
plant and bacterial polysaccharides, 643
proteoglycans, 641
- Deuterostomes, 351–360
evolutionary background, 351–352
frogs, 353–355, 354f
mice (*Mus musculus*), 357–359
cell type-specific mutations, 358
conditional knockouts, 358f
environmentally driven phenotypes, 359
mutations affecting entire pathways, 357–358
mutations affecting specific extensions/modifications, 358
strain differences/genetic modifiers, 359
sea urchins, 352–353, 353f
zebrafish (*Danio rerio*), 355–357, 356f
appearance of, 356f
glycans under study, 356f
lectins, 355–356
novel genes, 357
- Development
biology of *Caenorhabditis elegans*, 321–322, 323f
future impact of glycosciences on study, 762
galectins, roles of, 476–477
glycans in, 522
glycosylation changes in, 16
Notch and, 154
oligosaccharide signals in early development, 517
sialic acids in, 193–194
- DFT (density functional theory), 686
- DGDG (digalactosyldiacylglycerol), 316–317, 317f
- DGDG synthase, 316
- DG42 gene, 198, 354, 517
- Dgl1 gene, 318
- Diabetes mellitus
glycation in, 26
O-GlcNAcylation and, 244f, 245, 249, 523
pathogenesis and complications of, 585–586
- Diacylglycerol (DAG), 270
- Diastrophic dystrophy (DTD), 580
- Dictyocaulus viviparus*, 332, 549
- Dictyonema glabratum*, 301
- Dictyostelium*
comitin, 237
discoidin family of lectins, 236
- lectins, 363
lysosomal enzymes, 431
phosphoglycosylation in, 74
Skp1, glycosylation of, 224, 226, 227f, 228
- Differentiation, glycosylation changes in, 16
- Digalactosyldiacylglycerol (DGDG), 316–317, 317f
- Digoxin, 317
- Dihydroxyacetone, 20, 20f
- Dihydroxyacetone synthase, 300
- Dioclea grandiflora* lectin, 416
- Dirofilaria immitis*, 332, 549
- Disaccharides
isomers, 28, 28f
nonreducing, 29, 29f
reducing end, 29, 29f
- Discoidin family of lectins, 236
- Disease
acquired human, 583–594
genetic disorders of glycan degradation, 553–567
genetic disorders of glycosylation, 569–581
glycosylation diversity, 262
herd immunity, 262
infectious, 527–537
metabolic diseases, glycan therapeutic approaches to, 734–736
- Dlp*, 343, 345, 345f, 346
- DNA, glycosylation of, 9
- DNase I, 431–432
- DNGR-1, 441
- Docking programs, 396–398
- Dolichol, phosphorylation of, 62
- Dolichol phosphate (Dol-P)
in archaea, 287, 289–291
inhibition of formation, 709
N-glycan synthesis on, 100–102, 103f
structure of, 102f
- Dolichol pyrophosphate (Dol-PP)
in archaea, 287, 291
tunicamycin inhibition of dolichol-PP-GlcNAc assembly, 703
- Dolichos biflorus* lectin, 166, 416, 418
- Dol-P-mannose flippase, 289
- DON (6-diazo-5-oxo-L-norleucine), 702
- DON (deoxynorleucine), 249
- Donath-Landsteiner antibodies, 169
- Donath-Landsteiner test, 588
- Double displacement mechanism, of glycosyltransferase, 71
- Dowling-Degos disease type 2, 154
- Dowling-Degos disease type 4, 156
- D-PDMP, 709
- DrGRIFIN, 471
- Drosophila melanogaster*
chitin, 346
galectins, 471
glycoproteins, 336–343
mutations affecting glycans, 337, 338t–339t, 339, 340f
N-linked glycans, 336–340, 337f, 340f
O-linked glycans, 340–343, 341f
- glycosaminoglycans (GAGs), 343–344, 345f
glycosphingolipids, 347–348
glycosylation engineering, 716t, 723
glycosyltransferases of, 95
historical perspective, 335–336
lectins, 347–348
morphogen signaling and organ size control, 344
Notch signaling pathway, 153–156, 154f, 342–343, 343f, 348
nucleotide sugar transporters, 348
OGT, 246, 247
proteoglycans, 210, 213, 215
proteoglycans and glycosaminoglycans, 343–346
sialic acids, 185
- Drug efflux pumps, 280
- Drugs
glycan-based, 733t
small-molecule, 729, 730f, 731, 731f
- DsiaT* gene, 185
- DTD (diastrophic dystrophy), 580
- Duanomycin, 58
- Duanosamine, 58
- DXD motif, 70–71
- Dystroglycan, 157–158
- Dystroglycanopathies, 576–578
- E**
- EBA-175, 489–490, 542
- EBL (erythrocyte-binding-like) proteins, 541–542
- Ebola virus, 722, 751
- EBR1 protein, 352
- ECD (electron capture dissociation), 648
- Ecdysteroid UDP-glucosyltransferase (EGT), of baculovirus, 93
- Echinobase, 352
- Echinocandin drugs, 303–304
- Echinococcus granulosus*, 549
- Echinoderms, sialic acids in, 182, 185
- Ectodomain shedding, 606
- EDEM (endoplasmic reticulum degradation enhancing α -mannosidase-like protein), 104, 507–508
- EET (enzyme enhancement therapy), 566
- EF-P protein, 228
- EGF. *See* Epidermal growth factor
- Egg bindin receptor 1, 352
- Egghead* (*egh*) gene, 346
- Egg jelly, sea urchin, 352
- EGT (ecdysteroid UDP-glucosyltransferase), of baculovirus, 93
- Ehlers–Danlos syndrome, 579
- Eichwald, E., 113
- Electrochemical impedance spectroscopy (EIS), 751
- Electrolectin, 469
- Electron capture dissociation (ECD), 648
- Electron impact (EI)-mass spectrometry, 646

- Electron transfer dissociation (ETD), 648, 664–665, 664f
- Electrophoresis, for study of glycan–protein interactions, 384
- Electrospray ionization (ESI)-MS, 646, 648
- Electrospray ionization (ESI) MS/MS ion fragmentation, 658, 660–661
- Elf-1, O-GlcNAcylation of, 247
- ELISA (enzyme-linked immunosorbent assay), for study of glycan–protein interactions, 381–382
- Embryology and development, glycans in, 522
- Embryonic stem (ES) cells, glycosylation mutants, 631
- EMT (epithelial-mesenchymal transition), 604, 607
- Encephalitozoon cuniculi*, glycosyltransferases of, 94
- Endo180, 409
- Endo- β -glucuronidase, 220, 606
- Endo- β -galactosidases, 642t. *See also* β -galactosidase
- Endo- β -N-acetylglucosaminidase, N-glycan degradation, 555f
- Endo- β -N-acetylglucosaminidase H (endo H), 424
- Endo- β 1-4xylanase 10A, 405f, 407, 411
- Endocarditis, 585
- Endocrinology
diabetes mellitus, 585–586
glycans in, 523
- Endocytic receptors, as C-type lectins, 440–441, 440f
- Endocytosis, internalization of cell-surface proteoglycans, 220
- EndoD, 659
- Endoglucanases, 310
- Endoglycoceramidas, 129
- Endoglycosidase
endoglycosidase F, 101
endoglycosidase F2, 641, 642t
endoglycosidase H (Endo H), 101, 424, 641, 642t
glycan detection, 641, 643f
specificity and uses, 642t
- Endoglycosidase D (EndoD), 659
- Endoglycosidases, 48
- Endo-N, 185
- Endo-N-acetylglucosaminidase (EndoT), 724
- Endoneuraminidase, 87, 642t
- Endoplasmic reticulum (ER)
eOGT, 240
ER-associated degradation (ERAD), 232, 296, 364, 405, 406f, 504, 508, 510–511, 517, 581
glycan biosynthesis, 12, 13
glycoprotein quality control, 503–511, 506f, 509f
machinery and viability, 510–511
O-glycosylation, 509–510
retrotranslocation and degradation of misfolded proteins, 508
glycosphingolipid synthesis, 129
GPI anchor synthesis, 142–146, 143f, 144f
N-glycosylation and, 101–106, 103f, 105f
nucleotide sugar transport, 55–61, 59f, 60t
plant glycolipids, 316
- Endoplasmic reticulum degradation
enhancing α -mannosidase-like proteins (EDEM)s, 104, 507–508
- Endoplasmic reticulum Golgi intermediate compartment 53 (ERGIC53), 419–420, 507, 510
- Endoplasmic reticulum (ER)/Golgi pathway
glycosylation in, 42, 43f
lectins and, 364
- Endopolygalacturonases, 514–515
- Endosialidase, 185, 642t
- Endosome
glycosphingolipids and, 131
mannose-6-phosphate receptors (MPRs), 429
multivesicular storage bodies, 564
- Endosulfatase, 220
- EndoT, 724
- Endotoxin, 272, 519. *See also* Lipid A
- Energy, renewable, 762
- Energy plots, 651, 651f
- Entamoeba*, 489, 547, 548f
- Envelope conformation, 24f, 25
- Environmentally driven phenotypes, in mouse mutants, 359
- Enzymatic synthesis, technological advances in, 764
- Enzyme enhancement therapy (EET), 566
- Enzyme-linked immunosorbent assay (ELISA), for study of glycan–protein interactions, 381–382
- Enzyme replacement therapy (ERT), 566, 567, 722, 735
- Enzymes, glycan-degrading, 642t
- Enzyme substrates, docking of, 398–399, 399f
- EOGT* gene, 156
- E-phytohemagglutinin (E-PHA), 418, 612, 613f, 617–618
- Epidermal growth factor (EGF), 68–69, 509, 601
- Epidermal growth factor (EGF)-like repeats in Notch, 342
O-linked modifications in, 152–156
description, 152, 153f
O-fucose, 152–155
O-GlcNAc, 156
O-glucose, 155–156
- Epidermal growth factor (EGF) receptor activity modulation by gangliosides, 80
in membrane microdomains, 131
tumor progression and, 601
- Epidermal permeability barrier, 132
- Epigenetics, O-GlcNAc regulation of, 247
- 4epi-Leg (4eLeg), 180f, 181
- 8epi-Leg (8eLeg), 180f, 181
- Epimerase, 218–219
- Epimerization
in chondroitin sulfate biosynthesis, 218
in heparan sulfate biosynthesis, 217f
in heparin biosynthesis, 219–220
- Epimers, 21
- Episialin, 599
- Epithelial-mesenchymal transition (EMT), 604, 607
- Epitope. *See* Antibody
- EPN motif, 436
- Eprodisate, 733t
- Epstein–Barr virus, 437, 450, 589
- Equilibrium dialysis, for study of glycan–protein interactions, 376–377
- Equisetum*, 311
- ER. *See* Endoplasmic reticulum
- ER-associated degradation (ERAD), 232, 405, 406f, 504, 508, 510–511
defects in, 581
lectins and, 364
NGLY1, 517
in yeast, 296
- Erb2*, 604
- ERGIC53 (endoplasmic reticulum Golgi intermediate compartment 53), 419–420, 507, 510
- ER–Golgi intermediate compartment (ERGIC), 419–420
- ERT (enzyme replacement therapy), 566, 567
- Erythrocyte acetylcholinesterase, 137
- Erythrocyte-binding-like (EBL) proteins, 541–542
- Erythrocyte glucose transport protein, 165
- Erythropoietin, 194–195, 731–732
- Erythrose, structure of, 22f
- Escherichia coli*
adhesins, 169, 365
autoglycosylation, 224
capsular polysaccharides, 280
capsule of *E. coli* K1, 93
enteropathogenic (EPEC), 532
enterotoxin, 191
fimbriae, 485–486, 485f–486f
galectins and, 476, 478
ganglioside GM1 as receptor for heat-labile enterotoxin (LT-1), 174
glycosylation engineering, 717t, 719–720
heat-labile enterotoxins, 134
K1, 93, 528
K99, 486
lipid A, 274
lipopolysaccharide (LPS), 272–276, 273f
NeuO enzyme, 188
O antigens, 37–38, 37f, 274
O8, 37, 37f
O168, 37f, 38
O5ab and O5ac, 37
osmoregulated periplasmic glucans, 277–278
P fimbriae, 590
pili, 485, 485f, 531, 746, 751
polysialic acids, 185

- Escherichia coli* (Continued)
 strain detection and discrimination using
 glyconanomalies, 751
 urinary tract infections, 590
- E-selectin, 122, 133, 193, 371, 445f,
 448, 602
- inflammatory skin diseases, 585
- inhibitors, 739, 740f
- Esterases, lysosomal, 554
- Esterification of hydroxyl groups, 27–28
- Estrogen receptors, O-GlcNAcylation
 of, 247
- ETD (electron transfer dissociation), 648
- Ethanol, 756
- Ethanolamine phosphate transferase, 145t
- Ethanolamine phosphodiesterase, 146t
- Eubacteria. *See* Bacteria
- E3 ubiquitin ligases, 232
- Eukaryotes. *See also specific groups*
 ER–Golgi pathway of glycan biosynthesis,
 42, 43f
- genomics of glycosylation, 94–95
- N-glycan
 structural diversity, 256, 257f
 synthesis, 101–108
- sialidases, 188–189
- sialyltransferase, 188
- topology of glycosylation, 229, 230f
- Eukaryotic initiation factor 2 (eIF2), 248
- EUROCarbDB, 670, 674
- Evolution
 ABO blood group and, 167
- coevolution arms race between pathogens
 and hosts, 83
- deuterostome, 351–352
- galectins, 471–472
- glycan diversity, 253–264
 bacterial and archaeal glycosylation,
 260
- evolutionary forces driving diversity,
 263–264
- glycosaminoglycans, 259
- glycosphingolipids, 259
- interspecies and intraspecies,
 261–262
- model organisms for study of, 262
- N-glycans, 254, 256, 257f, 258
- nuclear and cytoplasmic, 259–260
- O-glycans, 258–259
- overview, 253–254, 255f
- sialic acids, 258
- terminal sequences, 256, 262
- glycosaminoglycans, 494
- of glycosylation, 16–17
 diversity and universality, 41–42
- “junk” glycans, 84
- glycosyltransferases, 263
- hyaluronan, 197–198
- lectins, 368–369
- mannose 6-phosphate recognition
 system, 431
- molecular mimicry of host glycans, 82,
 260–261
- Red Queen effect, 263, 461, 462f
- sialic acid evolutionary history, 179, 181
- distribution of sialic acids, 185
- human loss of Neu5Gc, 185–186
- variations in sialic acids, 258
- Siglec (sialic acid-binding,
 immunoglobulin-like lectin), 454,
 461, 462f
- sulfated GAG-binding proteins, 369
- viruses, glycosylation of, 260
- EW29 lectin, 407
- Exoglycosidase, 553–554, 555f, 559,
 561–562, 564. *See also specific*
 enzymes
 glycan detection, 641, 643f
- heparan sulfate degradation, 220
- O-glycans and, 116
- sequencing GPI glycans, 140
- specificity and uses, 642t
- Exoglycosidases, 48
- Exopolysaccharide (EPS), 36, 38, 266, 278,
 279f, 280, 533
- Exosomes, 149
- Exostosis, congenital, 359, 579
- Exotoxin A, 421
- Exotoxins, 421. *See also* Toxins
- EXT1, 216, 634
- EXT2, 216
- EXT1/EXT2 genes, 357, 579
- EXTL2, 67
- EXTL3, 69, 216
- Extracellular matrix (ECM)
 hyaluronan function in, 200–203, 202f
- proteoglycans in, 209f, 210, 211t–212t,
 213, 220
- Extracellular polysaccharide. *See*
 Exopolysaccharide (EPS)
- Extremophiles, 283
- Extrinsic recognition, 78, 78f, 81–82
- F**
- Fabry disease, 557t, 563, 566,
 567, 735
- FACE (fluorophore-assisted carbohydrate
 electrophoresis), 644–645
- Factor H, 192, 528, 601
- Factor IIa, 587
- Factor Xa, 587
- Fast atom bombardment (FAB)-MS, 646,
 648
- Fatty acid analogs, 710
- Favin, 417
- FCMD (Fukuyama muscular dystrophy),
 576, 578
- Fdl, 337, 723
- Fdl mutants, 337, 339, 340f
- Fermentation, 756
- Ferroplasma acidophilum*, 287
- Fertilization, glycan involvement in, 521
- FGFR (fibroblast growth factor receptor),
 499–500, 502, 518
- FGFs. *See* Fibroblast growth factors
- FHA (filamentous hemagglutinin), 531
- Fibrillin1 (FBN1), 575
- Fibrinogen, abnormal glycosylation of, 588
- Fibroblast growth factor receptor (FGFR),
 499–500, 502, 518
- Fibroblast growth factors (FGFs)
 fibroblast growth factor 2 (FGF2)
 binding, 499–500, 501f
- heparin interaction, 499–500, 501f
- structure, 501f
- used for selection of mutants deficient
 in heparan sulfate, 630
- fibroblast growth factor 23 (FGF23),
 defects in, 578
- fibroblast growth factor (FGF-1) β -trefoil
 R-type domain, 405f
- heparan sulfate binding, 217f, 219
- Fibromodulin, 211t
- Ficolins, 365
- Field-effect transistor (FET) sensors, 751
- Filamentous hemagglutinin (FHA), 531
- Fimbriae, 364, 485–486, 490, 531, 532f, 590
- FimH, 485–486, 486f, 490
- Fischer, Emil, 20, 294, 388
- Fischer projection
 conversion to chair projection, 24f
- conversion to Haworth projection, 23, 23f
- monosaccharide, 21, 22f
- FKRP (fukutin-related protein) genes,
 576–578
- FKTN (fukutin) gene, 576–578
- Flippase, 102, 289
- Flow cytometry, 621
- Fluorescence polarization, for study of
 glycan–protein interaction,
 379–381
- Fluorophore-assisted carbohydrate
 electrophoresis (FACE), 644–645
- Folding. *See* Protein folding
- Follicle-stimulating hormone (FSH),
 171–173
- Fondaparinux, 730f
- Fontan surgery, 586
- Foot-and-mouth disease virus (FMDV),
 binding to heparan sulfate, 483
- Forsman antigen, 130, 170f, 171
- Fourier transform mass spectrometry
 (FTMS), 648
- Free glycans, as signaling molecules,
 513–519
- Fringe, 89, 153f, 154–155, 155f, 342
- Fringe connection (*fric*), 348
- fringe* gene, 153, 342
- Frogs, 353–355, 354f
- Frontal affinity chromatography, 377–378,
 378f
- Fructoaldolase, 734
- Fructose-6-phosphate amidotransferase, 702
- Fructose transport, 52
- FSP (fucose sulfate polymer), from sea
 urchin egg jelly, 352
- F-spondin, 157
- FTMS (Fourier transform mass
 spectrometry), 648
- F-type lectins, 368, 369
- FUCA2, 537

- Fucoidans, 316
- Fucose, 28
activation of, 52t
in *Caenorhabditis elegans* N-glycans, 324, 324f
metabolism, overview, 56–57
structure of, 22f
transport, 53
- Fucose sulfate polymer (FSP), from sea urchin egg jelly, 352
- Fucosidase
defect in, 556t
N-glycan degradation, 555f
specificity and uses, 642t
- Fucosidosis, 556t
- Fucosylation
altered in cancer, 598, 599f
in arthropods, 336, 342
O-fucosylation
epidermal growth factor (EGF)-like repeats, 152–156
thrombospondin type-1 repeats (TSRs), 156–157, 156f
in *Schistosoma*, 549, 549f
- Fucosyltransferase, 226
 α -fucosyltransferase
 α 1-3/ α 1-4FucT, 167–168, 168f
 α 1-2 fucosyltransferase (α 1-2FucT), 164–168
 α 1-6 fucosyltransferase, arthropod, 336
Caenorhabditis elegans, 323, 324f, 328
- N-glycan modification, 110
- O-fucosyltransferase
epidermal growth factor (EGF), action on, 68, 69
knockout in mice, 357–358
thrombospondin repeats (TSR), action on, 68, 69
- plant, 314, 315f
- protein O-fucosyltransferases I and II
in *Caenorhabditis elegans*, 324–326, 328–329
mutants defective in, 635
POFUT1, 152, 154
POFUT2, 157
specificity, 66–67
- Fukutin (FKTN), 158
- Fukutin* gene, 152, 570t, 578
- Fukutin-related protein (FKRP), 158
- Fukuyama congenital muscular dystrophy, 157
- Fukuyama muscular dystrophy (FCMD), 576, 578
- Fullerenes, 745f, 748
- Functional groups
of monosaccharides, 27–28
protection of in chemical synthesis of glycans, 683
- Fungi, 293–304. *See also* Yeast; *specific species*
capsule biosynthesis in *Cryptococcus neoformans*, 302–303, 303f
cell wall, 294–295, 295f
diversity, 293–294
glycans as drug targets, 303–304
glycolipids, 298, 299, 301
glycosylation engineering, 733–734
harnessing yeast for production, 300–301
historical perspective, 294
as model systems, 294–300
overview, 294–295
pathogenic, 301–304
protein glycosylation, 295–298, 297f, 298f
- Furanose, 23–25, 23f, 39
- Furans, 757
- Furrowed (Fw) lectin, 348
- Fused lobes (fdl)* gene, 336, 337, 339, 340f
- FUT1, 164, 167
- FUT2, 164–167, 167–168
- FUT3, 167–168
- FUT7, 607
- FUT8, 598
- Future directions, 761–768
impact on science and society, 761–763
basic and applied research, 761–762
health and development, 762
industry and materials, 763
renewable energy, 762
major fundamental questions, 765–768
technological advances to elucidate structure/functions, 763–765
analytical methods, 763–764
chemical and enzymatic synthesis, 764
genomics and enzymology of glycans, 764
high-throughput analyses, 764–765
need for more facile methods, 765
- G**
- GAGs. *See* Glycosaminoglycans
- Galabiose, 486
- Galactitol, 575–576
- Galactokinase (GALK), defects in, 575, 575f
- Galactolipids, plant, 236, 316–317, 317f
- Galactose
activation of, 52t
metabolism, overview, 57
structure of, 22f
sulfation, 215–216
- Galactosemia, 575–576, 575f, 734–735
- Galactose-1-phosphate uridylyltransferase (GALT), 575–576, 575f, 734–735
- Galactose-6-sulfatase, degradation of keratan sulfate by, 561f, 562
- Galactosialidosis, 556t, 558
- Galactosidase
 α -galactosidase
deficiency, 557t
glycolipid degradation, 563, 563f
N-glycan degradation, 558
recombinant, 567
saposins and, 563
 β -galactosidase
deficiency, 556t, 557t
degradation of keratan sulfate, 561f
glycan detection, 641
glycolipid degradation, 563, 563f
N-glycan degradation, 555f, 558
saposins and, 563
specificity and uses, 642t
- Galactosylceramide (GalCer)
evolutionary variations in, 259
role in myelination, 132
structure, 125, 126f
synthesis, 129–130, 132
- Galactosyltransferase (GalT)
 α 1-4 galactosyltransferase (α 1-4GalT), 169
 α 1-3 galactosyltransferase (α 1-3GalT), 170–171, 170f
arthropod, 336
 β 1-3 galactosyltransferase (β 1-3GalT), 162f, 169f, 172–173, 172f, 175f
Caenorhabditis elegans, 323, 326
C1GALT1 (core-1 galactosyltransferase), 357
galactosyltransferase I, 579
galactosyltransferase II, 579
- Galactoxylomannan (GalXM), 303f
- Gal α 1-3Gal epitope, 170–171, 170f
- Galanthus nivalis* agglutinin, 747
- GalCer. *See* Galactosylceramide
- Galectin-related proteins (GRPs), 471
- Galectins, 236–237, 302, 363, 364, 368, 369, 469–479, 522
biosynthesis and export, 474f, 476
Caenorhabditis elegans, 331
functions, 476–479
in adipogenesis, 478
in apoptosis, 477
in cancer, 477
in development, 476–477
in immune responses and inflammation, 478–479
induction of cell surface phosphatidylserine exposure, 477
in infection, 478–479
in tissue regeneration, 476–477
glycan ligands, 474–476
historical background, 469–470
insect, 348
members of family, 470–471, 470f
sequence motifs, 92
structure, 415, 415f, 472–474, 473f, 474f
taxonomic distribution and evolution, 471–472
- Gal/GalNAc receptor. *See* Asialoglycoprotein receptor
- GALK (galactokinase), defects in, 575, 575f
- GalNAc. *See* N-acetylgalactosamine
- GalNAc β 1-4GlcNAc, 163
- GalNAcT. *See* N-acetylgalactosaminyltransferase
- GALNT7, 607
- GALNT3* gene, 578
- Gal 6-O-sulfotransferases, 216
- Galsulfase, 733t
- GALT (galactose-1-phosphate uridylyltransferase), 575–576, 575f, 734–735

- Gangliosides, 525
 antibodies against, 134, 592
 bacterial toxins and, 134
 in cancer, 601, 601f
 cancer and, 135
 classification and nomenclature, 127, 128f
 discovery, 126
 evolutionary variations in, 259
 GM1, 133, 134, 174, 487, 488f, 586
 GM2, 130, 133–135, 173–174, 173f, 564, 566, 607, 738
 GM3, 130, 133–134, 359, 581, 603
 GM1 gangliosidosis, 556t, 557, 566t
 GM2 gangliosidosis, 556t, 564, 566
 GT1b, 126f
 immunogens present on cancer cells, 738
 myelin-associated glycoprotein (MAG)
 binding to, 460–461
 regulation by, 133
 structure, 11
 synthesis, 132
- Gangliosidosis, 56t, 556, 564, 566
- Gas chromatography, 645
- Gas gangrene, 590
- Gastroenterology, 586
 glycans in, 523–524
 infections, 586
 protein-losing enteropathy, 586
 ulcerative colitis, 586
- Gaucher's disease, 126, 132, 134, 557t, 563, 566, 567, 709, 735
- GBGT1, 171
- GBPs. *See* Glycan-binding proteins
- GD1, 607
- GD2, 603, 608, 739
- GD3, 603
- GDP-Fucose transporter, 574
- GDP-Fuc pyrophosphorylase, 574
- Gellan, 38
- Gemtuzumab, 462
- Gene editing, 718, 719f, 727
- Gene knockouts, in mice, 357–359, 358f
- Gene therapy, 566
- Genetic disorders
 of glycan degradation, 553–567
 blocking, 565–566
 glycoproteins, 556–559, 556t
 glycosaminoglycan, 557t, 559–562
 glycosphingoglycan, 557t, 562–564, 563f
 monosaccharide salvage, 565
 recycling, 564–565
 therapy for lysosomal enzyme deficiencies, 566–567
 of glycosylation, 569–581
 galactosemia, 575–576, 575f
 glycosphingolipid synthesis defects, 581
 glycosylphosphatidylinositol anchors (GPI anchors), 580
 muscular dystrophies, 576–578, 577f
 N-glycan biosynthesis defects, 570–575, 571t, 573f
 O-glycans synthesis defects, 571t, 578
 overview, 569–570, 570f, 571t
 phenotypic expression and genetic background, 581
 proteoglycan synthesis defects, 579–580
- Genomics
 of glycans, technological advances in, 764
 historical perspective on, 653–654
 relationship of glycome to genome and proteome, 654–655
- Genomics of glycosylation, 89–97
 gene families
 glycan-binding proteins, 91–92
 glycoside hydrolase, 91
 glycosyltransferase, 91
 organisms
 Archaea, 93–94
 bacteria, 93
 eukaryotes, 94–95
 invertebrates, 95
 plants, 94
 vertebrates, 94–95
 viruses, 92–93
 overview, 90
 relationship to glycomics, 96–97
- Gentiobiose, structure of, 28, 28f
- Geodia cydonium* galectins, 471
- GFAT (glucosamine:fructose aminotransferase) pathway, 249, 586
- Giardia lamblia*, 550
- Gibberellic acid signaling, in *Arabidopsis*, 245
- Gingivitis, 584
- GIPLs. *See* Glycosylinositolphospholipids
- GlcA. *See* Glucuronic acid
- GlcCer. *See* Glucosylceramide
- GlcN. *See* Glucosamine
- GlcNAc. *See* N-acetylglucosamine
- GlcNAc 6-O-sulfotransferases, 216
- GlcNAc phosphodiester glycosidase, 427
- GlcNAc-1-phosphotransferase, 69, 102, 357, 425–427, 426f
- GlcNAc phosphotransferase (GPT), 703
- GlcNAc-PI de-N-acetylase, 145t
- GlcNAcstatin, 706, 706f
- GlcNAcT. *See*
 N-acetylglucosaminyltransferase (GlcNAcT)
- GlcNAc transferase. *See*
 N-acetylglucosaminyltransferase (GlcNAcT)
- Gliolectin, 348
- Globo-H, 607, 730f, 739
- Globopentylceramide, 170f, 171
- Globoside, 170f, 171
- Glucans
 bacterial osmoregulated periplasmic, 277–278
 mixed-linkage, 311
- Glucaric acid, structure of, 26f
- Glucocerebrosidase, 567, 722
 glycolipid degradation, 562
 treatment, 735
- Glucocerebrosidase deficiency, 709, 735
- Glucosaminidase, 706
- Glucosylceramide, 306f, 310
- Glucuronic acid, structure of, 26f
- Gluconolactone, structure of, 26f
- Glucopyranose, 32
- Glucosamine, 249
 conformation, 496f
 formation of, 57
 for osteoarthritis, 737
 sulfation in heparan sulfate, 35
- Glucosamine:fructose aminotransferase (GFAT) pathway, 245, 586
- Glucose
 activation of, 52t
 cyclization, 23f
 in glycogen, 34
 metabolism, overview, 53–54
 open-chain and ring forms, 5f
 oxidation, 25–26, 26f
 structure, 21f–25f
 transporters, 52–53, 244f
- Glucose toxicity, O-GlcNAc and, 249
- Glucose transporter (GLUT), 52–53, 244f
- Glucosidase
 α-glucosidase
 α-glucosidase I, 295, 504, 504f, 506f
 α-glucosidase II, 295, 323, 324f, 504–505, 504f, 506f, 507
 Caenorhabditis elegans, 323, 324f
 recombinant, 567
 Humicola insolens Cel7B endoglucosidase, 696, 696f
 inhibition of, 104, 548, 706, 707t
 in N-glycan synthesis, 104, 105f
- Glucosinolates, 317
- Glucosylceramide (GlcCer), 126–127
 accumulation in storage disease, 134
 defects in synthesis, 132
 discovery, 126
 evolutionary variations in, 259
 hydrolysis of, 692, 692f
 skin barrier function and, 524
 synthesis, 129–130, 691–692, 692f
- Glucosylceramide synthase
 inhibition of, 566
 mechanism, 691–692, 692f
- Glucosyltransferase
 bacterial, 278
 defects in, 151
 O-glucosyltransferase, 156, 342
 UDP-Glc:glycoprotein glucosyltransferase (UGGT), 418
- Glucuronic acid (GlcA)
 activation of, 52t
 conformation, 496f
 in hyaluronan, 198f
 metabolism, overview, 54
 structure, 21, 26f
 transport, 53
- Glucuronoarabinoxylan, 311
- Glucuronolactone, structure of, 26f
- Glucuronosyltransferases, 176f

- Glucuronoxylan, 306f, 310, 313
Glucuronoxylomannanogalactan, 303, 303f
Glucuronoxylomannans, 303, 303f
GLUT (glucose transporter), 52–53, 244f, 523
Glutaminylglycan, 286
GLYCAM package, 651
GLYCAM-Web, 398, 675
Glycan(s)
 biological roles of, 2, 16, 77–88
 biosynthesis, 13
 location of, 42–44, 43f
 in biotechnology and pharmaceutical industry, 729–730
 Caenorhabditis elegans, 323–324, 324f, 325f
 N-glycans, 323, 324f
 O-glycans, 323–324, 325f
 characterization of N- and O-glycans released from proteins, 657–663
 chemical synthesis, 681–689
 chemoenzymatic synthesis, 691–698
 classes, 8, 10–12, 10f, 658
 conjugated, 31
 as “dark matter” of the biological universe, 2
 degradation, 13, 553–567
 blocking, 565–566
 glycoproteins, 556–559, 556t
 glycosaminoglycan, 557t, 559–562
 glycosphingoglycan, 557t, 562–564, 563f
 monosaccharide salvage, 565
 recycling, 564–565
 therapy for lysosomal enzyme deficiencies, 566–567
 diversity of, 8, 12
 evolution of diversity, 253–264
 genomics and enzymology of, 764
 junk, 84
 major fundamental questions for the future, 765–768
 in medicine and biotechnology, 17
 microarray, 14
 microheterogeneity of structure, 83
 modifications of, 73–74
 monosaccharides as basic structural unit of, 3, 5–6
 in nanotechnology, bioenergy, and materials science, 17
 nonreducing end, 6
 O-fucose, 152–155
 O-GlcNAc, 156
 O-mannose, 157–158, 158f
 pathogen, molecular mimicry of host glycans by, 260–261
 phosphorylated, 178
 recycling of, 48
 reducing end, 5
 release from glycoconjugate, 644
 as secondary gene products, 12
 structural analysis of, 639–652
 symbols and conventions for drawing, 8, 9f
 in systemic physiology, 521–525
 term defined, 2
 terminology, 19–20
 turnover, 13, 48
Glycan array, 92, 382, 383f, 618–619, 618f
Glycan-binding proteins (GBPs). *See also* Glycosaminoglycan (GAG)-binding proteins
 animal, 362–363, 365, 367f
 bacterial, 281, 363–365, 367f
 biological functions, 363–365
 cell adhesion, 364–365
 immunity and infection, 365
 trafficking, targeting, and clearance of proteins, 363–364
 Caenorhabditis elegans, 331–332
 classes of, 361–362, 362f
 C-type lectins, 435–450
 extrinsic, 78, 78f
 finding natural ligands for, 86
 gene families, 91–92
 genomics, 90
 identifying by biochemical function and structural similarity, 369
 interference by soluble glycans or structural mimics, 86–87
 intrinsic, 78, 78f
 isolating glycosylation defects using, 630
 I-type lectins, 453–466
 lectin discovery and history, 362–363
 methods of finding, 86
 microbial lectins, 487–490
 multivalency, 366, 370, 370f
 overview, 361–371
 parasites and, 550
 plant, 362, 367f, 368
 principles of glycan recognition, 373–384
 R-type lectins, 401–411
 software tools for data interpretation, 675
 sulfated glycosaminoglycan-binding proteins, 361–363, 369
 terminology, 371
 viral, 363, 365, 367f
GlycanBuilder, 674
Glycan extensions, regulated glycosylation of, 161–163
 I and i blood groups, 163, 164f
 poly-N-acetylglucosamines (poly-LacNAc), 163, 164f
 type-1 glycan units, 162f, 163
 type-2 glycan units (LacNAc), 162–163, 162f
Glycan foraging, 523
Glycan libraries, 14
Glycan Miner Tool, 674
Glycan Pathway Predictor (GPP) tool, 672
Glycan–protein interactions
 techniques to study, 376–384
 affinity chromatography, 377–378, 378f
 agglutination, 383
 atomic force microscopy, 381
 cDNA expression, 384
 electrophoresis, 384
 enzyme-linked immunosorbent assay (ELISA), 381–382
 equilibrium dialysis, 376–377
 fluorescence polarization, 379–381
 glycan microarrays, 382, 383f
 isothermal titration calorimetry, 378, 379f
 kinetics and near-equilibrium methods, 376–381
 mass spectroscopy, 381
 nonequilibrium methods, 381–384
 nuclear magnetic resonance (NMR) spectroscopy, 381
 precipitation, 383–384
 surface plasmon resonance, 378–379, 380f
 thermodynamics, 375, 375f
 valency of interactions, 374–375, 374f
Glycan–protein linkages, 10, 11f
Glycan recognition
 antibody, lectin, and CBM uses in, 616–619
 blocking, 739
 structural biology of, 387–399
 computational modeling, 394–399
 crystallography, 388–391
 future prospects, 399
 nuclear magnetic resonance, 391–394
 overview, 387–388
 techniques to study, 376–384
 affinity chromatography, 377–378, 378f
 agglutination, 383
 atomic force microscopy, 381
 cDNA expression, 384
 electrophoresis, 384
 enzyme-linked immunosorbent assay (ELISA), 381–382
 equilibrium dialysis, 376–377
 fluorescence polarization, 379–381
 glycan microarrays, 382, 383f
 isothermal titration calorimetry, 378, 379f
 kinetics and near-equilibrium methods, 376–381
 mass spectroscopy, 381
 nonequilibrium methods, 381–384
 nuclear magnetic resonance (NMR) spectroscopy, 381
 precipitation, 383–384
 surface plasmon resonance, 378–379, 380f
 thermodynamics, 375, 375f
 valency of interactions, 374–375, 374f
Glycan-recognizing probes, 84–85, 611–623, 657
 animal cell glycosylation mutant generation, 622
 background, 611–612
 cell-surface glycoconjugates, characterization of, 621–622
 cloning glycosyltransferase genes by expression, 622–623
 glycan purification, 619–621, 620f

- Glycan-recognizing probes (*Continued*)
glycan recognition, 616–619
lectins commonly used in glycan analysis, 612–613, 612f–615f
monoclonal antibody generation, 613–616
- Glycaric acid, 26, 26f
- Glycation, 26
- Glyceraldehyde, 20, 20f, 22f
- Glycerol, as cryoprotectant in crystallography, 389
- Glyco (Glycomics Ontology), 673, 677
- GlycoBase, 675
- Glycobiology
defined, 1
evolutionary considerations in, 16–17
general principles of, 4t–5t
genomic view of, 89–97
historical background, 2–3, 3f
- Glycocalyx, 6, 7, 7f, 79, 251
- Glycoconjugate(s)
biosynthesis, 13
chemical synthesis, 681–689
chemoenzymatic synthesis, 691–698
classes, 8, 10–12, 10f
cytoplasmic, 229–233
defined, 5, 20
glycan release from, 644
monosaccharides as common units, 8
plant, 317
turnover, 48
- Glyco3D, 389, 675
- GlycoDelete, 724
- Glycodendrimers, 745f, 751
- Glycoengineering. *See* Glycosylation engineering
- Glycoform, 12, 109
- Glycogen, 34, 53, 80, 224
- Glycogenin, 53, 224, 228
- Glycogen synthase, 224
- Glycogimmickry, 82
- Glycoglycerol lipids, 316
- Glycoinformatics, 667–678. *See also* Informatics
- Glycoinositol phospholipids (GIPLs), 139–140
- Glycolipid
ABO blood group determinants on, 165, 165f
Caenorhabditis elegans, 330–331, 331f
characterization by mass spectrometry, 658
degradation, 562–564, 563f
activator proteins, 563
defects in, 557t
recycling, 565
specialized issues, 562–563
topology for degradation, 564
detection, 641
fungal, 298, 299, 301
glycan-binding proteins (GBPs), 370
glycosylation of extensions, 162f
inhibitors, 709–710, 709f
mutants in synthesis, 634–635
plant, 316–317, 317f
structure, 11
- Glycome, 14–15, 89–90, 96–97
future questions concerning, 767
relationship to the genome and proteome, 654–655
tool for characterizing, 656–657
- GlycomeDB, 670, 672
- Glycome Informatics Consortium (GLIC), 678
- Glycomics, 96–97, 653–665. *See also* Informatics
characterization of N- and O-glycans released from proteins, 657–663
comparative, 655
critical role in systems biology, 668f
described, 653, 654
future of glycomics analyses, 662–663
historical perspective, 653–654
Minimum Information Required for A Glycomics Experiment (MIRAGE) initiative, 669
overview, 14–15
relationship of glycome to genome and proteome, 654–655
tool for characterizing the glycome, 656–657
workflow analysis for a purified glycoprotein, 656f
workflow analysis of glycosylation of a complex mixture of proteins, 657f
- Glycomics Ontology (Glyco), 673, 677
- Glycomimetics, 739, 740f
- GlycoMod, 673
- Glyconanomaterials, 17, 743–752
carbon-based nanoparticles, 748–750
in diagnosis and therapy, 751
glycodendrimers, 745f, 751
inorganic nanoparticles, 744–747
overview, 743–744
polysaccharide-based nanoparticles, 750
types and applications, 744
- Glycone, 5, 29
- Glyconic acid, 26, 26f
- Glyconutrients, 737–738
- GlycoPattern, 675
- Glycopeptidase A, 642t
- Glycopeptidase F, 642t
- Glycopeptide. *See* Glycoprotein
- Glycophorin A, erythrocyte, 542
- Glycoprofiling, 658
- Glycoprotein
ABO blood group determinants on, 165, 165f
Caenorhabditis elegans, 326–329
cytoplasmic, 229–233
degradation, 556–559
of complex N-glycans, 555f, 558
defects in, 556t
of O-glycans, 559
of oligomannosyl N-glycans, 558
recycling, 564–565
detection of, 641–643
engineering recombinant, 733–734
glycosylation engineering, 733–734
major fundamental questions for the future, 766
microheterogeneity of, 12, 15
plant, 313–316
S-layer, 284, 287, 289–291
structure, 10, 10f
therapeutic uses, 731–732, 733f
- Glycoproteomics, 15, 653–665, 674
described, 653, 654
determining heterogeneous site glycosylation, 664–665
historical perspective, 653–654
limitations and prospects of, 665
relationship of glycome to genome and proteome, 654–655
target-driven, 663–665
tool for characterizing the glycome, 656–657
workflow analysis for a purified glycoprotein, 656f
workflow analysis of glycosylation of a complex mixture of proteins, 657f
- GlycoRDE, 673, 677
- Glycosaminoglycan (GAG)-binding proteins, 493–502
antithrombin, 498–499, 498f
attributes of, 500–502
conformation, 495–497, 496f
examples, 494t
fibroblast growth factor 2 (FGF2), 499–500, 501f
methods for measuring binding, 494–495, 495t
overview, 493–494
specificity, 497–498
sulfated, 361–363, 369
- Glycosaminoglycan lyases
glycan detection and, 641
specificity and uses, 642t
- Glycosaminoglycans (GAGs)
abundance in nature, 254
atherosclerosis, role in, 584
biosynthesis, 216–219
Caenorhabditis elegans, 329–330, 330f
cardiovascular physiology, role in, 522–523
cell signaling and, 518–519, 518f
cellular regulation of structures, 36
characterization by mass spectrometry, 658
composition, 208, 210f
convergent evolution, 494
degradation, 557t, 559–562
description, 34
development, role in, 522
diversity, 34, 208–213, 210f
drugs targeting, 733t
in ER–Golgi pathway, 43f
evolutionary variations in, 259
historical perspectives, 207
information content, 767
insect, 343–344, 345f
linkages to proteins, 213–216

- metabolic labeling, 640
 - mutants in biosynthesis, 634, 634t
 - nucleocytoplasmic, 234–235
 - protective function of GAG chains, 80
 - purification and analysis, 208
 - regulation of assembly, 219
 - roles in systemic physiology, 522–525
 - structure, 10, 11
 - structure–function relationships of
 - animal, 34–36
 - sulfated, 207–220
 - changes in cancer, 606
 - proteins that bind to, 213, 493–502
 - sulfotransferase role in production of, 73
 - therapeutic uses, 736
 - Glycoscience
 - future directions of, 761–768
 - impact on science and society, 761–763
 - major fundamental questions, 765–768
 - technological advances to elucidate structure/functions, 763–765
 - glycosylation engineering in, 726–727
 - Glycosciences.de portal, 674
 - Glycosidase, 12. *See also* Endoglycosidase; Exoglycosidase
 - eliminating specific glycan structures by, 87
 - inverting, 692
 - lysosomal, 554, 555f, 559
 - mechanism, 691–692
 - mutations and storage diseases, 134
 - retaining, 692
 - roles of, 66, 73
 - for structural analysis, 641, 643f
 - structural diversity, 73
 - Glycoside hydrolase
 - classification, 91
 - gene families, 91
 - genomics, 90–91
 - modular, 95–96
 - Glycoside primers, 708–709, 708t
 - Glycosidic linkage
 - α (1-4)-linkage, 34
 - α (1-6)-linkage, 34
 - bacterial polysaccharides, 38–39
 - β 1-4, chemical resistance of, 254
 - cis*, 683
 - C-mannosylation and, 159
 - flexibility of, 29
 - formation, 27, 27f
 - in glycogen, 34
 - oligosaccharide branching and, 32
 - overview, 3–5, 28–30
 - peptide bond analogy, 28
 - stereoselective formation, 682–683, 682f
 - torsion angles, 29, 30f, 33, 33f, 38–39
 - trans*, 683
 - Glycosignaling domains, 131
 - Glycosphingolipid, 125–135. *See also* Glycolipid
 - altered expression in cancer, 603
 - breakdown, 131
 - Caenorhabditis elegans*, 323, 331f
 - classes and nomenclature, 126–127, 127f
 - degradation, 562–564, 563f
 - activator proteins, 562, 563–564
 - recycling, 565
 - specialized issues, 562–563
 - topology for degradation, 564
 - description, 125
 - discovery, 125–126
 - disease, 134–135
 - autoimmune diseases, 134
 - bacterial toxins and, 134
 - cancer, 135
 - lysosomal storage diseases, 131, 134
 - microbial adhesins and, 135
 - drugs targeting, 733t
 - in ER–Golgi pathway, 43f
 - evolutionary variations in, 258
 - functions, 131–135
 - cell–cell recognition, 132
 - enriched membrane microdomains, 131
 - epidermal permeability barrier, 132
 - inflammation, 133
 - myelination, 132, 133
 - physiological, 132–133
 - regulatory, 133
 - inhibitors, 709–710, 709f
 - insect, 346–347, 347f
 - isolation, purification, and analysis, 129
 - skin barrier function and, 524
 - storage diseases, 134
 - structure, 10f, 11, 126f
 - synthesis, 129–131
 - brain glycosphingolipids, 128f, 130
 - defects in, 581
- GlycoSuiteDB, 670, 672
- Glycosylasparaginase, 558
- Glycosylation. *See also* Glycosyl transferase
- bacteria, 276–277
 - biological consequences of altering, 79
 - cell biology of, 13
 - cellular organization of, 41–48
 - ER–Golgi pathway, 42, 43f
 - in eubacteria and Archaea, 44
 - nuclear and cytoplasmic, 43
 - plasma membrane, 43–44
 - changes in cancer, 597–608
 - changes in development, differentiation, and malignancy, 16
 - chemical tools for inhibiting, 701–712
 - congenital disorders of glycosylation type II, 47
 - defects in, 15–16
 - determining heterogeneous site glycosylation, 664–665
 - discovery of novel types of, 151–152
 - of DNA, 9
 - donors for, 42
 - in eukaryotic secretion pathway, 44–48
 - evolution of, 16–17
 - excessive, 575
 - genetic disorders of, 87–88, 569–581, 762
 - genomics of, 90–97
 - impact on licensing, patentability, and serum half-life of therapeutic glycoproteins, 732, 734
 - inhibitors, 85–86, 565
 - interspecies and intraspecies differences in, 83, 261–262
 - major fundamental questions for the future, 768
 - microheterogeneity, 12, 15
 - modulatory role of, 80
 - mutants of cultured cells, 627–636
 - nucleocytoplasmic, 223–237
 - bacterial glycosyltransferase toxins, 228–229
 - DNA, 9
 - evolutionary variations in glycans, 259–260
 - examples, 225t
 - glycogenin, 224
 - hydroxyproline-linked Skp1 glycans, 224, 226, 227f, 228
 - mitochondria and chloroplasts, 235–236
 - prokaryotic monoglycosylation, 228
 - widespread nature of, 229–235
 - O-fucose, 152–157, 152t, 153f–155f
 - O-glycans in collagens, 159
 - precursors, 51–62
 - activated sugar donors, 51–52, 51f, 52t, 56f
 - control of, 61
 - donors for glycan modifications, 61–62, 62t
 - lipid carrier synthesis, 62
 - nucleotide sugar transport, 58–61, 59f, 60t
 - sources of intracellular monosaccharides, 53–58, 54f–56f
 - sugar transport, 52–53
 - reglycosylation of glycoproteins, 564–565
 - regulation of glycan extensions, 161–163
 - I and i blood groups, 163, 164f
 - poly-N-acetylglucosamines (poly-LacNAc), 163, 164f
 - type-1 glycan units, 162f, 163
 - type-2 glycan units (LacNAc), 162–163, 162f
 - species-specific features, overview of, 714f
 - tools used to study, 14
 - transglycosylation, 695–698
 - universality of, 41–42
- Glycosylation engineering
- in bacteria, 717t, 719–720
 - enabled by knowledge of pathways, 715
 - examples of major achievements, 716t–717t
 - future perspectives, 727–728
 - glycoproteins, 733–734
 - in glycoscience, 726–727
 - goals, 713–715
 - in/out strategies, 718–719, 719f
 - knockdown, 718

- Glycosylation engineering (*Continued*)
 knockout and knockin by genome editing, 718
 overexpression, 718
 in insect cells, 716t, 723
 in mammalian cells, 716t, 724–726
 in plant cells, 717t, 722–723
 in yeast, 716t–717t, 721–722
- Glycosylation-modified phenotypes, 16
- Glycosylation motifs, 68t
- Glycosylceramides, in fungi, 298
- Glycosyl donors, 51–52, 51f, 52t, 61, 62t
- Glycosylinositolphospholipids (GIPLs)
 Leishmania, 547
 Trypanosoma cruzi, 544, 545f
- Glycosylphosphatidylinositol anchor (GPI anchor), 126, 137–150
 biological functions, 148–149
 biosynthesis and trafficking, 143f–144f, 145t–146t, 147f, 588
 chemistry of, 140–142, 141f
 defects, 580
 description, 137
 discovery, 137–138
 disease and, 149–150
 diversity of, 138
 in ER–Golgi pathway, 42, 43f
 GPI-anchored proteins
 Caenorhabditis elegans, 323, 330
 detection of, 643
 Entamoeba, 547
 identification of, 140
 Leishmania, 547
 in membrane lipid rafts, 131
 myelin-associated glycoprotein (MAG) binding to, 460
 inhibition of, 709–710
 knockout in mice, 358
 loss of expression in cancer, 603–604
 membrane proteins, 146–148
 mutants in biosynthesis, 633
 non-protein-linked, 139–140
 plant, 314
 proteoglycans and, 209f, 213
 structure, 6f, 10, 10f, 138–140, 139f
 as tools in cell biology, 148
 in trypanosomes, 543–544, 544f
 yeast, 297–302, 299f
- Glycosylphosphatidylinositols (GPIs), malaria pathogenesis and, 542
- Glycosyltransferase, 12
 A/B, 164
 Arabidopsis, 94
 archaeal, 289–291
 bacterial, 269, 277
 bacteriophage-encoded, 229
 baculovirus, 93, 260
 Caenorhabditis elegans, 325–326
 catalytic mechanisms, 71–73, 72f
 chemoenzymatic synthesis of glycans, 692–694, 693f–695f
 classification, 91
 cloning glycosyltransferase genes by expression, 622–623
 computational modeling, 398–399, 399f
 Dictyostelium, 226
 distribution of, 13
 donors, 42, 65
 double displacement mechanism of, 71
 Drosophila melanogaster, 95
 Encephalitozoon cuniculi, 94
 evolution, 263
 fold types, 70
 Fringe, 89
 gene families, 91
 general properties, 65–66
 genomics, 90
 glycoengineering and, 722–723, 725
 in glycosphingolipid synthesis, 130
 Golgi, 232
 human chorionic gonadotropin, action on, 68–69, 69f
 humans, 94, 95
 inhibitors, 707, 707t
 invertebrates, 95
 inverting, 70–71, 72f
 kinetic mechanisms, 73
 knockout in mice, 358
 with limited intrinsic functions, 263
 localization of, 42, 44, 45–48
 mechanism, 691–692
 Methanococcoides burtonii, 93
 Methanosarcina voltae, 94
 Methanosphaera stadtmanae, 93
 modular, 95, 96f
 multiglycosyl transferase complexes, 130
 mutations, 631, 633, 635
 Nanoarchaeum equitans, 94
 in N-glycan synthesis, 109
 nucleocytoplasmic, 229–230, 230f, 233–234
 O-glycans and, 118, 118t, 120
 Ostreococcus tauri, 94
 peptidoglycan, 70
 plant, 307, 313, 318
 Plasmodium falciparum, 94
 poplar, 94
 protein/glycoprotein acceptors, 67–69
 relationship of glycome to genome and proteome, 654–655
 rice, 94
 schistosome, 550
 sequence families, 69–70, 70f
 SN2 reaction mechanism, 71, 72f
 specificity, 66–67, 66f, 68t
 ST6Gal1, 398–399, 399f
 topology, 44–45, 46f
 toxins, 228–229
 UDP-Glc:glycoprotein glycosyltransferase (UGGT), 504–507, 506f
 UGGT, 504–507, 506f
 vertebrate, 94
 viral, 260
- Glycosyltransferase genes
 Caenorhabditis elegans, 325–326
 mimivirus, 93
 nematodes, 325–326
- Glycosynapse, 131
- Glycosynthases and chemoenzymatic synthesis of glycans, 695–698, 696f–697f
- Glycotransferase, glycosylation engineering and, 715, 718, 719f, 720
- GlycoWorkbench, 674
- Glycuronic acid, 25–26, 26f
- Glypican
 family, 209f, 212t, 213
 insect, 343, 344
 nuclear accumulation, 235
- GlyTouCan, 672, 673, 674
- GlyVicinity, 676
- GM1, 133, 134, 174, 487, 488f, 586
- GM2, 130, 133–135, 173–174, 173f, 564, 566, 607, 738
- GM3, 130, 133–134, 359, 581, 603
- GM2 activator protein, 564
- GM1 gangliosidosis, 556t, 557t
- GM2 gangliosidosis, 556t
- GM2/GD2 synthase, 133
- GMI-1070, 447, 587
- GNE (UDP-GlcNAc epimerase/N-acetylmannosamine kinase), 734
- GNE gene, 186, 188
- GNE myopathy, 571t, 578
- Goblet cells, 115
- Gold nanoparticles, 744–746, 745f, 746f
- Golgi apparatus
 enzymes
 localization of glycosyltransferases, 44, 45–48, 46f
 topology, 44–45, 46f
 ER–Golgi pathway of glycan biosynthesis, 42, 43f
 glycan biosynthesis, 12, 13
 glycoprotein quality control, 503, 505, 506f, 507
 glycosphingolipid recycling, 565
 glycosphingolipid synthesis, 129
 glycosyltransferase, 232
 GPI-anchored proteins and, 143f, 144, 146
 lysosomal enzyme processing, 425–427, 426f, 429, 430f
 N-glycan processing, 101, 104, 105f, 106–109
 nucleotide sugar transport, 58–61, 59f, 60t
 O-GalNAc glycans and, 117–118
 O-mannose glycans, 157–158, 158f
 plant glycoproteins, 314
 reglycosylation and recycling of glycoproteins, 565
 sialoglycan synthesis, 188
- Gottschalk, Alfred, 481
- GPI anchor. *See*
 Glycosylphosphatidylinositol anchor (GPI anchor)
- GPI-anchored proteins
 Caenorhabditis elegans, 323, 330
 Entamoeba, 547
 inhibition of GPI anchors, 709–710

- Leishmania*, 547
in membrane lipid rafts, 131
myelin-associated glycoprotein (MAG)
binding to, 460
- GPI phospholipase D (GPI-PLD), 140
GPIs (glycosylphosphatidylinositols),
malaria pathogenesis and, 542
GPI transamidase, 144, 145t, 147f, 297
GPP tool (Glycan Pathway Predictor tool),
672
- G proteins, Rho family of, 228
GPT (GlcNAc phosphotransferase), 703
Gram-negative bacteria, 266, 267f, 269,
272–276, 273f, 275f, 279f, 280,
529–530, 532
Gram-positive bacteria, 266, 267f, 268–270,
271f, 280
Gram staining, 266
Graphene, 745f, 750
Griffith, Frederick, 529
GRIFIN protein, 471
GRITS toolbox, 674
GROMOS, 395
Group A streptococcus (GAS), 528–529
Group B streptococcus (GBS), 458, 463,
528–529
Growth factor receptors, glycosylation
of, 80
GRPs (galectin-related proteins), 471
GSI-B4, 614f, 622, 623
GT1b ganglioside, 126f
Guillain-Barré syndrome, 134, 171, 531, 592
Gulose, structure of, 22f
Gut microbiota, glycan-based interactions
between host and, 531–533
GXYLT genes, 156
- ## H
- HADDOCK, 396
Haemonchus contortus, 332, 549, 549f
Haemophilus influenzae
capsule, 39, 528–529
Siglec binding and, 463
type b (Hib), 738
Halobacterium salinarum, 284, 287, 289
Halococcus morrhuae, 286
Haloferax volcanii, 289–291, 289f
Halogenation, of glycans, 74
Halomucin, 286
Halophiles, 289–290
Haloquadratum walsbyi, 286
Hanganutziu-Deicher antibodies, 601
H antigen, 164–167, 165f–166f
HAPLN (hyaluronan and proteoglycan link
proteins) subfamily, 201,
201f, 203
HARE (hyaluronan receptor for
endocytosis), 200, 203
Has gene family, 198–200
Haworth, Walter Norman, 294
Haworth projections, 23–25, 23f–24f
HCD (higher-energy collision dissociation),
664–665, 664f
- HCELL (hematopoietic cell E/L-selectin
ligand), 446, 448, 449
Health, future impact of glycosciences on
study, 762
Heat-shock proteins
chaperones, 503–504
O-GlcNAcylation of, 245, 250
Hedgehog, 344
Helicobacter pylori, 191, 524, 537
binding of Lewis type glycans, 586
Lewis blood group and, 169
O antigens, 37f, 38
pathogenesis and ABO blood group, 167
Helix pomatia agglutinin (HPA), 612, 615f
Helminths. *See* Parasitic infections
Hemagglutinin, 82, 189–191, 192t
discovery, 481
filamentous hemagglutinin (FHA), 531
glycan-binding proteins (GBPs), 363, 365
influenza virus, 363, 481, 482–483, 483t,
484f, 490, 534–535, 534f
phytohemagglutinin, 362
recognition of glycans, 590
recognition of sialic acid, 174
specificity, 482
structure, 481, 482–483, 484f
Hematology, 587–589
anticoagulants, 587
cold agglutinin disease, 589
glycans in, 522
paroxysmal cold hemoglobinuria, 588
paroxysmal nocturnal hemoglobinuria,
588
plasma fibrinogen, abnormal
glycosylation, 588
Tn polyagglutinability syndrome, 589
transfusion reactions, 587
Hematopoietic cell E/L-selectin ligand
(HCELL), 446, 448, 449
Hemiactal
conversion into acetal, 27, 27f
formation of, 23–25, 23f
Hemicellulose, 309–312, 313
abundance in nature, 254
bioenergy and, 756
Hemoglobinuria
paroxysmal cold, 169, 588
paroxysmal nocturnal, 149, 588, 604
Hemolin, 454
Hemolytic-uremic syndrome, 590
HEMPAS (hereditary erythroblastic
multinuclearity with a positive
acidified serum lysis test), 575
Heparanase, 87, 220, 518, 606
Heparan-N-sulfatase
deficiency, 557t
heparan sulfate degradation, 560f
Heparan sulfate, 67
acquired anticoagulation due to
circulating, 587–588
antithrombin interaction, 498
atherosclerosis, role in, 584
biosynthesis, 36
Caenorhabditis elegans, 323–324, 326, 330
cell signaling and, 518
changes in cancer, 606
defects in formation, 579
degradation, 559–561, 560f
diabetes and, 585–586
docking of oligomers, 396–398, 397f
evolutionary diversity, 259
expression of HS proteoglycans, 500
FGF binding, 499–500
glycosaminoglycan binding, 493, 495, 496
insect, 343–345
in intestinal basement membrane, 524
mutants in biosynthesis, 630, 634, 634t
mutation in mice, 357
nuclear uptake, 234–235
Plasmodium circumsporozoite interaction
with, 541
protein-losing enteropathy, role in, 586
proteoglycans, 207, 209, 213
biosynthesis, 217f, 218–219
heparin distinguishes from, 219–220
heparin lyases, 218
linkages, 214, 215f, 216
processing and turnover, 220
structure, 210f, 217f
regulation of structure, 36
structure, 34, 35f
structure–function relationships of
animal, 34–36
sulfation levels of, 35
systemic lupus erythematosus, role in, 591
as viral adhesion receptor, 483–484, 485f,
535–536
Heparan synthases, 95, 96f
Heparin, 213, 219
anticoagulant, 34, 207, 220
antithrombin interaction, 36, 498–499,
498f, 736
biosynthesis, 218
clinical use as anticoagulant, 587
conformation, 495–497, 496f
differences from heparan sulfate,
219–220
discovery of, 363
fibroblast growth factor 2 (FGF2)
binding, 499–500, 501f
glycosaminoglycan binding, 493,
496–497
linkages, 214, 216
low-molecular-weight, 220, 587, 608, 736
mast cell, 499
nanoparticles, 750
recombinant, 736
structure, 11, 210f
target diseases and mode of action, 733t
therapeutic uses, 736
thrombin interaction, 36
unfractionated, 587, 608, 736
Heparinase, 642t
Heparin cofactor II, 219
Heparin-induced thrombocytopenia, 587
Heparin lyases, 218, 222, 642t
Heparin octasaccharide decoy
liposomes, 490

- Heparitinase, 642t
Hepatitis B virus M protein, folding of, 510
Hepatology, glycans in, 524
Hepatoma, 588
Hepta-glucoside, in plant defense response, 514, 515f
Herd immunity, 262
Hereditary inclusion body myopathy (HIBM), 186, 734
Hereditary multiple exostosis (HME), defects in formation, 588t, 579
Hereditary spastic paraplegia, 133, 134
Hermaphrodite, *Caenorhabditis elegans* as, 321–322, 322f
Herpes simplex virus (HSV)
 adhesins, 365
 binding to heparan sulfate proteoglycans, 483–484
 latent, recurrent infections, 365
 mannose 6-phosphate on glycoproteins, 432
 mechanism of entry into host cells, 534f, 535–536
Herpesvirus, binding to heparan sulfate proteoglycans, 483–484, 535–536
Heterogeneous ribonucleoprotein complexes (HnRNP), 236
Heteronuclear multiple-bond correlation (HMBC), 650
Heteronuclear single-quantum coherence (HSQC), 649–650
Heteropolysaccharides, archaea, 286–287
Heteroxylans, 313
Hexoaminidase, 244
Hexopyranoses, 39
Hexosamine biosynthetic pathway, 244, 250
Hexosamines, 8
Hexosaminidase. *See also* O-GlcNAcase
 arthropod, 336, 337
 in N-glycan synthesis, 106
Hexoses, 8
Hexuronic acid, in glycosaminoglycans (GAG), 34
HIF (hypoxia-inducible factor), 607
High-density lipoprotein (HDL) cholesterol, 584
Higher-energy collision dissociation (HCD), 664–665, 664f
High-mobility-group proteins (HMGs), 231
High-performance capillary electrophoresis (HPCE), 645
High-performance liquid chromatography (HPLC), 644
 future advances, 763
 glycan purification, 619
 in glycomics/glycoproteomics, 658–661
 methods of studying sialic acids, 190
 software tools for data interpretation, 675
High-pH anion-exchange chromatography-pulsed amperometric detection (HPAEC-PAD), 645
High-throughput analyses, 764–765
Histoplasma capsulatum, 298
HIV. *See* Human immunodeficiency virus; Human immunodeficiency virus (HIV)
HMBC (heteronuclear multiple-bond correlation), 650
HME (hereditary multiple exostosis), defects in formation, 588t, 579
HNK-1, 450
HNK-1 antigen, 176f, 177
HnRNP (heterogeneous ribonucleoprotein complexes), 236
Homogalacturonans, 308f, 311–312, 314
Honeybee effect, 574
Hoppe-Seyler, F., 113
HPAEC-PAD (high-pH anion-exchange chromatography-pulsed amperometric detection), 645
Hrd1 complex, 508
HRGPs (hydroxyproline-rich glycoproteins), in plants, 314
HSP-70, 466
Hsp60 gene family, 503
Hsp70 gene family, 503
HSQC (heteronuclear single-quantum coherence), 649–650
Hs2st and *Hs6st* mutants, *Drosophila*, 344
HSV. *See* Herpes simplex virus
Htm1p, 296, 508
Human chorionic gonadotropin, glycosyltransferase action on, 68–69, 69f
Human immunodeficiency virus (HIV)
 binding to heparan sulfate, 483, 484
 galectins and, 478
 gp120, 510, 536
 mechanism of entry into host cells, 534f, 536
 NMR of neutralizing antibody, 394, 394f
 sialoadhesin and, 458
 trans-infection, 536
 Vpu protein, 511
Human intelectin 1 (Hint-1), 355
Human Proteome Organization Proteomics Standards Initiative (HUPO-PSI), 669
Humans. *See also* Acquired human diseases
 evolutionary loss of Neu5Gc (5-*N*-glycolylneuraminic acid), 185–186
 glycoside hydrolases of, 94
 glycosyltransferases of, 94, 95
Humicola insolens, 696
Hummel–Dreyer method, 377
Hunter syndrome, 557t
Hurler–Scheie syndrome, 557t, 559, 567
Hurler syndrome, 557t, 559, 567
Hyaladerins, 221
HYAL gene family, 200
Hyaluronan, 197–206, 466
 assembly at plasma membrane, 44
 binding proteins, 203–204, 203f
 binding to CD44, 518, 518f, 532, 604, 605f, 607–608
 biophysical properties, 198
 biosynthesis, 198–199, 199f
 capsule, 12, 93, 205, 205f, 528
 cell signaling and, 204–205, 518, 518f
 changes in cancer, 604, 605f
 degradation, 559, 560f
 evolutionary perspective, 197–198
 function in the extracellular matrix, 200–203, 202f
 heart development, role in, 522
 history, 198
 inhibition of synthesis, 709
 insect, 343
 in nuclei, 235
 structure, 11, 198, 198f, 210f
 target diseases and mode of action, 733t
 therapeutic uses, 205–206, 736
 turnover, 200
Hyaluronan and proteoglycan link proteins (HAPLN) subfamily, 201, 201f, 203
Hyaluronan-binding proteins, 203–204, 203f
Hyaluronan synthases, 198–199, 199f, 205
Hyaluronic acid
 biosynthesis, 36
 nanoparticles, 750
 structure, 35f
Hyaluronic acid synthase, 36, 235
Hyaluronidase, 200, 220, 557t, 559, 560f, 562, 733t
Hydrazones, 26
Hydrogen deuterium exchange (HDX) mass spectroscopy, 381
Hydrolase
 lectin nucleotide phosphohydrolase (LNP), 516
 lysosomal, 554
 phosphorylated N-glycans on, 108–109
Hydrophilic interaction liquid chromatography (HILIC), 658, 660, 661
Hydroxyl groups
 of monosaccharides
 deoxygenation of, 28
 esterification of, 27–28
 methylation of, 27
 selective modification of, 683–684, 683f
Hydroxyproline-linked glycans, 224, 226, 227f, 228
Hydroxyproline-rich glycoproteins (HRGPs), in plants, 314
Hyperglycemia, O-GlcNAcylation and, 523
Hypoxia, tumor, 607
Hypoxia-inducible factor (HIF), 607
I
I and i blood groups, 163, 164f, 589
ICAM-1 (intracellular adhesion molecule-1), 454
I-cell disease, 424, 424f, 425, 427, 432, 575
IDGF (imaginal disc growth factor), 348
Id1D mutant, 631, 632f, 632t
IdoA2S, 35, 35f
Idose, structure of, 22f

- Iduronate sulfatase
 deficiency, 557t
 degradation of dermatan sulfate and
 chondroitin sulfate, 561, 561f
 heparan sulfate degradation, 560, 560f
 recombinant, 567
- Iduronic acid (IdoA), 36
 conformation, 495–496, 496f
 formation of, 52, 55
 sulfation in heparan sulfate, 35
- Iduronidase. *See* α -iduronidase
- IgA nephropathy, 591
- IgE-binding protein, 470
- IGF (insulin-like growth factor)-II, 431
- IgG Fc domain, 522
- IgM isoagglutinins, 166–167
- Imaginal disc growth factor (IDGF), 348
- Imiglucerase, 733t, 735
- Immortomouse, 631
- Immunoglobulin superfamily (IgSF),
 453–466, 453–468
 historical background, 454
 non-Siglec, 454–455
 Siglecs, 454–466
- Immunogold staining, 745
- Immunology, 589–590
 evasion by bacteria, 528
 glycan-binding proteins (GBPs) and,
 365
 glycans in, 522
 immune responses
 roles of, 477–478
 Schistosoma infection, 549–550
 innate immunity
 in *Caenorhabditis elegans*, 328
 C-type lectin functions in, 441, 442, 443f
 glycans as modulators of, 519
 pentraxins, 420
- Immunomodulatory glycans, 82
- Immunoreceptor tyrosine-based activation
 motif (ITAM), 442, 455f, 457
- Immunoreceptor tyrosine-based inhibitory
 motif (ITIM), 442, 455f, 457–459,
 462–463, 462f, 465
- Infectious disease, 527–537. *See also specific
 diseases*
 bacterial
 glycan-based interactions between host
 and gut microbiota, 531–533
 mechanisms of colonization and
 invasion, 531–533
 surface glycans as virulence factors,
 528–531
 galectins role in, 478
 gastrointestinal, 586
 glycan-binding proteins (GBPs) and,
 365
 plant defense response to, 514–515, 515f
 role of glycans in acquired diseases, 590
 viral, 533–536
- Inflammation
 galectins, roles of, 477–478
 glycosphingolipids, role of, 133
 selectins and, 444, 446, 448–449
 selectins and skin diseases, 585
 ulcerative colitis, 586
- Inflammatory bowel disease, O-glycans
 and, 115
- Influenza virus, 182, 188–191, 194
 binding to sialic acid, 174, 534–535, 534f
 hemagglutinin, 363, 481, 482–483, 483t,
 484f, 490
 mechanism of entry into host cells,
 534–535, 534f
 neuraminidase inhibitors, 710–711,
 710f–711f, 731, 731f
 sialidase, 482–483, 490, 535
 tropism, tissue and species, 535
- Informatics, 667–678
 accumulation versus curation, 670, 672
 databases, 669–672, 671t
 future perspectives, 677–678
 collaboration, 678
 computational needs, 677
 development of Web services, 677
 functional connections, 677–678
 long-range, 678
 semantic web and ontologies, 677
 interdisciplinary efforts, 676
 need for in glycobiology, 667–669
 past and present efforts, 670
 software tools for data interpretation,
 673–676
 glycan attachment sites on proteins,
 676
 glycan-binding data interpretation, 675
 liquid chromatography, 675
 mass spectrometry, 673–674
 NMR, 675
 3D glycan structure modeling,
 675–676
 standardization and ontologies,
 672–673
- Information, flow of biological, 2
- Inhibitors, 701–712
 advantages of, 701–702
 classes of, 702t
 directed synthesis of, 707
 of glycolipids, 709–710, 709f
 glycoside primers, 708–709, 708t
 of GPI anchors, 709–710
 metabolic, 702–703
 of O-GalNAc initiation of mucin-type
 glycans, 705–706, 706f
 of O-GlcNAc modification, 706–707,
 706f
 plant alkaloids, 704–705, 705t
 rational design using crystal structures,
 710–712, 710f–711f
 neuraminidase inhibitors, 710–711,
 710f–711f
 sulfotransferase inhibitors, 711–712
 substrate analogs, 707, 707t
 tunicamycin, 703–704, 704f
- Innate immunity
 in *Caenorhabditis elegans*, 328
 C-type lectin functions in, 441,
 442, 443f
 glycans as modulators of, 519
 pentraxins, 420
- Inositol acylation, 142
- Inositol acyltransferase (inositol acyl-T),
 145t
- Inositol deacylase, 146t
- Inositolphosphoceramides, 317
- Insect cells, glycosylation engineering in,
 716t, 723
- Insects. *See* Arthropoda; *specific insects*
- Insulin-like growth factor (IGF)-II,
 431, 523
- Insulin receptor
 activity modulation by gangliosides, 80
 in membrane microdomains, 131
 regulation by ganglioside GM3, 133
- Insulin signaling, O-GlcNAc and, 244f,
 245, 249
- Intelectin, 389, 390f
- Inter- α -trypsin inhibitor, 202
- Interferon- γ (IFN- γ), 586
- Interleukin-5 (IL-5), 464
- International Union of Biochemistry and
 Molecular Biology (IUBMB), 91
- Intracellular adhesion molecule-1
 (ICAM-1), 454
- Intrinsic recognition, 78, 78f, 81
- Invasin, from *Yersinia pseudotuberculosis*,
 437
- Invasion factors, 532
- Invertebrates
 glycosaminoglycans (GAGs), 208
 glycosyltransferases of, 95
 sialic acid diversity, 258
- Investigators influencing glycobiology, 3f
- Ion-exchange chromatography, 619
- Isoagglutinins, 166–167
- Isomers, disaccharide, 28, 28f
- Isoprene, in dolichol, 101
- Isoprenoid synthase domain protein
 (ISPD), 158
- Isothermal titration calorimetry, 378, 379f
- ITAM (immunoreceptor tyrosine-based
 activation motif), 442, 455f, 457
- ITIM (immunoreceptor tyrosine-based
 inhibitory motif), 442, 455f,
 457–459, 462–463, 462f, 465
- I-type lectins, 368, 453–466
 historical background, 453–454
 insect, 348
 non-Siglec, 454–455
 Siglecs, 453–466
- IUBMB (International Union of
 Biochemistry and Molecular
 Biology), 91
- J**
- Jagged, 152, 154, 155f, 342
- Japan Consortium for Glycobiology and
 Glycotechnology Database
 (JCGGDB), 676
- JCGGDB (Japan Consortium for
 Glycobiology and Glycotechnology
 Database), 676
- Jelly-roll fold, 414, 414f, 421

K

Kar2p, 510
Kdn (2-keto-deoxynonulosonic acid)
 structure, 180, 180f
 synthesis of, 186
Kdo. *See* Keto-deoxyoctulosonic acid (Kdo)
KEGG BRITE, 676
KEGG GLYCAN, 91, 672, 676
KEGG PATHWAY, 672
Keratanase, 642t
Keratan sulfate, 177
 changes in cancer, 606
 in cornea, 580
 degradation, 561f, 562
 poly-LacNAc, 163
 proteoglycans, 207–210
 biosynthesis, 216, 217f
 linkages, 213–214, 214f
 structure, 214, 214f, 219f
 types, 213–214, 214f
 small leucine-rich proteoglycans (SLRPs),
 210
 structure, 34, 35f
Keratocan, 211t
Keto-deoxyoctulosonic acid (Kdo)
 in lipid A, 274–275, 278
 structure, 181
Ketohehexoses, 21
Ketone group, 3, 5
Ketose, 3, 20
Kidney, role of glycans in, 524
Kifunensin, 704, 705t
Killer-cell immunoglobulin-like receptors
 (KIRs), 442
Kinetics
 of glycan–protein interactions, 376–382
 of glycosaminoglycan–protein binding,
 494–495
KIRs (killer-cell immunoglobulin-like
 receptors), 442
Klebsiella pneumoniae, mannose receptor
 binding, 408
Kluyveromyces lactis, 300–301, 622
Knockdown, 718
Knockin, 718
Knockout, 718, 727
Kornfeld, Stuart, 424
Krabbe disease, 557t, 563
Kyoto Encyclopedia of Genes and Genomes
 (KEGG) Glycan database, 91

L

LacdiNAc, 163, 549, 549f
LacNAc. *See* N-acetylglucosamine
Lactase, 735
Lactation, 170
Lactobacillus helveticus, 37f
Lactobacillus plantarum, 228
Lactone, 26, 26f
Lactonization, 26, 26f
Lacto-N-neotetraose, 490
Lactose, 170
Lactose intolerance, 735

LAD-II (leukocyte adhesion deficiency
 type II), 574
Laminaran, 316
Laminin, 99, 157–158, 158f, 159, 213, 524
Laminin G domain-like (LG) modules, 420
Landsteiner, Karl, 164
Langerin, 442
LARGE, 158, 178
LARGE gene, 576, 578
Laronidase, 733t
Laser-induced fluorescence (LIF), 660
Layilin, 436
L configuration, 21
LDL (low-density lipoprotein) cholesterol,
 584
LDN (LacdiNAc), 549, 549f
LecA and LecB, 390, 390f
LecRKs (L-type lectin receptor kinases), 421
Lecticans, 210, 211t
Lectin(s), 16
 animal, 362–363, 365, 367f
 Caenorhabditis elegans, 331–332
 Drosophila melanogaster, 347–348
 frogs, 355
 insect, 347–348
 R-type lectins, 407–411
 bacteria, 363–365, 367f
 carbohydrate-recognition domains
 (CRDs), 365–366, 366f, 368–371,
 370f
 classification based on structural
 similarities, 366–369, 367f
 commonly used in glycan analysis,
 612–613, 612f–615f
 C-type, 435–450
 databases, 672
 discovery and history, 362–363
 folding and oligomerization facilitate
 binding to cell surfaces, 390–391,
 391f
 galectins, 469–479
 glycan ligands for, 369–371, 370f
 glycosaminoglycan-binding proteins
 compared, 362t
 interactions in carbohydrate-binding
 sites, 389–390, 390f
 I-type, 453–466
 L-type, 413–421
 microbial, 411, 481–490
 background, 481–482
 bacterial adhesion to glycans, 485–486,
 485f–486f, 487t
 parasite, 489–490, 489t
 therapeutic implications, 490
 toxins that bind glycans, 487–489,
 488f, 488t
 viral glycan-binding proteins,
 482–484, 483t, 484f–485f
 natural ligands, 369–370
 nuclear and cytoplasmic, 230–231,
 236–237
 organization of, 365–366, 366f
 plant, 362, 367f, 368
 discovery and history, 362

L-type lectins, 414f, 415–418, 415f,
 417f
 mutants selected for resistance to, 630,
 631
 R-type, 402–407
P-type, 423–433
R-type, 401–411
 sequence motifs, 91–92
 sulfated glycosaminoglycan-binding
 proteins, 361–363, 369
 use in
 animal cell glycosylation mutant
 generation, 622
 cell-surface glycoconjugate
 characterization, 621–622
 cloning glycosyltransferase genes by
 expression, 622–623
 glycan purification, 619–621, 620f
 glycan recognition, 616–619
 viral, 363, 365, 367f
 X-lectins, 355
Lectin-3D portal, 389, 391f
Lectin fold, 415, 420
Lectin nucleotide phosphohydrolase
 (LNP), 516
Leech, *trans*-sialidase, 421
Legionaminic acid (Leg), 180f, 181
Legionella pneumophila toxin, 229
Legume lectin fold, 92
Leguminous plants
 L-type lectins from, 413–418
 nitrogen fixation and, 515–516
Leishmania, 545–547, 546f
 galectins and, 478
 lipophosphoglycan of, 139, 146
 mannose receptor binding, 408
 nucleotide sugar transporter, 61
 UDP-Gal transporter, 623
Leloir, Luis F., 294
Lemma minor, 58
Lens culinaris lectin, 612, 614f, 620f
LERP (lysosomal enzyme receptor protein),
 348
Leukemia inhibitory factor (LIF), 432
Leukocyte adhesion deficiency type II
 (LAD-II), 328, 574
Leukocytes
 inhibition of selectin-mediated
 trafficking, 739
 tethering and rolling, 444
Lewis blood group antigens, 116, 121,
 167–169, 168f
 functions, 168–169
 Helicobacter pylori pathogenesis and, 169
 structure, 168f
 transfusion reactions, 168
Lewis^x (Le^x) antigen
 formation of, 168
 Lewis^x–Lewis^x interaction in mouse
 embryogenesis, 81
 in *Schistosoma*, 549, 549f
LFNG gene, 154
LH (lutropin), 171, 172f
Licensing, 732

- Lichens, 301
LIF (laser-induced fluorescence), 660
LIF (leukemia inhibitory factor), 432
Liftases, 131, 563
Ligands, glycans as
 extrinsic recognition, 81–82
 finding ligands for specific receptors, 86
 finding receptors for specific glycans, 86
 intrinsic recognition, 81
Lignin, 309, 312–313, 756–757
Lignocellulosic biomass, 756–757
Limb-girdle muscular dystrophy, 157
LIMP-2, 432
Linkage analysis, 646–651, 647f
 determination of linkage positions, 646
 mass spectroscopy, 646, 648–649
 NMR spectroscopy, 649–651, 650f
Link module, 201–204, 202f, 203f
Lipid A, 272–276, 273f, 275f, 529–531
 glycoengineering, 719
 innate immune system activation, 519
Lipid II, 269
Lipid-linked oligosaccharide (LLO)
 defects in biosynthesis, 572, 573f, 574
 glycoengineering, 719–720
Lipid rafts
 GPI proteins and, 147–148
 intracellular signaling and, 131
 of membrane glycosphingolipids, 131
 size, 131
Lipids, synthesis of carrier, 62
Lipoarabinomannans, 271f, 272
Lipoglycan, archaea, 287
Lipomannan, 272
Lipooligosaccharide (LOS), 274, 530
Lipopetidophosphoglycan (LPPG)
 Entamoeba histolytica, 547, 548f
 Trypanosoma cruzi, 544–545, 545f
Lipophosphoglycan (LPG), 139
 Entamoeba, 547
 Leishmania, 545–547, 546f
Lipopolysaccharide (LPS), 266, 272–276,
 529–531, 530f
 assembly and export, 274–276, 275f
 glycoengineering, 719
 innate immune system activation, 519
 O antigens, 36–38, 37f
 structure and function, 273–274, 273f
Lipoteichoic acids, 36, 266, 270, 271f
Liquid chromatography
 in glycomics/glycoproteomics, 658, 660
 software tools for data interpretation, 675
Listeria monocytogenes, 245
Liver
 fibrinogen glycosylation, 588
 role of glycans in, 524
LLO. *See* Lipid-linked oligosaccharide
LNP (lectin nucleotide phosphohydrolase),
 516
Localized surface plasmon resonance
 (LSPR), 744–746
Locoweed, 565
Longispora albida, 411
LOS (lipooligosaccharide), 274, 530
Lou Gehrig's disease, O-GlcNAc
 and, 248
Low-density lipoprotein (LDL) cholesterol,
 586
Low molecular-weight heparins (LMWH),
 220, 587, 608, 736
LoxP recombination sites, 358, 358f
LPG. *See* Lipophosphoglycan
L-phytohemagglutinin, 416, 598, 612,
 612f, 618
LPPG. *See* Lipopeptidophosphoglycan
LPS. *See* Lipopolysaccharide
L-selectin, 73–74, 177, 193, 364, 442, 445f,
 448–449, 500, 602–603
LSPR (localized surface plasmon
 resonance), 744–746
L-type lectin receptor kinases (LecRKs), 421
L-type lectins, 368, 413–421
 Clostridium neurotoxins, 421
 common features, 414–415, 415f
 exotoxin A, 421
 historical background, 413–414
 leech intramolecular trans-sialidase, 421
 pentraxins, 420
 plant lectins, 415–418
 distribution and localization, 415–416
 function, 418
 structure, 416–418, 417f
 in protein quality control and sorting,
 418–420
 rotavirus, 421
 Vibrio cholerae sialidase, 421
Lumbricus terrestris, 407
Lumican, 211t
Lunatic fringe, 153
Lutropin (LH), 171, 172f
Lymphangiogenesis, 443
Lysosomal enzyme replacement therapy,
 566–567, 735
Lysosomal enzymes
 genetic defects
 overview, 554, 556, 556t–557t
 therapy, 566–567
 glycan-binding proteins (GBPs), 364
 glycan degradation, 553–567
 blocking, 565–566
 glycoproteins, 556–559, 556t
 glycosaminoglycan, 557t, 559–562
 glycosphingolipid, 557t, 562–564,
 563f
 monosaccharide salvage, 565
 recycling, 564–565
 therapy for lysosomal enzyme
 deficiencies, 566–567, 735
 hydrolases
 glycosphingolipid breakdown, 131
 phosphorylated N-glycans on,
 108–109
 I-cell disease, 424, 424f, 427, 432
 mannose 6-phosphate receptors (MPRs)
 and
 evolutionary origins of system, 431
 genetic defects in, 428–429
 subcellular trafficking, 429–430, 430f
 mannose 6-phosphate recognition
 marker
 discovery, 424
 generation of, 425–427, 425f
 overview, 553–554
 trafficking, 423, 429–433, 430f
Lysosomal lyases, 178
Lysosomal storage disorders, 510, 709, 735
 overview, 554, 556, 556t–557t
 therapy, 566–567
Lysosome
 degradation of oligomannosyl N-glycans,
 508, 509f
 glycosphingolipid storage diseases, 131,
 134
 monosaccharide salvage, 53
 multivesicular storage bodies, 564
 proteoglycan degradation, 218, 220
 role of mannose-6-phosphate (Man-6-P)
 in enzyme trafficking, 81
Lysozyme, 388
Lysyl hydroxylases, 159
LYVE1 receptor, 200
Lyxose, structure of, 22f
- M**
- Maackia amurensis*, 418
Maackia amurensis hemagglutinin (MAH),
 407
Maackia amurensis lectin/leukoagglutinin
 (MAL), 190, 406–407, 615f, 617,
 620f, 623, 635f, 640, 641f
MacLeod, Colin, 529
Macroglycolipids, ABH determinants, 165
Macrophage
 integrin, 368
 mannose receptor, 364
 Siglecs and, 454, 457–458, 461–462,
 464–466
Macrophage C-type lectin (MCL), 442
Macrophage galactose-binding lectin
 (MGL), 442
Macrophage mannose receptor (MMR),
 436, 442
Mactosylceramide, 346
Macular corneal dystrophy (MCD), 580
MAG (myelin-associated glycoprotein), 133,
 454, 455f, 457, 459–461
Magnetic nanoparticles, 745f, 746–747,
 747f
Magnetic resonance imaging (MRI)
 magnetic nanoparticles, 746–747, 747f
 molecular, 747
MAH (*Maackia amurensis* hemagglutinin),
 407
Maillard reactions, 585
Major histocompatibility complex (MHC),
 212t, 213
 ER quality control, 510
 masking of presentation by
 mucins, 600
MAL. *See* *Maackia amurensis* lectin/
 leukoagglutinin

- Malaria, 167, 186, 191, 489–490, 542–543, 542f
- MALDI (matrix-assisted laser desorption ionization)-MS, 646, 648
- Malectin, 368
- Malignancy. *See also* Cancer glycosylation changes in, 16 sialic acids in, 194
- Maltose, structure of, 28, 28f, 33, 33f
- Mammalian cells, glycosylation engineering in, 716t, 724–726
- Manic fringe, 153
- Mannans, in fungi, 294–303, 296f
- Mannoproteins, 295, 295f, 300
- Mannosamine, 710
- Mannose
activation of, 52t
in arthropods, 336–337
C-mannosylation, 159, 159f
congenital disorders of glycosylation and, 576–577, 577f
fungi and, 294–303
metabolism, overview, 55–56
phosphorylation, 178
structure of, 22f
toxicity, 55
transport, 53
- Mannose analogs, 709–710
- Mannose-binding lectin (MBL), 91–92, 441
- Mannose-binding protein-A (MBP-A), 436, 437f, 438f
- Mannose-6-phosphate (Man-6-P)
accumulation of, 574
diversity of biological roles of, 82
on nonlysosomal proteins, 431–432
P-type lectins, 423–433
role in trafficking of lysosomal enzymes, 81
- Mannose-6-phosphate receptors (MPRs)
CD-MPR (cation-dependent MPR), 427–429, 428f, 431
CI-MPR (cation-independent MPR), 427–432
common features, 427–428
discovery of, 363
enzyme replacement therapy, implications of, 429–430
evolutionary origins of M6P recognition system, 431
genetic defects in, 428–429
homology domain-containing proteins
function in secretory pathway, 432–433
nonlysosomal proteins and, 431–432
subcellular trafficking, 429–430, 430f
- Mannose-6-phosphate recognition marker
discovery, 424
generation of, 425–427, 425f
- Mannose receptor, 407–408
- Mannose receptor family, 407–409
- Mannosidase. *See* α -mannosidase; β -mannosidase
- Mannostatin A, 704, 705t
- Mannosyltransferase, 157
 α 1-6-mannosyltransferase, yeast, 721
 α 2-mannosyltransferase, 710
arthropod, 346
nuclear, 233
O-mannosyltransferase, 157
yeast, 297
- Mannosyltransferase-1 (MT-1), 145t
- Mannosyltransferase-2 (MT-2), 145t
- Mannosyltransferase-3 (MT-3), 145t
- Man-6-P receptors, 178
- MAPK (mitogen-activated protein kinase), 440
- Marfan syndrome, 575
- Maroteaux-Lamy, 557t
- Masking, Siglecs and, 457
- Mas1* mutation, 336–337
- Mass spectrometry (MS), 14
future advances, 763
in glycomics/glycoproteomics, 657–665, 662f, 664f
glycosphingolipid analysis, 129
high-throughput analyses, 764–765
hydrogen deuterium exchange (HDX), 381
linkage analysis, 646, 648–649
methods of studying sialic acids, 190
monosaccharides composition analysis, 645
O-GlcNAc detection, 241–242
O-glycan analysis, 116–117
software tools for data interpretation, 673–674
study of glycan–protein interactions, 381
- Mast cells
heparin release from, 499
heparin sulfate production, 499
- Materials science, glycans in, 17
- Matrix-assisted laser desorption ionization (MALDI)-MS, 646, 648, 657
characterization of released glycans, 660–661
high-throughput analyses, 764–765
- MBL (mannose-binding lectin), 91–92, 441
- MBL-associated serine proteases 1 and 2 (MASP-1 and -2), 441
- MBL2* gene, 441
- MBP-A (mannose-binding protein-A), 436, 437f, 438f
- McCarty, Maclyn, 529
- MCD (macular corneal dystrophy), 580
- MCL (macrophage C-type lectin), 442
- McLean, Jay, 363
- m*-DAP (*meso*-diaminopimelic acid), 269
- MDL-1 (myeloid-DAP12-associating lectin), 442
- MDOs (membrane-derived oligosaccharides), 277
- Medicine, glycans in, 17
- Melanoma, 135, 601, 603, 607–608, 739
- Membrane
basement membrane proteoglycans, 213
glycosphingolipids in plasma, 129, 131–132
glycosylation reactions at plasma, 43–44
membrane-derived oligosaccharides (MDOs), 277
proteoglycans, 209f, 212t, 213, 220
- Membrane-derived oligosaccharides (MDOs), 277
- Membrane microdomains,
glycosphingolipid-enriched, 131
- meso*-diaminopimelic acid (*m*-DAP), 269
- Metabolic diseases, glycan therapeutic approaches to, 734–736
chaperone therapy, 735–736
lysosomal enzyme replacement therapy, 735
salvage versus de novo synthesis, 734
special diets, 734–735
substrate reduction therapy (SRT), 735
- Metabolic inhibition, of glycosylation, 85–86
- Metabolic inhibitors, 702–703
- Metabolic labeling, 640–641
- Metabolism
diabetes mellitus, 585–586
glycogen, 53
- Metachromatic leukodystrophy, 557t, 563
- Metalloglycodendrimers, 745f
- Methanocaldococcus jannaschii*, 292
- Methanochondroitin, 93, 287
- Methanococcoides burtonii*,
glycosyltransferases of, 93
- Methanococcus maripaludis*, 290
- Methanococcus voltae*, 290
- Methanogens, 290–291
- Methanopyrus*, 284
- Methanosaepta concilii*, 284
- Methanosarcina barkeri*,
methanochondroitin of, 93, 287
- Methanosarcina voltae*, glycosyltransferases of, 94
- Methanosphaera stadtmanae*,
glycosyltransferases of, 93
- Methanospirillum hungatei*, 284, 291
- Methanothermobacter feravidus*, 284
- Methanoterris igneus*, 292
- Methyl α -mannoside, 490
- Methylation
donors for glycan modification, 61, 62t
of hydroxyl groups, 27
4-methylumbelliferone, 206, 709
- Meyer, Karl, 197
- MGAT1*, 106, 107f, 108, 110, 337, 339, 357, 631, 724
- MGAT2*, 359, 723
- MGAT3*, 598, 599f, 607, 618, 724
- MGAT4*, 598, 599f
- MGAT5*, 477, 598, 599f, 607
- MGAT5B*, 158
- MGDG (monogalactosyldiacylglycerol), 316–319, 317f
- MGDG synthase, 316, 319
- MGEA5* gene, 244
- MGL (macrophage galactose-binding lectin), 442

- Microarrays, glycan, 92, 382, 383f, 618–619, 618f
- Microbacterium nematophilum*, 328
- Microbial lectins, 481–490
background, 481–482
bacterial adhesin to glycans, 485–486, 485f–486f, 487t
parasite, 489–490, 489t
therapeutic implications, 490
toxins that bind glycans, 487–489, 488f, 488t
viral glycan-binding proteins, 482–484, 483t, 484f–485f
- Microbial T-type proteins, 411
- Microbial vaccines, 738
- Microbiome, 767
- Microbiota, glycan-based interactions
between host and gut, 531–533
- Microheterogeneity
of glycan structure, 83
glycoproteins, 12, 15
N-glycans, 109
- Microorganisms, sialidases of, 189
- microRNAs, 607
- Miglitol, 730f
- Miglustat, 730f
- Milk
impairment of gut pathogens, 586
oligosaccharides, 82, 170, 738
- Miller-Fisher syndromes, 592
- Mimecan, 211t
- Mimivirus glycosyltransferase, 93, 260
- Mincle, 365, 369, 442
- mind-the-gap* gene, 348
- Minimum Information Required for A
Glycomics Experiment (MIRAGE)
initiative, 669
- Mitochondria
glycosylation in, 235–236
mOGT, 243
- Mitogen-activated protein kinase
(MAPK), 440
- Mixed-bed lectin chromatography, 619
- Mixed-linkage glucans, 311
- MMR (macrophage mannose receptor),
436, 442
- MND (motor neuron disease), 248
- Mnn* mutants, 299, 300
- Modeccin, 405
- Modeling, 3D glycan structure, 675–676
- Model organism
fungi, 294–300
humans, 360
for studying glycan diversity, 262
Xenopus laevis, 353
zebrafish, 355–357
- Molecular docking programs, 396–399
- Molecular dynamics, 395–399, 496, 651
- Molecular mechanics, 395, 651
- Molecular mimicry of host glycans, 78,
78f, 82
by pathogens, 260–261
“stealing” of sialic acids, 185
- Monoclonal antibody. *See also* Antibody
generation to glycan antigens, 613–616
mammalian glycan antigens recognized
by, 615–616, 616f–617f
O-GlcNAc detection, 242
- Monogalactosyldiacylglycerol synthases,
319
- Monogalactosyldiacylglycerol (MGDG),
316–319, 317f
- Monoglycosylation, prokaryotes, 228
- Monosaccharides
abbreviations, 21
activation and interconversion of, 53–58,
54f–56f
acyclic, 21, 22f, 25
aldoses versus ketoses, 20
anomeric carbon, 25, 27
biosynthesis and turnover, 14f
chemistry at anomeric center, 25–27
glycosidic bond formation, 27, 27f
mutarotation, 25
oxidation, 25–26, 26f
reduction, 25–26, 26f
Schiff base formation, 26, 27f
chemistry of functional groups, 27–28
amino groups, 28
deoxygenation of hydroxyl groups, 28
esterification of hydroxyl groups,
27–28
methylation of hydroxyl groups, 27
chiral anomeric center, 5
commonly found in vertebrates, 22f
as common units glycoconjugates, 8
composition analysis of a glycan, 645
cyclic form, 21, 23–25, 23f–24f
defined, 14
empirical formula, 20
evolutionary diversity, 256, 258
future questions concerning, 767
Haworth projections, 23–25, 23f–24f
intracellular sources of, 53–58, 54f–56f
linkages between, 5, 7–8
open-chain form, 3, 5f
ring form, 3, 5f
stereoisomerism, 20–21, 25
as structural unit of glycans, 3, 5–6
structure, 20–25, 20f–24f
symbols for, 8, 9f
transporters, 52–53
- Monosaccharide salvage, 565
- Morell, Anatol, 362
- Morgan, T.H., 335
- Morphogens, 344
- Morquio A and B, 557t
- Mosquitocidal toxin (MTX), 407
- Motor neuron disease (MND), 248
- Mouse (*Mus musculus*)
cell lines with glycosylation mutation, 631
genetic defects in glycosylation, 88
mutations, 357–359
affecting entire pathways, 357–358
affecting specific extensions/
modifications, 358
cell type-specific, 358
conditional knockouts, 358f
environmentally driven phenotypes,
359
strain differences/genetic
modifiers, 359
“no fear,” 359
OGT gene, 245
- MPI (mannose-6-phosphate isomerase),
mutations in, 571t, 572, 574
- MPRs. *See* Mannose-6-phosphate receptors
- MPS (mucopolysaccharidoses), 556, 557t,
559, 567
- MS. *See* Mass spectrometry
- MSD (multiple sulfatase deficiency),
557t, 562
- MS/MS, 648–649
- MTX (mosquitocidal toxin), 407
- M-type lectins, 368
- MUC1, 115, 122, 599
- MUC16, 607
- Mucins, 10, 371
ABH determinants, 165
barrier function of, 523–524
bronchial asthma, role in, 593
discovery and background, 113–114
disease and, 115, 122
gut barrier, 523–524
halomucin, 286
increased in cancer, 599–600, 601f
O-GalNAc glycans, 113–122, 705–706,
706f
purification of, 116–117
roles of, 113, 115, 121–122
salivary gland, 523
sialic acids, 191
structure, 113, 114f, 114t, 115–116
Trypanosoma cruzi, 544, 545f
- Mucopolipidoses, 427
- Mucopolysaccharides, 207
- Mucopolysaccharidoses (MPS), 556, 557t,
559, 567, 735
- Multiple myeloma, 134
- Multiple sulfatase deficiency (MSD), 557t,
562
- Multivalent interactions, 366, 370,
370f, 743
- Multivesicular storage bodies (MVB), 564
- Multiwalled carbon nanotubes (MWCNTs),
748
- Murein. *See* Peptidoglycan
- mur* mutants of *Arabidopsis*, 318
- MurNAc (*N*-acetylmuramic acid),
268–271, 268f
- Muscle-eye-brain disease, 157, 576,
578
- Muscular dystrophies, 576–578
- Musculoskeletal biology, glycans in, 524
- Mus musculus*. *See* Mouse
- Mutants
elucidating glycan function by study of,
87–88
genetic defects in glycosylation, 87–88
glycosylation of cultured cells, 627–636
mouse studies, 357–359

- Mutarotation, 25
MVB (multivesicular storage bodies), 564
Mycobacteria, cell wall of, 267f, 272
Mycobacterium bovis, C-type lectins and, 442
Mycobacterium tuberculosis
cell wall, 365
C-type lectins and, 442
exopolysaccharides, 278
glycans of, 93
mannose receptor binding, 408
Mycoplasma pneumoniae, cold agglutinin disease, 589
Mycorrhizal symbiosis, 82
Myelin, 127, 131, 132, 133, 259
Myelin-associated glycoprotein (MAG), 133, 454, 455f, 457, 459–461, 525
Myeloglobins, 133
Myeloid C-type lectins, 442–444
Myeloid-DAP12-associating lectin (MDL-1), 442
Myeloid inhibitory CTL-like receptor (MICL), 442
myo-Inositol phosphate, 298, 302
myo-Inositol phosphate linkers, 298
Myristic acid, 710
- N**
- N-acetylgalactosamine (GalNAc)
activation of, 52t
azido analogs of, 641
formation of, 57
O-GalNAc glycans, 113–122
in proteoglycan biosynthesis, 213, 215f, 216, 217f, 219
structure, 22f
terminal
Sd^a antigen, 173, 173f
sulfated terminal β -linked on pituitary hormones, 171–173, 172f
N-acetylgalactosamine 4-sulfatase, 561f
deficiency, 557t
recombinant, 567
N-acetylgalactosaminyltransferase (GalNAcT), 69, 69f
 α 1-3GalNAcT, 166f, 170f
 β 1-3GalNAcT, 169, 169f
 β 1-4GalNAcT, 163, 171–173, 172f, 173f
Caenorhabditis elegans, 325–326
glycosphingolipid synthesis, 130, 133
polypeptide-
N-acetylgalactosaminyltransferase (ppGalNAcT), arthropod, 340, 341f
UDP-GalNAc:polypeptide
 α -N-acetylgalactosaminyltransferases (ppGalNAcTs), 409–411, 410f
N-acetylglucosamine (GlcNAc), 67
activation of, 52t
in arthropods, 336, 339, 340, 342, 346, 348
azido analogs of, 641
in *Caenorhabditis elegans*, 323, 328, 330
in hyaluronan, 198f
Kluyveromyces lactis, 301
metabolism, overview, 57
oral supplementation, 734
in peptidoglycan, 268, 268f
in plants, 307, 314, 318
in proteoglycan biosynthesis, 215f, 217f, 218–220
structure, 22f
N-acetylglucosamine-6-sulfatase deficiency, 557t
degradation of keratan sulfate, 561f
heparan sulfate degradation, 560f
N-acetylglucosaminyltransferase (GlcNAcT), 145t. *See also* O-GlcNAc transferase (OGT)
arthropod, 342
 β 1-3GlcNAcT, 162f, 169f, 176f
 β 1-6GlcNAcT, 163, 164f
GlcNAcT-I, arthropod, 336, 337f
GlcNAcT-III in cancer, 598
GlcNAc-TV, enhanced expression in cancer, 598
in N-glycan synthesis, 106, 107f
in *Xenopus*, 355
N-acetyllactosamine (LacNAc), 162–163, 162f
in arthropods, 339
in cancer, 598
formation, 67
in N-glycan synthesis, 108, 108f
N-acetylmannosamine, 734
N-acetylmuramic acid (MurNAc), 268–271, 268f
N-acetylneuraminic acid (NeuAc), 126f, 130. *See also* Neu5Ac (5-N-acetylneuraminic acid)
metabolism of, 187f
N-deacetylation, 74
structure, 22f
N-acetyltransferase, in heparan sulfate degradation, 560
NAG-thiazole, 706, 706f
NANA. *See* Neu5Ac (5-N-acetylneuraminic acid)
Nanoarchaeum equitans, glycosyltransferases of, 94
Nanotechnology, glycans in, 17, 743–752
carbon-based nanoparticles, 748–750
carbon nanotubes, 745f, 748–750, 749f
fullerenes, 745f, 748
graphene, 745f, 750
cellulose nanomaterials, 758–759, 758f, 759f
glycodendrimers, 745f, 751
glyconanomaterials in diagnosis and therapy, 751
inorganic nanoparticles, 744–747
gold nanoparticles, 744–746, 745f, 746f
magnetic nanoparticles, 745f, 746–747, 747f
quantum dots, 745f, 747
overview, 743–744
polysaccharide-based nanoparticles, 750
types and applications, 744
Naringin, 317
Natowicz syndrome, 557t
Natronococcus, 286
Natural killer (NK) cells, 442, 457, 458, 464–465
N-butyldeoxynojirimycin, 566, 709, 733t, 735
NCAM. *See* Neural cell adhesion molecule
N-deacetylase/N-sulfotransferase (Ndst), 344, 634
N-deacetylation, 74
Necator americanus, 332
Neisseria
lipooligosaccharide (LOS), 274
N. gonorrhoeae sialyltransferase, 185
N. meningitidis
capsule, 38, 93, 280, 528
galectin binding, 476
sialoadhesin and, 458
vaccines, 738
O-glycosylation, 277
Nematodes, 321–332
developmental biology, 321–322, 322f
functional analysis of glycoconjugates, 326–331
glycan-binding proteins, 331–332
glycans, 323–324, 324f, 325f
glycolipids, 330–331, 331f
glycosyltransferase genes, 325–326
parasitic, 332
proteoglycans and glycosaminoglycans, 329–330, 330f
Nephrology, 591
glycans in, 524
IgA nephropathy, 591
nephrotic syndrome, 591
systemic lupus erythematosus (SLE), 591
Nephropathy
diabetic, 585–586
IgA, 591
Nephrotic syndrome, 591
Nerve growth factor receptor, in membrane microdomains, 131
NeuAc. *See* N-acetylneuraminic acid
Neu5Ac (5-N-acetylneuraminic acid).
See also N-acetylneuraminic acid (NeuAc)
in cancer, 601f
influenza binding, 534
structure, 180–182, 180f
Neu2en5Ac (2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid), 182
Neufeld, Elizabeth, 423–424
Neu5Gc. *See* N-glycolylneuraminic acid (Neu5Gc)
NEU genes/proteins, 188–189
Neural cell adhesion molecule (NCAM), 183, 454, 525, 528
GPI-anchored form, 138
polysialic acid and, 80, 83, 88
sialylated glycans and, 175–177
Neural development, proteoglycans in, 345–346

- Neuraminic acid, structure of, 180–182, 180f
- Neuraminidase, 188–189, 482. *See also* Sialidase
- inhibitors, 710–711, 710f–711f, 731, 731f
- N-glycan degradation, 558
- specificity and uses, 642t
- Neurobiology, glycans in, 525
- Neurocan, 201f, 202, 210, 211t
- Neurodegenerative disease, O-GlcNAc and, 248
- Neurofibrillary tangles, 592
- Neurofibromatosis type I, 347
- Neurofilaments, O-GlcNAc and, 246
- Neurology and psychiatry, 592–593
- Alzheimer's disease, 592–593
- autoimmune neural damage, 592
- Neuropilin-2, 185
- NF- κ B, 247, 440, 530, 530f
- NG2, 212t, 213
- NGLY1, 517
- N-glycan(s), 99–110
- ABO blood group determinants on, 165, 165f
- altered branching and fucosylation in cancer, 598, 599f
- in archaea, 287–291, 288f, 289f
- arthropod, 336–340, 337f, 340f
- biosynthesis, 13
- branching, 32–33, 32f, 598, 599f
- of *Caenorhabditis elegans*, 323, 324f
- chaperone recognition by, 504
- characterization of N-glycans released from proteins, 657–663
- chemoenzymatic synthesis of library of, 694, 695f
- classes and nomenclature, 100, 100f
- defects in biosynthesis, 100, 110, 570–575, 571t, 573f
- diagnosis, 570–572
- features of, 570–572, 571t
- type I congenital disorders, 572, 574
- type II congenital disorders, 574–575
- degradation
- complex glycans, 555f, 558
- oligomannosyl glycans, 558
- degradation of oligomannosyl, 508, 509f
- description, 99
- discovery, 99
- in ER–Golgi pathway, 42, 43f
- evolutionary variations in, 254, 256, 257f, 258
- functions of, 109–110
- in fungi, 295–296, 298f, 300–303
- glycosylation of extensions, 162f
- heterogeneity, 109
- isolation, purification, and analysis, 101
- keratan sulfate, 213
- lectin recognition of, 612–613, 613f
- mannose 6-phosphate (M6P) recognition marker, 424–427, 425f
- mutants in synthesis, 631
- pituitary glycoprotein hormones, 171–173, 172f
- plant, 314, 315f, 316
- in *Plasmodium*, 543
- poly-LacNAc extensions, 163
- predicting sites of N-glycosylation, 101
- protein folding and, 504–508, 506f, 509f
- roles in systemic physiology, 522–525
- structural diversity of, 256, 257f
- structure, 6f, 10, 10f
- synthesis, 101, 102–111
- capping (decoration) reactions, 106, 108
- dolichol-linked precursor, 101–102, 103f
- early processing, 104–106, 105f
- elongation, 106
- late processing, 106, 107f
- maturation, 106–108, 107f, 108f
- phosphorylation, 108
- transferases and transporters in, 109
- transfer of glycan to protein, 102, 104
- use as tags, 100
- N-glycanase, 232, 235, 508, 517, 641, 643f
- N-glycolylneuraminic acid (Neu5Gc), 130
- accumulation of dietary in human tissues, 188, 189
- antibodies against, 186, 195
- cancer and, 601–602, 601f
- E. coli* binding to, 486
- human evolutionary loss of, 185–186
- pathogens targeting, 186
- Siglec binding, 465
- structure, 180, 180f
- N-glycosidase F, 233
- N-glycosylation, 48
- in archaea, 287–291, 289f
- bacteria, 276–277
- cytoplasmic, 231–236
- defects in, 522
- evolution of, 254, 256, 257f, 258
- in fungi, 295, 300
- glycoengineering
- in bacteria, 720
- in insect cells, 723
- in mammalian cells, 724–726
- in plant cells, 722
- in yeast, 721
- of plasma proteins, 522
- in *Plasmodium*, 543
- predicting sites of, 100–101
- protein folding and, 504–508, 506f, 509f
- N-glycosyltransferase, bacterial, 720
- Nicotiana tabacum*, glycosylation engineering in, 717t, 722
- Nidogens, 213
- Nitrous acid deamination of the glucosamine, in GPI anchors, 140, 141f
- NK cells, 442, 457, 458, 464–465
- NKT cells, 133
- NLSs (nuclear localization signals), glycans as, 233
- NMR. *See* Nuclear magnetic resonance (NMR) spectroscopy
- Nobel laureates, 3f
- Nodes of Ranvier, 132
- Nod factor, 515–516, 516f
- NOD-like receptors (NLRs), 266
- NOEs (nuclear Overhauser effects), 650–651
- Nogo receptor (NgR) family, 460
- Nonreducing end, 6, 29, 29f
- Nonsecretor, 168, 170
- Nonulosonic acids, 179–195
- abbreviated names, 181
- classification, 181
- defined, 8
- discovery, 180–181
- diversity of, 767
- evolution, 179, 181, 258
- structure, 180–181, 180f
- Norovirus, 167
- Notch, 151–156, 154f, 155f, 342–343, 343f, 348, 357–358, 509–510, 522
- N-sulfate, 11–12
- Nuclear factor κ B (NF- κ B), 247, 440, 530, 530f
- Nuclear localization signals (NLSs), glycans as, 233
- Nuclear magnetic resonance (NMR) spectroscopy, 14
- chemical-shift mapping of
- protein-binding sites for glycans, 392–393, 393f
- future advances, 763
- glycan recognition, 391–394
- glycosphingolipid analysis, 129
- identification of ligand interaction surfaces and bound ligand chemistry, 393–394, 394f
- isotopic labeling, 391
- linkage analysis, 649–651, 650f
- O-glycan analysis, 116
- software tools for data interpretation, 675
- study of glycan–protein interactions, 381
- Nuclear Overhauser effects (NOEs), 393, 650–651
- Nuclear pore proteins, 241
- Nucleocytoplasmic glycosylation, 223–237
- bacterial glycosyltransferase toxins, 228–229
- evolutionary variations in glycans, 259–260
- examples, 225t
- glycogenin, 224
- hydroxyproline-linked Skp1 glycans, 224, 226, 227f, 228
- mitochondria and chloroplasts, 235–236
- prokaryotic monoglycosylation, 228
- widespread nature of, 229–235
- Nucleotide sugar
- analogs as inhibitors of glycosylation, 707
- control of levels, 61
- plants, 307
- sugar donors, 51–52, 52t
- transporters, 58–61, 59f, 60t, 348

Nucleus, glycosylation reactions in, 49
Numbering of carbon atoms, 20, 24
Nutrient storage, polymerized glycans
for, 80

O

- O-acetylation, 74, 112
O-acetyltransferases, 188, 189
O-antigen, 274, 530
Oesophagostomum dentatum, 332
O-fucose
on epidermal growth factor (EGF)-like
repeats in *Caenorhabditis
elegans*, 324
glycosylation, 152–157, 152t, 153f–155f
roles in systemic physiology, 522–524
in thrombospondin type 1 repeats,
156–157
O-fucose glycans, 152–155
O-fucosylation, in *Plasmodium*, 543
O-fucosyltransferase, 342
epidermal growth factor (EGF), action
on, 68, 69
knockout in mice, 357–358
protein O-fucosyltransferases I and II
in *Caenorhabditis elegans*, 324–326,
328–329
POFUT1, 68–69, 89, 152, 154, 357,
509–510, 635
POFUT2, 68–69, 157, 509
thrombospondin repeats (TSR), action
on, 68, 69
Ofut1, 509
O-GalNAc glycan, 113–122
biosynthesis, 117–121
complex glycans, 121
core, 116–117, 117f, 119f, 120–122
polypeptide-N-
acetylgalactosaminyltransferases,
118–120
synthesis of cores, 120–121
defects, 578–579
description, 113
discovery, 113
embryology and development, role in,
522
endocrinology, role in, 523
functions, 121–122
inhibition of initiation of mucin-type
glycans, 705–706, 706f
isolation, purification, and analysis,
116–117
mucin glycoproteins, 113–115, 114f, 114t
O-GalNAc transferase, mutants defective
in, 635
O-GlcNAc, 323, 325, 342
changes in cancer, 606–607
O-GlcNAcase (OGA), 144f, 244–245,
247–249, 323
cancer and, 606
inhibitors of, 706–707, 706f
O-GlcNAc modification, 239–250, 240f
cellular location, 240, 240f, 241f
detection, difficulties of, 240–242
dynamic nature of, 245
enzymes controlling cycling, 242–245,
243f, 244f
examples of O-GlcNAcylated proteins,
242t, 245–246
functions, 247–250
cancer and, 249
diabetes and glucose toxicity, 249
epigenetics and transcription,
regulation of, 247
neurodegenerative diseases, 248
protein translation, stability and
turnover, regulation of, 247–248
stress survival, 250
historical background, 239–242
inhibitors of, 706–707, 706f
O-phosphate, interplay with, 246–247
ubiquity in metazoans, 245–246
O-GlcNAc transferase (OGT), 68, 260
action of, 243–244
biological functions, 247–249
Caenorhabditis elegans, 25, 323
cancer and, 606
inhibitors of, 706–707, 706f
interplay with O-phosphorylation,
246–247
knockout in mice, 357
O-GlcNAc cycling, role in, 243–244, 243f
regulation, 243–244, 243f
structure, 243
ubiquity in metazoans, 245–246
variants, 243
O-GlcNAcylation. *See also* O-acetylation
cancer and, 606
diabetes mellitus and, 244f, 245, 249, 523,
585
dynamic interplay between
O-GlcNAcylation and
O-phosphorylation, 246–247
endocrinology, role in, 523
future questions concerning, 767
heat-shock proteins, 245, 250
neurobiology, role in, 525
tau, 248
O-glucosyltransferase, 342
O-glycan(s). *See also* O-GalNAc glycan
ABO blood group determinants on, 165f
arthropods, 340–343, 341f
basidiomycete, 301
branching, 32, 32f
of *Caenorhabditis elegans*, 323–324, 325f
characterization of O-glycans released
from proteins, 657–663
degradation of, 559
in ER–Golgi pathway, 42, 43f
evolutionary variations in, 258–259
fungal, 296, 297f, 300–303
glycosylation of extensions, 162f
in IgA nephropathy, 591
inhibitors of, 705–706, 706f
keratan sulfate, 213
mutants in synthesis, 634–635
plants, 313–314
poly-LacNAc extensions, 163
structure, 10, 10f
truncated in cancer, 599–600, 601f
O-glycanase, 116, 641, 659
O-glycosylation, 48, 115–116, 118–119, 122
bacteria, 277
cytoplasmic, 223–229
defects in, 571t, 576–578, 577f
endoplasmic reticulum (ER) glycoprotein
quality control, 509–510
glycoengineering
in bacteria, 720
in insect cells, 723
in mammalian cells, 724–726
in plant cells, 722–723
in yeast, 721–722
in *Plasmodium*, 543
OGT. *See* O-GlcNAc transferase
Old World primates, glycosylation, 262
Oleandrin, 317
Oligochitins, 515
Oligochitosans, 515
Oligogalacturonides, 514, 515f, 516
Oligomannose, 100, 100f
Oligomannosyl N-glycans, degradation of,
558
Oligosaccharides, 31–39
branching, diversity from, 31–33, 32f
defined, 3, 19
milk, 82, 170, 738
nomenclature, 28–29
raffinose, 306
repeating units, 39t
signals in early development, 516–517,
517f
Oligosaccharins, 514
Oligosaccharyltransferase (OST), 517
glycoengineering, 720
in N-glycan synthesis, 102, 103f, 104
O-mannose, cytoplasmic, 231, 232
O-mannose glycans, 157–158, 158f
O-mannosylation
pathway defects, 571t, 576–578, 577f
Saccharomyces cerevisiae, 510
O-mannosyltransferase, 157
Onchocerca volvulus, 332
Onco-fetal antigens, 597
Oncology. *See* Cancer
“One enzyme–one linkage” hypothesis, 66
Ontology, 673, 677
Open-chain form of monosaccharides, 3, 5f
O-phosphate, O-GlcNAc interplay with,
246–247
Optimer (computer program), 686, 688
Oral biology, glycans in, 523
Organic acids, 757
Oseltamivir, 730f, 731, 731f
Osmoregulated periplasmic glucans,
277–278
OST. *See* Oligosaccharyltransferase
Osteoarthritis, 205, 737
Osteochondrodysplasia, 580
Osteoclasts, Siglecs and, 457, 461
Osteoglycin, 211t

- Ostreococcus tauri*, 94, 307, 307t
O-sulfate, 12
O-sulfotransferase, 216, 218–219
Overexpression, 718
Oxidation of monosaccharides, 25–26, 26f
Oxygen-regulated protein 150, 232
- P**
- p53, O-GlcNAcylation of, 247
p62, O-GlcNAcylation of, 241
p67, O-GlcNAcylation of, 248
PAI-1 (plasminogen activator inhibitor-1), 586
Paired immunoglobulin-like receptor B (PirB), 460
Paired immunoglobulin-like type 2 receptors (PILR), 454
Palade, George E., 42
Palmer, John, 197
PAMPs. *See* Pathogen-associated molecular patterns
PAPS (phosphoadenosine-5'-phosphosulfate), 74
Para-Bombay phenotype, 167
Parafusin, 232
Paragloboside, 169, 169f
Parasitic infections, 539–550
 Acanthamoeba, 550
 background on, 539–541
 distribution of diseases, 540t
 major helminth, 539, 541, 541t
 major protozoal, 539, 540t
 table of glycan-recognizing proteins, 543t
 Cryptosporidium parvum, 550
 Entamoeba, 489, 547, 548f
 Giardia lamblia, 550
 Haemonchus contortus, 549, 549f
 lectins, 489–490, 489t
 Leishmania, 545–547, 546f
 Plasmodium, 489–490, 541–543, 542f
 Schistosoma, 547–550, 548f, 549f
 Teladorsagia circumcincta, 550
 Toxocara, 550
 Trichinella spiralis, 550
 trypanosomes, 543–545, 544f, 545f
Parasitism, defined, 539
Parelaphostrongylus tenuis, 332
Parkinson's dystonia, 248
Paroxysmal cold hemoglobinuria, 169, 588
Paroxysmal nocturnal hemoglobinuria (PNH), 149, 588, 604
Partially methylated alditol acetates, 646
Parvovirus B19, P blood group antigens and, 170
PAS (periodic acid–Schiff) reaction, 640
Pasteur, Louis, 294
Pasteurella, hyaluronan synthesis, 93, 199, 205
Patenting, 732
Pathogen-associated molecular patterns (PAMPs), 82, 265–266, 270, 274, 441, 442, 519, 530
Pathogens
 detection using glycanomaterials, 751
 glycan-based interactions between host and gut microbiota, 531–533
 molecular mimicry of host glycans by, 78, 82, 260–261
 scavenging sialic acids from extracellular space, 189
 sialic acid recognition, 191–192, 192f
 sialidases, 189
 targeting Neu5Gc (5-N-glycolylneuraminic acid), 186
PaTox, 532
Pattern-recognition receptors (PRRs), 420, 441, 442, 444, 519
Paucimannose, 106
 in arthropods, 336
 insects, 723
 plants, 307, 314, 315f, 316, 722
Paucimannosidic glycans, 323, 324f, 327
PBCV-1 virus, 233–234, 260
P blood group, 169–170, 169f, 531, 588, 590
PCPL (podocalyxin-like protein), 449
PDB. *See* Protein Data Bank
PDI (protein disulfide isomerases), 504, 508
PDX-1, O-GlcNAcylation of, 247
Pea lectin, 417
Peanut agglutinin, 416, 417f, 747
Pectin(s), 33–34, 306–307, 308f, 309, 311–313, 514, 755
Penicillin, 270
Pentoses, 8
Pentraxins, 368, 420
Peptic ulcer disease, 586
Peptide-N-glycanase (PNGase), 508
Peptide-N-glycosidase A (PNGase A), 101, 642t, 644, 659
Peptide-N-glycosidase F (PNGase F), 101, 641, 642t, 644, 659
Peptidoglycan, 266–270
 assembly, 269–270
 structure, arrangement and function, 268–269, 268f
Periodate oxidation, 640
Periodic acid–Schiff (PAS) reaction, 640
Periplasm, 266, 272
Perkinsus marinus, 478–479
Perlecan, 209f, 211t, 213, 330, 343
Peroxisome, methanol oxidation in, 300
Pertussis toxin, 436
PEST sequence, O-GlcNAcylation within, 246
Peters plus syndrome, 157
Pgant genes, 340, 341f
PGIP (polygalacturonase-inhibiting proteins), 515
PglB, *Campylobacter jejuni*, 720
PGM (phosphoglucomutase) protein family, 232
Phage display, 614
Phagocytosis, 365, 441, 528
PHAL (phytohemagglutinin L), 416
Pharmaceutical industry, glycans in, 729–740
Pharmacological chaperone therapy (PCT), 566
Pharmacology, sialic acids in, 194–195
Phaseolus vulgaris, 612
Phosphacan, 212t, 213, 214
Phosphatidylinositol, 10
Phosphatidylinositol mannosides, 272
Phosphoadenosine-5'-phosphosulfate (PAPS), 74
Phosphodiester linkages, 39
Phosphoethanolamine, 10, 530
Phospho-GlcNAc transferase, 178
Phosphoglucomutase (PGM) protein family, 232
Phosphoglycosylation, 74
Phospholipase A2 receptor (PLA2), 408–409
Phospholipase C (PLC), 137, 141f
Phospholipomannan antigens (PLMs), 302
Phosphomannomutase, knockout in mice, 357
Phosphomannomutase 2 (PMM2) gene, 357, 571t, 572
Phosphomannose isomerase, 55
Phosphopeptidomannans, 302
Phosphorylated glycans, 178
Phosphorylation
 donors for glycan modification, 61, 62t
 of glycans, 74
 of N-glycans, 108
Photorhabdus asymbiotica, 532
Phylogeny of life on earth, 254, 255f
Physiology. *See* Systemic physiology, glycans in
Phytoalexins, 514
Phytohemagglutinin, 362
Phytohemagglutinin E (E-PHA), 418, 612, 613f, 617–618
Phytohemagglutinin L (PHAL), 416, 598, 612, 613f, 618
Phytophthora infestans, 301
Phytophthora megasperma, 514
Phytosphingosine, 126
Pichia pastoris, 300, 717t, 721
Pieris brassicae, 407
Pierisin-1, 407
Pierisin-2, 407
Pieris rapae, 407
PIGA, 148–149, 588, 603–604
PIG genes, 580
Pili, 364, 485, 485f, 531, 532f, 746, 751
Pituitary glycoprotein hormones, 171–173, 172f, 523
PKD1 gene, 450
P^K transferase, 169
PLA2 (phospholipase A2) receptor, 408–409
Plant lectins, 362, 367f, 368
 L-type lectins, 415–418
 distribution and localization, 415–416
 function, 418
 structure, 416–418, 417f

- Plant lectins (*Continued*)
mutants selected for resistance to, 630, 631
R-type, 402–407
- Plants, 17, 305–319
alkaloids as inhibitors of glycosylation, 704–705, 705t
bioenergy and materials science, 755–759
cell wall, 305, 307–313, 755–756
primary cell wall glycans, 309–312
secondary cell wall glycans, 312–313, 756
defense response, glycan signaling and, 514–515, 515f
diverse sugars in, 58
genomics of glycosylation, 94
glycan diversity, 306–307
glycan-modifying enzymes, 307
glycolipids, 316–317, 317f
glycosylation engineering, 717t, 722–723, 733–734
glycosyltransferases, 307, 313, 318
humanized, 734
Lewis antigens, 169
mono- and digalactolipids, 236
mutants, analysis of, 317–319
N-glycans, 314, 315f, 316
nitrogen fixation and, 515–516, 516f
nucleotide sugars, 307
O-glycans, 313–314
oligosaccharide signals in early development, 516–517, 517f
pectins, 33–34
polysaccharides, detection of, 643
secondary metabolites, 317
- Plasma fibrinogen, 588
- Plasma membrane
glycosphingolipids in, 129, 131–132
glycosylation reactions at, 43–44
- Plasminogen, as CI-MPR ligand, 431
- Plasminogen activator inhibitor-1 (PAI-1), 586
- Plasmodium*, 94, 191, 489–490, 542–543, 542f, 543t
- Platelet endothelial cell adhesion molecule (PECAM)-1, 454
- Platelet factor-4, 587
- PLC (phospholipase C), 137, 141f
- PLE (protein-losing enteropathy), 586
- PLMs (phospholipomannan antigens), 302
- PMT (polypeptide mannosyltransferase), 296, 721
- PNAG (poly-N-acetylglucosamine), 280, 533
- Pneumococcal vaccine, 278, 738
- Pneumocystis carinii*, mannose receptor binding, 408
- PNGase A, 101, 642t, 644, 659
- PNGase F, 101, 641, 642t, 644, 659
- PNH (paroxysmal nocturnal hemoglobinuria), 149, 588, 604
- Podocalyxin, 524, 591
- Podocalyxin-like protein (PCLP), 449
- Podoplanin, 443
- POFUT1, 68–69, 89, 357
- POFUT2, 68–69
- POGLUT* gene, 156
- Polycomb group genes, 342
- Polycystin-1, 450
- Polygalacturonase-inhibiting proteins (PGIP), 515
- Polyglycosylceramides, ABH determinants, 165
- Polylectosamines, 11
- Poly-N-acetylglucosamine (PNAG), 280, 533
- Poly-N-acetylglucosamine, 163
ABO group antigens, 165
β1-6GlcNAc-branched, 163, 164f
in cancer, 598
formation of, 162–163, 162f
I and i blood groups, 163, 164f
keratan sulfate, 208, 214, 216
structure, 11
- Polypeptide β-xylosyltransferase 2, 95, 96f
- Polypeptide mannosyltransferase (PMT), 721
- Polypeptide
N-acetylgalactosaminyltransferase (ppGalNAcT), 95, 96f
arthropod, 340, 341f
evolutionary variation, 258–259
inhibitors of, 705–706, 706f
- Polysaccharide(s), 31–39
abundance in nature, 254
bacterial, 36–39, 37f
capsules, 266, 278, 279f, 280, 528–529, 529f
detection of, 643
exopolysaccharide, 266, 278, 279f, 280
lipopolysaccharide (LPS), 266, 272–276, 273f, 275f
bioconversion, 757
cell-surface of animals, 34–36
charged, 38
defined, 19
heteropolysaccharides, archaea, 286–287
mucopolysaccharides, 207
O-antigen, 274–276
plant, 306, 757–758
repeating units, 39t
storage, 33
structural, 33–34
use of term, 3
vaccines, 738
- Polysaccharide A, 82
- Polysaccharide-based nanoparticles, 750
- Polysaccharide intercellular adhesin, 280
- Polysialic acid, 12, 80, 176, 176f, 183–185
- POMGNT1, 157–158, 576, 577f, 578
- POMGNT2, 157–158
- POMK, 158
- Pompe disease, 556, 566, 567, 735
- POMT1/POMT2* (protein O-mannosyltransferases I and II), 157, 571t, 576–577, 577f, 721
- Poplar, 94
- Porcine reproductive and respiratory syndrome virus, 458
- Porphyromonas gingivalis*, 737
- Posttranslational modification, 12
- PPG (proteophosphoglycan), of *Leishmania*, 546f, 547
- Precipitation
lectin for, 621–622
for study of glycan–protein interactions, 383–384
- Primates, 360
- Prion diseases, 150
- Probiotic bacteria, 280
- Procyclins, 543, 544f
- ProfilePSTMM, 674
- Prokaryotes. *See also* Archaea; Bacteria
glycan diversity, 260
monoglycosylation, 228
N-glycosylation, 254
nonulosonic acids, 181
sialyltransferase, 188
topology of glycosylation, 229, 230f
- Prolectin, 443
- Proliferin, mannose 6-phosphate on, 432
- Prolyl-4-hydroxylase, 722
- Properdin, 157
- Prosaposin, 563
- Prostate cancer, 739
- Proteasome, 654–655
- Protective groups, 681–684, 683f
- Protective protein/cathepsin A defect in, 556t
N-glycan degradation, 558
- Protein(s)
glycan attachment sites on, 676
glycosylation, site-specific structural diversity in, 12
- Proteinaceous sheaths, archaea, 284, 286
- Proteinases, 554
- Protein Data Bank (PDB), 388, 651, 672, 675–676
- Protein disulfide isomerases (PDI), 504, 508
- Protein folding, 503–511
calnexin/calreticulin (CNX/CRT), role of, 504–505, 506f
chaperones, 503–504
determination of proper, 504–507
diseases associated with, 510–511
misfolded proteins, retrotranslocation and degradation of, 508
removal of misfolded glycoproteins from CNX/CRT/UGGT cycle, 507–508
UDP-Glc:glycoprotein glycosyltransferase (UGGT), role of, 504–507, 506f
- Protein-losing enteropathy (PLE), 586, 736
- Protein mannosyltransferases (PMTs), in yeast, 296
- Protein O-fucosyltransferases I and II (POFUT1 and POFUT2)
in *Caenorhabditis elegans*, 324–326, 328–329
ER quality control and, 509–510
mutants defective in POFUT1, 635

- POFUT1, 68–69, 89, 152, 154, 357, 509–510, 635
POFUT2, 68–69, 157, 509
Protein O-mannoside
 β1-2GlcNAc-transferase (POMGNT), 576, 577f, 578
Protein O-mannosyltransferases I and II (POMT), 157, 571t, 576–577, 577f, 721
Proteinuria, 585
Proteoglycan(s), 207–220
 Caenorhabditis elegans, 329–330, 330f
 chondroitin sulfate, 207, 209–210, 209f, 213
 biosynthesis, 215f, 216, 217f, 218–219
 degradation, 218, 220
 galactose sulfation, 215
 linkages, 214
 structure, 210f, 209
 types, 218t
 composition, 208, 209f
 with C-type lectin domains, 449–450
 defects in synthesis, 579–580
 dermatan sulfate, 207, 209–210, 209f, 219
 biosynthesis, 217f, 218
 processing and turnover, 22–, 220
 small leucine-rich proteoglycans (SLRPs), 210
 structure, 210f, 214, 217f
 detection, 641
 diversity, 208–213, 209f, 211t–212t
 basement membrane, 213, 220
 membrane-bound, 209f, 212t, 213
 secretory granule, 208
 in extracellular matrix, 209f, 210, 211t–212t, 213, 220
 functions, 208–213
 heparan sulfate, 207, 209, 213
 biosynthesis, 217f, 218–219
 heparin distinguishes from, 219–220
 heparin lyases, 218
 linkages, 214, 215f, 216
 processing and turnover, 220
 structure, 210f, 217f
 historical perspective, 207–208
 information content, 767
 insect, 343–346
 keratan sulfate, 207–210
 biosynthesis, 216, 217f
 linkages, 213–214, 214f
 structure, 214, 214f, 219f
 types, 213–214, 214f
 mutants in assembly, 634, 634t
 part-time, 209, 213
 processing and turnover, 222–223, 223f, 224f
 protein ligands, 224–225, 225t
 purification and analysis, 208
 small leucine-rich proteoglycans (SLRPs), 210, 211t
 structure, 10, 10f
Proteomics, 654
Proteophosphoglycans (PPG), of
 Leishmania, 546f, 547
Protozoans. *See* Parasitic infections
PRRs (pattern-recognition receptors), 441, 442, 444
PSA (polysialic acid), 176, 176f
Psathyrella velutina, 391
P-selectin, 193, 370, 371, 445f, 446–447, 500, 602–603
P-selectin glycoprotein ligand-1 (PSGL-1), 445f, 446–448, 585
Pseudallescheria boydii, 297f
Pseudaminic acid, 180f, 181, 277
Pseudo-hurler polydystrophy, 427
Pseudomonas
 biofilm, 280
 EF-P protein, 228
 P. aeruginosa
 in *Caenorhabditis elegans*, 328
 cystic fibrosis, 594
 exotoxin A, 421
 LecA and LecB, 390, 390f
 solution phase synthesis of
 exopolysaccharide repeating unit, 684, 685f
Pseudomurein, 283, 284, 286f
Pseudopeptidoglycan. *See* Pseudomurein
PSGL-1 (P-selectin glycoprotein ligand-1), 370–371, 445f, 446–448, 585
PSP (pancreatic stone protein), 450
Psychiatry, 592–593
P-type lectins, 364, 423–433
 historical background, 423–427, 424f
 mannose 6-phosphate receptors (MPRs)
 CD-MPR (cation-dependent MPR), 427–429, 428f, 431
 CI-MPR (cation-independent MPR), 427–432
 common features, 427–428
 enzyme replacement therapy, implications of, 429–430
 evolutionary origins of M6P recognition system, 431
 genetic defects in, 428–429
 nonlysosomal proteins and, 431–432
 subcellular trafficking, 429–433, 430f
 mannose 6-phosphate recognition marker
 discovery, 424
 generation of, 425–427, 425f
PUGNAc, 706, 706f
Pulmonary arterial hypertension (PAH), 594
Pulmonary physiology, glycans in, 523
Pulmonary system, 593–594
 acute respiratory distress syndrome, 593–594
 bronchial asthma, 593
 cystic fibrosis, 594
 vascular disease, 594
Pulmonary vascular disease, 594
Pulsed amperometric detection, 644–645
Purification of glycans, 619–621, 620f
Pyranose, 23, 23f
Pyruvate lyases, Sia-specific, 190
Pyruvylation
 donors for glycan modification, 61, 62t
 of glycans, 74

Q
Quality control, 503–511
 disease and, 510–511
 endoplasmic reticulum glycoprotein
 quality control, 503–511, 506f, 509f
O-glycosylation, 509–510
protein folding
 chaperones, role of, 503–504
 determination of proper, 504–507
 model of, 506f
 removal of misfolded glycoproteins
 from CNX/CRT/UGGT cycle, 507–508
 retrotranslocation and degradation of
 misfolded proteins, 508
Quantum dots, 745f, 747
Quantum mechanical methods, 395
Quartz crystal microbalance, 751

R
Radiation suicide, 630
Radical fringe, 153
Raetz, Christian, 274
Raffinose oligosaccharides, 306
RAGE (receptor for advanced glycation end products), 585
Rana catesbeiana, galectins, 472
Rational design using crystal structures, 710–712, 710f–711f
Rb tumor suppressor protein,
 O-GlcNAcylation of, 247
RCA-I lectin, 402–404
RDF (Resource Description Framework), 673, 677
Receptor
 adhesin, 531–532, 532f
 finding that recognize specific glycans, 86
 mutants, study of, 88
 Receptor for advanced glycation end products (RAGE), 585
 Receptor for hyaluronan-mediated motility (RHAMM), 204
 Receptor-mediated endocytosis, 438
Red blood cell
 ABH determinants, 164–167
 Lewis antigens, 167–169, 168f
 P blood group, 169–170, 169f
 transfusion reaction, 167, 168, 169
Red Queen effect, 263, 461, 462f
Reducing end, 5, 29, 29f
Reducing power, 5–6
Reducing sugars, 25
Reduction of monosaccharides, 25–26, 26f
Reductive amination, 26
Reg3α, 450

- Regiochemistry, controlling in chemical synthesis of glycans and glycoconjugates, 681–682
- Regioisomers, 28
- Regulatory switches, glycans as, 2
- Relenza, 182, 189, 194, 535, 711, 730f, 731, 731f
- Renewable energy, 762
- Reperfusion injury, 584
- Replica plating, 629f, 630
- Reproductive biology, glycans in, 521
- Research, impact of glycosciences on future, 761–762
- Resource Description Framework (RDF), 673, 677
- RESTful, 677
- Retroviral gene trap, 628, 629f
- RHAMM (receptor for hyaluronan-mediated motility), 204
- Rhamnogalacturonan(s), 311–312
- Rhamnogalacturonan I, 308f, 314
- Rhamnogalacturonan II, 307, 308f, 311–312
- Rhamsan, 37f, 38
- Rheumatoid arthritis, changes in IgG glycosylation in, 589–590
- Rhizobium*, 418, 482, 515–516
- Rho family proteins, 228
- Rho GTPase, 532
- Ribose, structure of, 22f
- Ribosome-inactivating protein type I (RIP-I), 404
- Rice, glycosyltransferases of, 94
- Ricin, 401–405, 404f, 405f
- Ricinus communis*, 401–405, 404f
- Ricinus communis* agglutinin (RCA), 614f, 619, 745
- Ring flip, 24
- Ring form of monosaccharides, 3, 5f, 21, 23–25, 23f–24f
- RINGS, 674, 675
- Rivipanel, 587
- RNA N-glycosidase, 405
- RNA polymerase II, O-GlcNAc and, 240, 246–247
- RNase 2, 159, 159f
- Robbins, Phil, 294
- Roseman, Saul, 66
- Rossmann fold, 70
- Rotated abdomen (rt)* gene, 342
- Rotavirus, 421, 483
- R-type domain, 403–404, 405f
- R-type lectins, 368, 401–411
- animal lectins, 407–411
 - DEC-205, 409
 - Endo180, 409
 - mannose receptor, 407–408
 - overview, 407
 - phospholipase A2 receptor, 408–409
 - UDP-GalNAc:polypeptide α -N-acetylgalactosaminyltransferases (ppGalNAcTs), 409–411, 410f
 - background, 401–402
 - members of superfamily, 402f
 - microbial, 411
 - plant lectins, 402–407
 - Ricinus communis* lectins, 402–405
 - general properties, 402–403
 - R-type domain, 403–404, 405f
 - toxicity of ricin, 404–405
- Rumi, 342
- ## S
- Saccharide, 19
- Saccharomyces cerevisiae*, 293–294
- ALG gene, 102
 - cell wall, 294
 - chitin synthesis, 294
 - ERAD complex, 508
 - glycolipids, 298, 299
 - GPI-anchors, 299, 299f
 - lysosomal enzymes, 431
 - mmm* mutants, 299, 300
 - as model yeast, 298–299
 - N-glycans and O-glycans, 299
 - nucleotide sugar transporter, 61
 - O-mannosylation, 510
 - polypeptide mannosyltransferase (PMT), 721
 - protein glycosylation in, 295–296
 - role of GPI anchors, 148
 - Yos9p, 507–508
- Safe harbor sites, genome, 718, 719t
- Salivary gland mucin, 523
- Salmonella*
- invasion factors, 532
 - pili, 531
 - S. enterica* O54 antigen, 37, 37f
 - S. typhi*, 191, 529
- Salt-and-pepper syndrome, 581
- Salvage pathways, for monosaccharides, 53
- Sambucus* (elderberry), 405–406
- Sambucus nigra*, 418
- Sambucus nigra* agglutinin (SNA), 190, 231, 406, 615f, 617, 623, 640
- Sambucus sieboldiana* lectin (SSA), 406
- Sandfly, 545–547, 546f
- Sandhoff disease, 557t, 566
- Sanfilippo A-D, 557t
- Sapogenin deficiency disease, 557t
- Sapogenins, 131, 562, 563–564
- Saturation transfer difference (STD), 381, 393–394, 394f
- SAXS (small-angle X-ray scattering), 388, 399
- Scheie syndrome, 557t, 559, 566
- Schekman, Randy, 294
- Schiff base formation, 26, 27f
- Schindler disease, 556t, 559
- Schistosoma*, 476, 547–550, 548f
- Schizophrenia, 184
- Schizophyllum commune*, 298
- Schizosaccharomyces pombe*, 295–296, 299–300, 510
- Schneckenbecken dysplasia, 580
- Scytonema* sp., 301
- Sd^a antigen, 173–174, 173f
- Sdc* mutants, 343, 345
- SDF1, 397
- SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis)
- characterization of released glycans, 659
 - glycan detection, 640, 643
 - O-GlcNAc detection, 240–241
- Sea squirt, 355
- Sea urchins, 352–353, 353f
- Seaweed, 316
- Secondary metabolites, plant, 317
- SECRET AGENT* gene, 245
- Secretory granules, proteoglycans in, 208
- Se* gene (secretor), 164–167
- Selaginella*
- Selectins, 364, 389, 522
- acute respiratory distress syndrome, role in, 594
 - atherosclerosis, role in, 584
 - bronchial asthma, role in, 593
 - C-type lectins, 444–449, 445f
 - E-selectin, 445f, 448
 - inflammatory skin diseases, role in, 585
 - inhibition of selectin-mediated leukocyte trafficking, 739
 - leukocyte tethering and rolling, 444
 - ligand expression increase in cancer, 602–603, 602f
 - L-selectin, 445f, 448–449
 - overview, 444–446
 - P-selectin, 445f, 446–447
 - PSGL-1, 445f, 446–448
 - reperfusion injury, role in, 584
 - sickle cell crisis, role in, 587
 - structure and functions, 445f
- Self antigens, 166
- Self-associated molecular patterns (SAMPs), 82, 258, 278, 466, 519, 522
- Semantic Web, 673, 677
- Seminolipid
- function of, 127
 - structure, 126f
- Separation of glycans, 644–645
- Serglycin, 212t, 213, 220
- Serial lectin affinity chromatography, 619, 620f
- Serine
- glycosaminoglycan chains linked by xylose to, 214–215
 - O-glycosylation, 113
- Serrate, 152, 154, 342
- Serum half-life, optimizing glycans of therapeutic glycoproteins for prolonged, 731–732
- SGLT (sodium-dependent glucose transporters), 52–53
- Sharon, Nathan, 482
- Shiga toxin, 134, 488, 488t
- Shigella dysenteriae*, 488, 488t
- Shigella flexneri*
- O antigens, 37f, 38
 - serotype conversion in, 93
- Sia-binding lectins, 193
- Sia-binding proteins, 191–192, 192t

- SIAE* gene, 189
- Sialic acid, 179–195
- abbreviated names, 181
 - activation of, 52, 52t
 - atherosclerosis, role in, 584
 - capsule, 93
 - changes in expression in cancer, 601–602, 601f
 - classification, 181
 - cytoplasmic glycoproteins, 231
 - desialylation of blood cells by circulating microbial sialidases during infections, 590
 - in development and malignancy, 193–194
 - discovery, 180–181
 - drugs targeting, 733t
 - evolutionary history, 179, 181
 - distribution of sialic acids, 185
 - human loss of Neu5Gc, 185–186
 - variations in sialic acids, 258
- family, 181–182
- functions, 190–193
- biophysical roles, 191
 - recognition by pathogens and toxins, 191–192, 192t
 - recognition within vertebrates, 192–193
- Sia-binding lectins, 193
- in gangliosides, 11, 130
- in glycocalyx, 7
- influenza virus binding to, 174, 534–535, 534f
- metabolism, 186–190
- modifications of sialic acids, 188
 - overview, 57–58
 - recycling and degradation, 189–190
 - release of sialic acids, 188–189
 - synthesis of sialoglycans, 186, 187f, 188
- methods of studying, 190
- modifications of, 188
- in nephrotic syndrome, 591
- in pharmacology, 194–195
- polysialic acid (PSA), 176, 176f, 183–185
- recycling and degradation, 189–190
- release of, 188–189
- secretion, 61
- sialoglycan diversity, 182–183, 183f
- structure, 180–182, 180f, 184f
- transport, 53
- in trypanosomes, 544
- ulcerative colitis and, 586
- virus hemagglutinin recognition of, 82
- Sialic acid-binding lectins, 190
- Sialidase, 44, 188–189, 457, 465, 525
- deficiency, 556t, 557t, 558
 - desialylation of blood cells, 87, 590
 - endosialidase, 642t
 - glycolipid degradation, 563f
 - influenza, 482–483, 490, 535
 - inhibitors, 710–711, 710f–711f
 - leech *trans*-sialidase, 421
 - N-glycan degradation, 555f, 558
 - pathogen secretion of, 590
 - saposins and, 563
 - specificity and uses, 642t
 - trypanosome *trans*-sialidases, 543–544
 - Vibrio cholerae*, 421, 591
 - as virulence factors, 189
 - viruses, 188–189, 194
- Sialidosis disease, 556t, 557t
- Sialidosis mucopolipidosis I, 556t
- Sialin, 189
- Sialoadhesin, 260, 454, 455f, 456, 456f
- discovery, 457
 - expression patterns and functions, 458
- Sialoglycans
- diversity, 182–183, 183f
 - synthesis of, 186, 187f, 188
- Sialoglycoproteins, 189, 191, 194
- Sialome, 182, 184f
- Sialotransferases
- genes encoding, 182
 - polysialic acid formation, 183–184
- Sialuria, 61, 188
- Sialylated glycans, 174–177
- α 2-3, 174, 175f
 - α 2-6, 174–175, 175f
 - α 2-8, 175–177, 176f
- Sialylation
- in arthropods, 339–340
 - glycoengineering, 720
- Sialyl Lewis^x epitopes, 122, 602, 607
- Sialylmotifs, 188
- Sialyl-Tn antigen, 600, 600f
- Sialyltransferase (SiaT)
- α 2-3, 67, 174, 175f
 - α 2-6, 174–175, 175f
 - α 2-8, 175–177, 176f
 - arthropod, 336, 339
 - domain structure of, 70, 70f
 - O-glycans and, 121
 - ST3GAL1, 723
 - ST6GAL1, 398–399, 399f, 601, 607
 - ST6GALNAC1, 600, 600f
- SiaT. *See* Sialyltransferase
- Sickle cell disease, 447, 587
- Siglec (sialic-acid-binding, immunoglobulin-like lectin), 185,
- 193, 364–365, 453–466, 522
 - bronchial asthma, role in, 593
 - CD22 (Siglec2), 457–459, 460f
 - CD33-related Siglecs (CD33rSiglecs)
 - CD33 (Siglec-3), 462–463
 - discovery, 454
 - domain structure, 455f
 - evolution, 454, 461, 462f
 - genomic organization, expression patterns, and functions, 461–465, 462f
 - Siglec-5 (CD170), 455f, 463, 466
 - Siglec-6, 455f, 463–464, 467
 - Siglec-7, 455f, 456, 456f, 457, 464
 - Siglec-8, 455f, 456, 457, 464
 - Siglec-9, 455f, 457, 464
 - Siglec-10, 455f, 465
 - Siglec-11, 455f, 457, 465, 466
 - Siglec-12, 466
 - Siglec-13, 466
 - Siglec-14, 455f, 457, 463, 466
 - Siglec-15, 455f, 457, 461
 - Siglec-16, 455f, 457, 465
 - Siglec-17, 466
 - common features, 455–457
 - masking and unmasking, 457
 - restricted patterns of expression, 457
 - tyrosine-based signaling motifs, 457
 - V-set domain, 455–456, 456f
- human-specific changes in Siglec biology, 465–466
- myelin-associated glycoprotein (MAG) (Siglec-4), 454, 455f, 457, 459–461
- nonsialylated ligands, 466
- sequence motifs, 92
- sialoadhesin (Siglec-1, CD169), 454, 455f, 456–458, 456f
- Siglec-E, 455f, 464
- Siglec-F, 455f, 457, 464–465, 593
- Siglec-G, 455f, 465
- Siglec-H, 455f, 457, 463
- Siglec receptors, 189
- Signaling
- by free glycans, 513–519
 - glycosaminoglycans (GAGs), 518–519, 518f
 - innate immunity activation, by bacterial glycans, 519
 - nature and scope of glycan systems, 513–514
 - Nod factors, 515–516, 516f
 - oligosaccharide signals in early development, 516–517, 517f
 - plant defense response, 514–515, 515f
 - future questions concerning, 766–767
 - hyaluronan and, 204–205
 - morphogen in *Drosophila*, 344
 - Notch, 153–156, 154f, 155f, 342–343, 343f, 348
- SIGN-RI, 442
- Simple carbohydrate
- SimpleCell strategy, 727
- Single-chain variable fragments (scFvs) of antibodies, 614
- Single-walled carbon nanotubes (SWCNTs), 748, 749f
- Size-exclusion chromatography, 644
- Skew conformation, 35
- Skin biology, glycans in, 524
- Skin diseases, inflammatory, 585
- Skin permeability, role of glycosphingolipids in, 132
- Skp1, glycosylation of, 224, 226, 227f, 228
- Slalom (*sl*), 348
- S-layer, 99, 270, 277
- archaeal, 284, 287, 289–291
 - biosynthesis, 44
- SLC35A2* gene, 574
- SLC35C1* gene, 574
- SLE (systemic lupus erythematosus), 591
- Sleeping sickness, 543
- SLe^x antigens, 446–449
- Slip bonds, 449

- Sly, William, 424
Sly syndrome, 557t
slytherin mutant, 356
Small-angle X-ray scattering (SAXS), 388, 399
Small leucine-rich proteoglycans (SLRPs), 210, 211t
Small-molecule drugs, 729, 730f, 731, 731f
SNA (*Sambucus nigra* agglutinin), 190, 231, 406, 615f, 617, 623, 640
SNAiL, 607
SN2 reaction mechanism
 acid glucosylceramidase, 692
 glycosyltransferase, 71, 72f
 sulfotransferase, 74
Sodium borohydride, 26, 26f
Sodium borotritide reduction, 140
Sodium cyanoborate, 26
Sodium-dependent glucose transporters (SGLT), 52–53
Software tools for data interpretation, 673–676
 glycan attachment sites on proteins, 676
 glycan-binding data interpretation, 675
 liquid chromatography, 675
 mass spectrometry, 673–674
 NMR, 675
 3D glycan structure modeling, 675–676
Solid-phase chemical synthesis of glycans and glycoconjugates, 684, 686, 687f
Solution phase chemical synthesis of glycans and glycoconjugates, 684, 685f
Sorbitol, in chewing gum, 737
Soybean agglutinin, 415–418, 415f
Sp1, O-GlcNAcylation of, 247
Space of Disse, 524
SPAM1 (sperm adhesion molecule1) gene, 200, 203
Sperm
 acrosome reaction, 352
 capacitation, 203
 glycosylphosphatidylinositol anchors and *SpHas* gene, 198, 199
Sphinganine, 126
Sphingolipid, 125, 131. *See also* Glycosphingolipid
Sphingolipid activator proteins (SAPs). *See* Saposins
Sphingolipid analogs, 709
Sphingomyelin, 125, 131
Sphingomyelinase, saposins and, 563
Sphingosine, 125, 126
Spongiform encephalopathy, 150
26S proteasome, O-GlcNAcylation of, 252
SPY gene, 245
Sqv mutants, *Caenorhabditis elegans*, 327f, 329
Srf mutants, *Caenorhabditis elegans*, 328
SRT (substrate reduction therapy), 134, 566, 735
SSA (*Sambucus sieboldiana* lectin), 406
SSEA-3 (stage-specific embryonic antigen-3), 607
Stabilin, 201f, 203
Stage-specific embryonic antigen-3 (SSEA-3), 607
Staphylococcus epidermidis, PNAG, 533
Starch, 5, 33–34, 80
STAT5, O-GlcNAc requirement of, 247
Stem cell niche, proteoglycans in, 344–345, 345f
Stem cells, cancer, 607
Stereochemistry
 at anomeric carbon, 32, 33
 controlling in chemical synthesis of glycans and glycoconjugates, 682–683, 682f
 glycosyltransferases and, 70–71, 72f
Stereoisomerism
 disaccharides, 28
 monosaccharides, 20–21, 25
Steviol glycosides, 317
ST3GAL1 sialyltransferase, 723
ST6GAL1 sialyltransferase, 398–399, 399f, 601, 607
Stillmark, Peter Hermann, 401
Streptococcus
 biofilms, 532, 533f
 hyaluronan synthesis, 198, 199, 205, 205f
 S. pneumoniae, 439, 447
 blockage of adherence, 490
 capsule, 278, 528, 529f
 hemolytic-uremic syndrome, 590
 sialidase, 189, 465
 S. pyogenes, 532
Streptomyces
 S. griseus, 58
 S. lividans xylanase 10A, 405f, 407, 411
 S. lysosuperificus
Streptomycin, 58
Streptose, 58
Streptozotocin, 706
Stress survival, O-GlcNAc and, 250
Strong anion-exchange chromatography, 644
Structural analysis of glycans, 639–652
 background, 639–640
 detection of glycans, 640–643
 glycolipids, 641
 glycoproteins, 641–643
 GPI-anchors, 643
 plant and bacterial polysaccharides, 643
 proteoglycans, 641
 linkage analysis, 646–651, 647f
 determination of linkage positions, 646
 mass spectroscopy, 646, 648–649
 NMR spectroscopy, 649–651, 650f
 monosaccharide composition analysis, 645
 release of glycans from glycoconjugates, 644
 separation of glycans, 644–645
 table of enzymes, 642t
 three-dimensional glycan structure, 651–652, 651f
ST8SIA1, 175, 177
ST8SIA2, 176
ST8SIA3, 176, 177
ST8SIA4, 176
ST8SIA5, 177
ST8SIA6, 175
S-type lectins, 469. *See also* Galectins
Substituted galacturonans, 311–312
Substrate reduction therapy (SRT), 134, 566, 735
Sucrose, structure of, 29, 29f
Sugar, 19
Sugar analogs, glycosylation inhibited by, 702–703
SugarBind, 675
Sugar ester, 28
Sulfatase
 arylsulfatase A (cerebrosidase sulfatase) deficiency, 557t, 563
 glycolipid degradation, 563, 563f
 saposins and, 563
 galactose-6-sulfatase degradation of keratan sulfate, 561f, 562
 heparan-N-sulfatase deficiency, 557t
 heparan sulfate degradation, 560f
 iduronate sulfatase deficiency, 557t
 degradation of dermatan sulfate and chondroitin sulfate, 561, 561f
 heparan sulfate degradation, 560, 560f
 recombinant, 567
 multiple sulfatase deficiency (MSD), 557t, 562
 N-acetylgalactosamine 4-sulfatase, 561f
 deficiency, 557t
 recombinant, 567
 N-acetylglucosamine-6-sulfatase, 560
 proteoglycan degradation, 220
Sulfated GAG-binding proteins, 16
Sulfated glycans, 177–178
 HNK-1 epitope, 177–178
 L-selectin ligands, 177
 pituitary glycoprotein hormones, 171–173, 172f
Sulfated glycosaminoglycan-binding proteins, 361–363, 369
Sulfated glycosaminoglycans, 207–220. *See also* Chondroitin sulfate; Dermatan sulfate; Heparan sulfate; Keratan sulfate
 changes in cancer, 606
 proteins that bind to, 213, 493–502
Sulfateless, (*sfl*) gene, 344
Sulfatide, role in myelination, 126, 129–130, 132
Sulfation, 73–74
 chondroitin, 215–218
 donors for glycan modification, 61, 62t
 heparan sulfate, 218–219
 heparin, 219
 inhibition by chlorate, 702
 keratan sulfate, 216

- Sulf enzymes, 44
Sulfolobus acidocaldarius, 291
Sulfoquinovosyldiacylglycerol, 317
Sulfotransferase
 CHSTs, 171, 177
 distribution of, 13
 donors, 74
 HNK-1 antigen and, 177
 inhibitors, 711–712
 keratan sulfate biosynthesis and, 216
 mechanism of action, 74
 roles of, 73–74
Sumner, James, 413
Support vector machines (SVMs), 676
Surface layer (S layer), 270, 277
Surface plasmon resonance, for study of
 glycan–protein interactions,
 378–379, 380f
Surfactant proteins SP-A and SP-D, 441
Sushi domains, 444
SV2, 212t
SVM (support vector machines), 676
Swainsonine, 109, 565, 598, 704, 705t
SWEET-II, 675
sxc locus, 342
Symbiosis, 82
Symbol Nomenclature for Glycans
 (SNFG), 8
Symbols and conventions for drawing
 glycans, 8, 9f
SynCAM 1, 185
Syndecan, 209f
 deletion in mice, 359
 family, 212t, 213
 insect, 343, 345
Syngas, 756
Synovial fluids, hyaluronan in, 198, 205
Systemic lupus erythematosus (SLE),
 458, 591
Systemic physiology, glycans in, 521–525
 airway and pulmonary physiology, 523
 cardiovascular physiology, 522–523
 embryology and development, 522
 endocrinology, 523
 gastroenterology, 523–524
 hematology, 522
 hepatology, 524
 immunology, 522
 musculoskeletal biology, 524
 nephrology, 524
 neurobiology, 525
 oral biology, 523
 reproductive biology, 521
 skin biology, 524
Systems biology
 critical role of glycomics in, 668f
 glycobiology as a part of, 677
- T**
- TACE (TNF- α -converting enzyme), 449
tACE (testis form angiotension converting
 enzyme), 149
Taenia solium, 539
Taglin, 550
TAIR (The Arabidopsis Information
 Resource), 318
Talglycerase, 722, 735
Talose, structure of, 22f
Tamiflu, 189, 194, 535, 711, 730f, 731, 731f
Tamm-Horsfall glycoprotein, 173, 486
T antigen, 115, 122, 600
Tau
 in Alzheimer's disease, 592
 O-GlcNAcylation of, 248
 paired helical filamentous (PHF)-tau, 248
 phosphorylation, 592
Tax, HTLV-1, 607
Tay-Sachs disease, 125–126, 134, 557t, 566
T4 bacteriophage, glycosyltransferase of, 93
T-cell receptor (TCR), galectin-3 and,
 477–478
Teichoic acids, 36, 39, 266, 270, 271f
Teichuronic acids, 271f
Teladorsagia circumcincta, 550
Tenascin-R, 450
Terminal sequences, evolutionary variations
 in, 256, 262
Terminology, glycan, 19–20
Testican, 343
Tetranectin, 436
Tetraselmis striata, 316
Tetratricopeptide repeats (TPRs), *OGT*,
 243, 243f
TGF- β (transforming growth factor β), 432
T helper 1 (Th1), 585
T helper 2 (Th2), 549
Therapeutic uses, 729–740
 blocking glycan recognition, 739
 glycan-based drugs, 733t
 glyconutrients, 737–738
 glycoproteins, 731–732, 733f
 glycosaminoglycans, 736
 in metabolic disease, 734–736
 chaperone therapy, 735–736
 lysosomal enzyme replacement
 therapy, 735
 salvage versus de novo synthesis, 734
 special diets, 734–735
 substrate reduction therapy (SRT), 735
 small-molecule drugs, 729, 730f,
 731, 731f
Thermodynamics
 glycan–protein binding, 375, 375f
 glycosaminoglycan–protein
 interactions, 495
Thermophiles, 291
Thermoplasma acidophilum, 287
Thiamet-G, 706, 706f
Thin-layer chromatography
 for glycan detection, 640–643
 in glycosphingolipid analysis, 129
3D glycan structure modeling, 675–676
Three prime repair exonuclease 1
 (TREX1), 517
Threose, structure of, 22f
Thrombin, 36, 498
Thrombocytopenia, heparin-induced, 587
Thrombomodulin, 212t, 213
Thrombospondin, 509
Thrombospondin repeats (TSRs)
 modifications of, 152t, 156–157, 156f
 O-fucosyltransferase action on, 68–69
Thy-1, 137, 633
Thyroglobulin, 432, 523
Thyroid hormones, 523
Thyrotropin (TSH), 171–172, 172f
Tissue-nonspecific alkaline
 phosphatase, 580
Tissue regeneration, role of galectins in,
 476–477
Titration calorimetry, for study of glycan-
 protein interactions, 478, 479f
TLC. *See* Thin-layer chromatography
TLRs (Toll-like receptors), 82, 444, 530,
 530f
TMEM5, 158
Tn antigen, 115, 122, 600, 600f
TNF- α -converting enzyme (TACE), 449
Tn syndrome, 589
TOCSY (total correlation spectroscopy),
 649–650
Toll-like receptors (TLRs), 82, 444, 530,
 530f
Topiramate, 730f
Torpedo acetylcholinesterase, 137
Torsion angles, 29, 30f, 33, 33f, 38–39
Total correlation spectroscopy (TOCSY),
 641t, 650
Toxins
 Bacillus thuringiensis (Bt), 330–331
 binding to glycans, 482, 487–489,
 488f, 488t
 cholera toxin, 134
 binding, 487, 488f
 ganglioside GM1 as toxin receptor, 174
 Clostridium, 228–229, 421
 C-type lectins, 436
 Escherichia coli
 ganglioside GM1 as receptor for heat-
 labile enterotoxin (LT-1), 174
 heat-labile enterotoxins, 134
 ganglioside GM1 as receptor for, 174
 as glycan-binding proteins, 363, 364
 glycosyltransferases, 228–229
 GPI-anchored proteins and, 150
 receptors for, 488t
 recognition of glycans, 590
 ricin, 401–405, 404f, 405f
 sialic acid recognition, 191–192, 192f
 structure, 488f
 Toxocara spp., 332, 550
 Toxoplasma gondii
 galectins, 471
 glycosylation, 226
TPRs (tetratricopeptide repeats), *OGT*,
 243, 243f
Transcription, O-GlcNAc regulation of, 247
Transcription activator-like effector
 nucleases (TALENs), 718, 727
Transcription factors, O-GlcNAc and, 247
Transcriptome, 653–655

- Transcriptomics, 653–654
Transferases, in N-glycan synthesis, 109
Transferred nuclear Overhauser effect (trNOE), 393
Transforming growth factor β (TGF- β), 432, 523
Transfusion reaction, 167, 168, 169, 587, 739
Transglycosylation, 695–698
trans-infection, 458, 536
Translation, O-GlcNAc regulation of, 247–248
Transmembrane signaling, GPI-anchored proteins and, 148
Transmission electron microscopy (TEM) cellulose nanomaterials, 759f
gold glyconanoparticles, 745–746, 746f
Transpeptidases, bacterial, 269
Transplantation rejection, 739–740
Transporters
in N-glycan synthesis, 109
nucleotide sugar, 58–61, 59f, 60t
sugar, 52–53
trans-sialidase, 182, 188
leech, 421
in trypanosomes, 188, 543–544, 710
as virulence factors, 189
Trehalose, structure of, 29, 29f
TREX1 (three prime repair exonuclease 1), 517
Trichinella spiralis, 332, 550
Trichomonas vaginalis, galectins and, 475, 479
Trichosanthes spp., 406
Trimeresurus albolabris, 450
Triple-helical structures, 159
Trol (*terribly reduced optic lobes*) gene, 343, 345
Trousseau's syndrome, 449, 603
Trypanosoma, 543–545, 544f, 545f
lysosomal enzymes, 431
T. brucei
base J, 229
GPI biosynthesis, 142, 143f, 144, 148, 710
VSG (variant surface glycoprotein), 137, 139, 149, 543, 544f
T. cruzi, 458, 544–545, 545f
trans-sialidases, 188, 543–544, 710
Tsetse fly, 543
TSH (thyrotropin), 171–172, 172f
TSRs. *See* Thrombospondin repeats
T-synthase, 589. *See also* β 1-3 galactosyltransferase (β 1-3GalT)
Tumor necrosis factor- α (TNF- α), 586
Tumor necrosis factor-stimulated gene 6 (*TSG-6*), 202–204, 203f
Tunicamycin, 86, 102, 109, 233, 703–704, 704f
Twist conformation, 24f, 25
Twisted (*tw*) gene, 342
Type-1 glycan units, 162f, 163
Type-2 glycan units, 162–163, 162f
Type II transmembrane proteins, 44–45, 46f
Typhoid fever, 529, 532
Typhoid toxin, 532
Tyrosine-based signaling motifs, Siglec, 457
Tyrosine kinases, in membrane lipid rafts, 131
Tyvelose, 550
- U**
Ubiquitination
of misfolded proteins, 503, 508
targeting proteins to multivesicular storage bodies (MVBs), 564
UDP-galactose-4'-epimerase, defects in, 575, 575f
UDP-Gal:ceramide β -galactosyltransferase, 132
UDP-GalNAc:polypeptide α -N-acetylgalactosaminyltransferases (ppGalNAcTs), 409–411, 410f
UDP-Gal transporter, 317–318, 623, 631
UDP-Glc/GlcNAc C4-epimerase, 723
UDP-Glc:glycoprotein glucosyltransferase (UGGT), 69, 73, 296, 418, 504–507, 506f
UDP-GlcNAc, 243–244, 243f, 244f, 249
UDP-GlcNAc-dependent GlcNAc-1-phosphotransferase, 425–427, 426f
UDP-GlcNAc epimerase/N-acetylmannosamine kinase (GNE), 734
UDP-Glc/UDP-GlcNAc-4-epimerase, 631
UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, 426
UGGT (UDP-Glc:glycoprotein glucosyltransferase), 69, 73, 296, 418, 504–507, 506f
Ulcerative colitis, 586
Unc-52 gene, 330
Undecaprenol, 269
Undecaprenyl pyrophosphoryl glycoside anchor, 37
UniCarbKB, 672, 674, 676, 678
UniProtKB, 676, 678
UPAR-associated protein (UPARAP), 409
Urinary tract infections
Escherichia coli, 590
P blood group antigens and, 169
Urokinase-type plasminogen activator receptor (uPAR), 431
Uronic acids, 8
Uroplakin Ia, 486
Uteroferrin, mannose 6-phosphate on, 431
- V**
VAA (*Viscum album* agglutinin), 405
Vaccine
cancer, 738–739
microbial, 738
Valency, glycan–protein interactions and, 374–375, 374f
Vancomycin, 270
Variable number of tandem repeat (VNTR) regions, in mucins, 114f, 115
Varicella zoster virus (VZV), 432
VEGF receptor 2, 477
Velaglucerase, 735
Verotoxin, 134
Versican, 201f, 202, 210, 211t
Vertebrate lectins, 363, 365, 367f
Vertebrates
glycoside hydrolases of, 94–95
glycosyltransferases of, 94
proteoglycans, 210, 211t–212t
sialic acids, 182, 183f, 185–186, 187f, 192–193
Vesicular integral membrane protein 36, 419–420
Vesicular integral protein 36 (VIP 36), 507
Vesicular stomatitis virus G protein, 510
Vibrio cholerae
cholera toxin, 487, 488f
ganglioside GM1 as toxin receptor, 174
sialidase, 421, 591
Vicia faba, 417
VIP36, 419–420
VIPL (VIP36-like), 420
Viral glycan-binding proteins, 482–484, 483t, 484f–485f
Viridans group streptococci, 584
Viridiplantae. *See* Plants
Virus. *See also specific viruses*
ABH glycans of enveloped viruses, 167
C-type lectins, 437
genomics of glycosylation, 92–93
glycosylation of, 260
hemagglutinin, 82
influenza virus, 363, 481, 482–483, 483t, 484f, 490, 534–535, 534f
recognition of glycans, 590
lectins, 363, 365, 367f
mechanism of entry into host cells, 534–536, 534f
N-linked glycan capsid protein, 233–234
O-GlcNAc, 245
sialidases, 188–189, 194
tissue tropism, 533
Viscum album agglutinin (VAA), 405, 623
Volibose, 730f
Volksensin, 405
Von Figura, Kurt, 424
Von Willebrand factor (VWF), 173–174
VP4, rotavirus, 421
VP8, rotavirus, 421
V-set domain, Siglec, 455–456, 456f
VSG, *Trypanosoma brucei*, 543, 544f
VZV (varicella zoster virus), 432
- W**
Waldenström's macroglobulinemia, 589
Walker–Warburg syndrome, 157, 571t, 576–578

Wall-associated kinases, 516–517
Wall teichoic acids, 266, 270, 271f
Weak anion-exchange chromatography, 644
Weibel–Palade bodies, 446
Weintraub, Herschel, 497
Welan, 38
Wheat-germ agglutinin, 228, 601
Whooping cough, 531
Wiley, Don, 481
Wingless (Wg), 344
Wisteria floribunda agglutinin (WFA),
615f, 623
WND motif, 436
Woese, Carl, 283
wollknäuel (*wol*), 337

X

Xanthomonas capestris, 280
Xenopus laevis, 353–355, 354f, 472
Xenotransplantation, 739–740
X-lectins, 355
XIHAS1 gene, 198
XL35 lectin, 355
X-ray crystallography, study of
glycan–protein interactions,
372–373
XXYLT1, 156

Xylitol, in chewing gum, 737
Xylogalacturonans, 311
Xyloglucan, 306f, 310–311, 516, 517f
Xylose
activation of, 52t
addition to N-glycans, 108
linkage of glycosaminoglycan chains to
serine, 214–215
metabolism, overview, 55, 55f
phosphorylation, 178
structure of, 22f
transport, 53
Xylosides, 708–709
Xylosylation, in proteoglycans, 215
Xylosyltransferase, 67, 156
N-glycan modification, 108
plant, 314, 315f
in proteoglycan biosynthesis,
214–215, 215f

Y

Yarrowia lipolytica, glycosylation
engineering in, 716t
Yeast, 293–304. *See also* Fungi; *specific*
species
bioenergy, 756
cell wall, 294–295, 295f

glycolipids, 298
glycosylation engineering, 716t–717t,
721–722, 733–734
glycosylphosphatidylinositol anchors
(GPI anchors), 297–302, 299f
harnessing for production, 300–301
historical perspective, 294
humanized, 300, 721
mannans, 294–303, 296f
model organisms, 298–300
protein glycosylation, 295–298,
297f, 298f
Yersinia, 328
LPS, 531
toxin, 229
Y. pestis, 531
Y. pseudotuberculosis, 437
Yos9p, 507–508
YY1, O-GlcNAcylation of, 247

Z

Zanamivir, 730f, 731, 731f
ZEB, 607
Zebrafish (*Danio rerio*), 355–357, 356f, 471,
476–478
Zika virus, 484
Zymosan, 440

This is a free sample of content from Essentials of Glycobiology, Third Edition.
[Click here](#) for more information on how to buy the book.